patient
chronic
obstruct
pulmonari
diseas
copd
often
breathless
despit
optim
medic
care
pulmonari
rehabilit
breathless
frequent
becom
disabl
copd
advanc
may
precipit
hospitalis
proactiv
manag
breathless
may
improv
patient
outcom
describ
develop
multidisciplinari
md
breathless
clinic
patient
copd
literatur
review
treatment
breathless
undertaken
two
randomis
control
trial
rct
report
md
clinic
england
focus
intervent
breathless
travel
grant
enabl
visit
clinic
meet
clinician
identifi
assess
paramet
treatment
option
outcom
measur
return
australia
framework
clinic
refin
rang
resourc
develop
includ
breathless
dvd
relax
cd
acquisit
afford
effect
handheld
fan
pedomet
order
evalu
servic
rct
design
control
ensur
evalu
plan
standardis
rigor
clinic
began
accept
referr
may
team
consist
respiratori
physician
specialist
respiratori
nurs
physiotherapist
occup
therapist
dietitian
clinic
psychologist
target
popul
patient
document
copd
remain
breathless
despit
standard
care
primari
outcom
rct
chronic
respiratori
questionnair
masteri
breathless
subscal
secondari
outcom
includ
breathless
intens
unpleas
confid
manag
breathless
measur
numer
rate
scale
develop
breathless
clinic
patient
copd
result
excit
option
patient
experienc
refractori
breathless
rct
object
assess
benefit
intervent
patient
patient
remain
breathless
may
offer
addit
psycholog
andor
pharmacolog
treatment
judith
meppem
travel
scholarship
nil
novemb
scdhb
introduc
nurs
lead
osa
assess
howev
june
due
high
unsustain
demand
servic
referr
criteria
chang
accept
referr
patient
high
risk
osa
like
reach
thresholdn
aim
critic
review
referr
demograph
outcom
data
patient
refer
via
sleep
pathway
compar
data
high
risk
referr
criteria
referr
demograph
outcom
data
calendar
year
analys
review
data
referr
januari
june
compar
data
juli
comparison
made
data
referr
receiv
osa
nurs
assess
referr
receiv
prior
new
criteria
introduc
referr
came
gener
practition
gp
referr
sourc
chang
patient
refer
prior
new
criteria
discharg
gp
new
criteria
signific
chang
number
qualiti
referr
result
reduc
workload
manag
patient
like
meet
treatment
criteria
new
criteria
major
patient
outcom
referr
treatment
higher
level
sleep
studi
suggest
new
referr
criteria
result
effici
system
nil
canterburi
district
health
board
aim
provid
servic
better
sooner
conveni
peopl
canterburi
histor
canterburi
three
special
nurs
servic
offer
assess
educ
respiratori
patient
commun
led
confus
role
nurs
servic
servic
primari
health
hospit
staff
refer
case
led
duplic
referr
servic
time
referr
sent
three
nurs
servic
aim
project
integr
three
commun
nurs
servic
integr
specialist
servic
christchurch
hospit
commun
respiratori
servic
formal
known
canterburi
initi
canbreath
local
asthma
societi
offer
coordin
approach
patient
educ
copd
asthma
streamlin
access
across
servicesto
stop
duplic
referr
across
servicesto
support
primari
health
manag
complex
respiratori
patient
within
commun
small
work
group
five
set
represent
three
respiratori
nurs
servic
develop
algorithm
outlin
referr
pathway
appropri
nurs
servic
via
singl
point
entri
patient
intervent
take
place
commun
may
includ
develop
manag
plan
referr
health
provid
increas
collabor
gener
practic
educ
joint
commun
visit
group
identifi
need
share
electron
platform
increas
visibl
patient
outcom
healthpathway
provid
inform
regard
integr
respiratori
nurs
servic
access
primari
secondari
care
project
simplifi
referr
process
singl
point
entrystop
duplic
referr
servic
provisionincreas
collabor
commun
nurs
provid
gener
practic
develop
integr
respiratori
nurs
servic
provid
better
sooner
conveni
intervent
peopl
canterburi
nil
manag
respiratori
condit
histor
secondari
care
respond
acut
hospit
present
chronic
obstruct
pulmonari
diseas
lead
caus
death
new
zealand
new
zealand
highest
preval
asthma
associ
high
death
rate
time
higher
pacif
time
higher
maori
aim
form
evid
base
pathway
integr
care
patient
diagnos
suspect
respiratori
diseas
earli
intervent
primari
care
develop
compet
workforcesector
boundari
remov
servic
practic
nurs
led
perform
spirometri
across
practic
spirometri
train
annual
accredit
respiratori
scientist
mentor
practic
nurs
rcn
bhb
inform
technolog
diagnost
support
care
plan
tool
lead
joint
care
plan
patient
direct
educ
enabl
good
understand
conditionempow
patient
activ
partner
health
long
term
monitor
support
obviou
growth
patient
knowledg
improv
qualiti
lifeimprov
servic
qualiti
primari
care
lead
greater
equiti
caredecreas
secondari
servic
referr
diagnosticsdecreas
bed
day
day
decreas
length
stay
decreas
emerg
presentationsadmissionssignific
engag
high
depriv
area
indigen
peopleimprov
health
literaci
addit
fund
primari
care
remov
barrier
cost
access
earli
intervent
provid
protect
time
patient
educ
diagnost
softwar
assist
health
practition
standardis
best
practic
intervent
ensur
accur
diagnosi
progress
evid
base
care
plan
optimis
medic
improv
qualiti
life
chang
manag
drove
staff
recognis
benefit
concern
particularli
patient
patient
quot
chang
life
given
back
nt
think
would
ever
feel
good
ever
chronic
obstruct
pulmonari
diseas
copd
common
respiratori
disord
inhal
medic
wide
use
control
symptom
improv
qualiti
life
patient
studi
shown
patient
copd
unabl
use
inhal
devic
correctli
result
inadequ
drug
deposit
figur
could
higher
sinc
influx
new
devic
past
month
assess
confid
compet
nurs
work
respiratori
ward
deliv
inhal
devic
educ
patient
subject
given
questionnair
evalu
confid
provid
inhal
devic
educ
patient
subject
ask
supervis
patient
take
inhal
medic
requir
often
done
subject
undertook
compet
assess
review
correct
step
use
differ
inhal
devic
subject
femal
experi
nurs
enrol
studi
subject
report
patient
supervis
take
inhal
medic
rate
confid
inhal
devic
knowledg
confid
moder
extrem
high
subject
could
correctli
perform
step
use
inhal
step
devic
talli
averag
total
score
correct
step
sd
correl
total
correct
step
year
nurs
confid
level
despit
confid
compet
knowledg
correct
step
inhal
use
requir
teach
inhal
techniqu
patient
poor
amongst
group
respiratori
ward
nurs
need
provid
ongo
educ
intervent
improv
inhal
devic
compet
nurs
work
respiratori
medicin
patient
receiv
educ
regard
correct
inhal
use
optimis
diseas
manag
chronic
obstruct
pulmonari
diseas
copd
progress
ill
lead
signific
morbid
mortal
despit
high
symptom
burden
copd
patient
limit
access
palli
care
mani
unawar
prognosi
advanc
care
plan
acp
crucial
patient
make
wish
known
unabl
speak
futur
howev
acp
routin
practic
mani
health
profession
reluct
initi
convers
explor
respiratori
nurs
knowledg
practic
regard
acp
patient
copd
anz
respiratori
nurs
invit
particip
onlin
survey
via
email
listserv
snowbal
question
cover
valid
knowledg
practic
data
analys
use
descript
statist
themat
analysi
free
respons
question
respiratori
nurs
particip
correctli
answer
key
knowledg
indic
unsur
regard
transfer
advanc
direct
ad
incorrectli
thought
formal
ad
templat
necessari
legal
bind
agreedstrongli
agre
acp
practic
indic
ambival
regard
person
confid
commun
bad
news
routin
initi
acp
agreedstrongli
agre
acp
part
profession
role
ambival
whether
acp
physician
respons
inde
themat
analysi
identifi
need
time
clear
guidanc
train
consist
concern
respiratori
nurs
well
place
commenc
acp
copd
patient
mani
uncertain
acp
legisl
unsur
member
clinic
team
engag
acp
discuss
variat
confid
undertak
acp
suggest
need
train
help
nurs
support
patient
articul
wish
data
collect
still
ongo
nil
zhou
n
p
et
al
knowledg
attitud
practic
behavior
oncolog
advanc
practic
nurs
regard
advanc
care
plan
patient
cancer
author
conflict
interest
declar
tsanz
state
special
interest
group
rcn
pcna
nzno
lfa
pcv
svha
adhb
safgp
clinician
facilit
circul
survey
dr
traci
smith
involv
studi
design
season
influenza
place
increas
demand
emerg
depart
hospit
resourc
limit
singl
room
capac
mean
patient
often
remain
emerg
depart
suboptim
ward
placement
increas
risk
transmiss
patient
staff
year
patient
clinic
decis
make
improv
due
develop
influenza
flowchart
base
current
best
practic
local
clinic
busi
rule
develop
resourc
dissemin
wide
singl
room
capac
exhaust
patient
meet
case
definit
cohort
respiratori
ward
viral
swab
taken
oseltamivir
cohort
room
ward
depend
demand
improv
placement
influenza
patient
june
septemb
total
patient
identifi
test
posit
influenza
b
overal
patient
test
posit
requir
admiss
despit
high
number
influenza
admiss
patient
isol
correctli
total
admiss
place
respiratori
ward
least
patient
cohort
four
bed
room
decreas
length
stay
reduct
number
patient
stay
ed
hour
appar
peak
winter
month
august
despit
higher
number
present
ed
overal
improv
awar
influenza
symptom
clinic
decis
line
matrix
despit
increas
present
peak
month
august
increas
familiar
risk
matrix
reflect
improv
manag
patient
total
patient
given
oseltamivir
thu
greatli
reduc
length
stay
singl
room
day
provid
patient
afebril
local
hospit
data
also
demonstr
absenc
influenza
outbreak
area
matrix
use
correctli
cohort
flowchart
direct
care
provid
guidanc
clinician
ensur
safe
appropri
placement
patient
thu
reduc
risk
influenza
outbreak
cohort
reduc
demand
respiratori
singl
room
emerg
depart
length
stay
remain
lower
yearli
predict
despit
higher
present
nil
nsw
health
influenza
control
guidelin
public
health
unit
updat
may
http
wwwhealthnswgovauinfectiouscontrolguidelinepagesinfluenzaaspxnsw
health
influenza
polici
influenza
minimis
transmiss
influenza
healthcar
facil
influenza
season
updat
june
http
australian
drug
inform
resourc
ausdi
oseltamivir
product
summari
http
ausdihcncomauproductsummaryhcn
updat
septemb
westernis
diet
typic
low
fibr
may
contribut
asthma
develop
progress
observ
data
shown
low
fibr
intak
associ
wors
airway
inflamm
lung
function
date
fibr
intervent
studi
human
asthma
howev
anim
model
airway
diseas
dietari
fibr
shown
modul
gut
microbiom
reduc
airway
inflamm
studi
aim
investig
effect
solubl
fibr
supplement
asthmat
adult
randomis
placebo
control
crossov
studi
stabl
asthmat
use
day
supplement
inulin
inulinprobiot
billion
cfu
placebo
clinic
assess
induc
sputum
faecal
collect
occur
treatment
select
sputum
dispers
total
differenti
leucocyt
count
perform
faecal
bacteria
determin
fluoresc
situ
hybridis
faecal
scfa
chang
asthma
control
acq
lung
function
gut
microbiota
scfa
induc
sputum
cell
count
analys
use
wilcoxon
spearman
correl
acq
improv
median
iqr
sputum
eosinophil
decreas
follow
inulin
intervent
signific
chang
bacteri
taxon
rel
abund
seen
bifidobacterium
increas
follow
inulinprobiot
supplement
trend
follow
inulin
supplement
anaerostip
increas
follow
inulin
inulinprobiot
supplement
unidentifi
erysipelotrichacea
taxon
roseburia
decreas
follow
inulin
supplement
total
faecal
scfa
acet
show
trend
increas
follow
inulin
supplement
chang
scfa
correl
chang
p
p
sputum
eosinophil
erysipelotrichacea
short
term
inulin
supplement
benefici
alter
gut
microbiom
improv
asthma
control
airway
inflamm
asthma
solubl
fibr
supplement
warrant
investig
potenti
addit
asthma
manag
strategi
john
hunter
hospit
charit
trust
poor
adher
import
contributor
inadequ
asthma
control
electron
monitor
provid
object
measur
inhal
adher
adher
often
express
mean
proport
prescrib
puff
taken
studi
period
may
adequ
reflect
variat
use
time
work
aim
develop
new
metric
examin
pattern
dose
time
better
quantifi
adher
retrospect
analysi
previous
publish
data
foster
et
al
jaci
compar
subject
uncontrol
asthma
receiv
inhal
remind
usag
feedback
irf
design
improv
prevent
adher
versu
remind
feedback
adher
particip
measur
electron
monitor
daili
dose
record
divid
pm
construct
curv
base
proport
prescrib
puff
taken
measur
whether
puff
taken
measur
time
calcul
differ
area
actual
expect
cumul
curv
auc
test
use
assess
differ
measur
group
examin
data
asthma
patient
asthma
control
test
age
year
irf
patient
took
dose
averag
patient
first
two
month
vs
prescrib
dose
p
also
shorter
averag
gap
dose
vs
p
auc
higher
compar
vs
vs
expect
auc
p
respect
partit
adher
measur
patient
differ
amount
medic
taken
well
gap
dose
studi
determin
relationship
pattern
aspect
symptom
control
futur
risk
nil
asthma
popul
sever
asthma
diagnos
good
asthma
control
achiev
high
dose
inhal
treatment
good
control
achiev
high
dose
inhal
treatment
previou
studi
larg
focus
clinic
aspect
sever
asthma
littl
explor
person
experi
live
condit
aim
review
qualit
literatur
examin
person
experi
adult
live
sever
asthma
conduct
systemat
review
identifi
qualit
public
person
experi
adult
live
sever
asthma
exclud
studi
patient
particip
research
method
compar
themat
analysi
approach
adopt
articl
five
studi
met
inclus
criteria
topic
includ
paper
notabl
medic
focuss
pauciti
literatur
physic
burden
asthma
symptom
analysi
reveal
side
effect
medic
particularli
oral
corticosteroid
commun
health
care
provid
physic
mental
burden
effect
relationship
work
leisur
play
domin
role
experi
feel
exclud
left
uninform
condit
common
experi
knowledg
first
systemat
review
qualit
literatur
regard
peopl
experi
live
sever
asthma
togeth
find
suggest
experi
sever
asthma
pose
challeng
person
autonomi
peopl
sever
asthma
make
effort
control
live
find
provid
import
signpost
deeper
explor
experi
find
suggest
pauciti
studi
explor
person
experi
live
sever
asthma
clearli
much
understood
cre
sever
asthma
medic
asthma
may
lead
poor
asthma
control
inappropri
escal
prescrib
treatment
issu
may
particularli
signific
patient
asthma
sinc
alfr
undertaken
systemat
evalu
patient
difficult
asthma
popul
examin
feasibl
use
electron
monitor
devic
emd
measur
prevent
inhal
adher
compar
result
clinician
assess
consecut
patient
difficult
asthma
refer
respiratori
specialist
underw
systemat
evalu
alfr
june
june
prevent
inhal
adher
assess
electron
monitor
devic
adherium
ltd
specialist
physician
asthma
nurs
assess
major
patient
inhal
icslaba
combin
therapi
signific
impair
lung
function
high
burden
diseas
patient
patient
inhal
incompat
emd
emd
malfunct
refus
accept
emd
return
emd
patient
return
useabl
emd
data
proport
patient
adher
prevent
time
patient
physician
nurs
assess
significantli
clinician
assess
poorli
sensit
physician
nurs
highli
specif
physician
nurs
detect
studi
difficult
asthma
true
rate
like
lie
among
patient
return
devic
includ
patient
refus
return
devic
clinician
assess
cohort
highli
unreli
object
assess
inhal
integr
part
systemat
evalu
difficult
asthma
author
acknowledg
unrestrict
grant
gsk
fund
electron
monitor
devic
gsk
contribut
studi
design
conduct
analysi
repeat
asthma
relat
emerg
depart
ed
present
associ
increas
risk
life
threaten
asthma
studi
aim
determin
streamlin
ed
discharg
process
would
improv
level
asthma
control
asthma
behaviour
encourag
patient
follow
gp
reduc
asthma
relat
ed
use
control
cohort
studi
design
evalu
asthma
ed
discharg
protocol
intervent
patient
present
intervent
site
provid
spacer
educ
resourc
asthma
control
pack
written
prompt
visit
gp
comprehens
educ
referr
asthma
week
post
discharg
control
site
patient
receiv
usual
care
referr
asthma
week
data
behaviour
health
outcom
collect
cohort
via
telephon
demograph
characterist
five
week
contact
point
rapid
signific
improv
level
asthma
control
deliveri
devic
accuraci
seen
systemat
formalis
discharg
process
implement
result
five
week
post
discharg
cost
deliv
asthma
ed
discharg
protocol
per
particip
repres
cost
per
patient
well
control
asthma
five
week
formalis
asthma
relat
ed
discharg
process
show
potenti
enhanc
longer
term
asthma
manag
patient
receiv
intervent
four
time
like
well
control
asthma
twice
like
use
deliveri
devic
correctli
australian
centr
health
servic
innov
aushsi
acut
exacerb
asthma
caus
signific
global
burden
ill
macrolid
antibiot
may
treat
persist
asthma
perform
random
placebo
control
trial
determin
whether
oral
azithromycin
decreas
frequenc
sever
asthma
exacerb
adult
symptomat
asthma
despit
current
use
inhal
corticosteroid
ic
bronchodil
labd
hear
impair
prolong
correct
qt
interv
screen
patient
random
receiv
azithromycin
patient
placebo
patient
time
per
week
week
azithromycin
reduc
sever
asthma
exacerb
compar
placebo
incid
rate
ratio
irr
confid
interv
ci
eosinophil
asthma
ea
azithromycin
reduc
sever
asthma
exacerb
irr
ci
reduc
proport
patient
experienc
least
one
sever
exacerb
placebo
azithromycin
azithromycin
reduc
exacerb
ea
defin
use
blood
eosinophil
irr
ci
asthma
phenotyp
ci
diarrhoea
common
azithromycin
treat
patient
vs
azithromycin
treat
patient
fewer
respiratori
infect
vs
p
adult
persist
symptomat
eosinophil
asthma
despit
icslabd
experi
fewer
sever
asthma
exacerb
treat
addit
oral
azithromycin
week
azithromycin
increas
gastrointestin
advers
effect
fewer
respiratori
infect
azithromycin
ad
icslabd
therapi
persist
eosinophil
asthma
reduc
sever
asthma
exacerb
nation
health
medic
research
council
australia
none
anzctr
aim
pulmonari
rehabilit
guidelin
guidelin
provid
recommend
practic
pulmonari
rehabilit
pr
specif
australian
new
zealand
nz
healthcar
context
write
group
expert
pr
lead
group
select
express
interest
guidelin
methodolog
adher
apprais
guidelin
research
evalu
agre
ii
criteria
nine
key
question
construct
accord
popul
intervent
compar
outcom
pico
format
review
copd
consum
group
appropri
systemat
review
undertaken
question
recommend
made
strength
recommend
base
grade
recommend
assess
develop
evalu
grade
criteria
guidelin
extern
review
panel
expert
australian
nz
respiratori
physician
physiotherapist
brief
guidelin
panel
recommend
peopl
mild
sever
copd
undergo
pr
improv
qualiti
life
exercis
capac
reduc
hospit
admiss
pr
could
offer
hospit
gym
commun
centr
home
could
provid
irrespect
avail
structur
educ
program
pr
offer
peopl
bronchiectasi
interstiti
lung
diseas
pulmonari
hypertens
latter
specialis
centr
due
insuffici
evid
guidelin
panel
unabl
make
recommend
relat
pr
program
length
beyond
week
optim
model
mainten
pr
use
supplement
oxygen
exercis
train
guidelin
document
discuss
need
cultur
appropri
pr
program
indigen
peopl
copd
australia
nz
reduc
gap
health
outcom
australian
new
zealand
pulmonari
rehabilit
guidelin
present
evalu
evid
nine
pico
question
recommend
provid
guidanc
clinician
polici
maker
lung
foundat
australia
fund
meet
teleconfer
provid
administr
support
strong
evid
support
pulmonari
rehabilit
pr
peopl
copd
yet
elig
receiv
pr
annual
theoret
domain
framework
tdf
integr
framework
explain
issu
around
implement
best
practic
evid
healthcar
set
tdf
use
understand
construct
influenc
referr
attend
complet
pr
peopl
copd
systemat
review
studi
qualit
quantit
report
data
relat
referr
uptak
andor
particip
pr
extract
data
map
one
domain
tdf
order
understand
natur
barrier
facilit
particip
individu
age
diagnosi
copd
health
profession
work
peopl
copd
total
refer
screen
studi
includ
relev
item
map
tdf
frequent
repres
domain
environ
includ
studi
map
item
includ
wait
time
burden
ill
travel
transport
health
system
resourc
frequent
repres
domain
knowledg
studi
eg
clinician
knowledg
referr
process
patient
understand
rehabilit
content
belief
consequ
studi
eg
belief
regard
role
safeti
exercis
expect
rehabilit
outcom
barrier
referr
uptak
particip
repres
item
map
tdf
domain
tdf
repres
howev
item
least
frequent
code
domain
optim
memori
methodolog
qualiti
includ
studi
fair
mean
qualiti
score
sd
benefit
pr
peopl
copd
well
establish
review
highlight
complex
interact
environ
knowledg
attitud
behaviour
influenc
uptak
particip
pr
overcom
challeng
associ
person
andor
healthcar
system
environ
imper
improv
access
uptak
pr
nil
bronchiol
signific
health
burden
global
clinic
diagnos
condit
characteris
tachypnoea
crackl
andor
wheez
children
year
although
typic
persist
symptom
may
continu
beyond
acut
phase
day
increas
burden
diseas
risk
review
aim
determin
efficaci
antibiot
compar
control
reduc
persist
respiratori
symptom
follow
acut
bronchiol
within
six
month
ill
previou
review
updat
august
use
follow
databas
cochran
airway
group
regist
trial
cochran
central
regist
control
trial
central
medlin
embas
http
clinicaltrialsgov
trial
portal
australian
new
zealand
clinic
trial
registri
two
review
author
independ
assess
articl
predetermin
select
criteria
randomis
control
trial
rct
compar
antibiot
control
phase
bronchiol
day
children
year
age
diagnos
bronchiol
paper
retriev
involv
children
includ
use
analysi
month
signific
differ
observ
treatment
group
primari
outcom
number
cure
follow
ci
number
respiratori
ill
ci
signific
differ
secondari
outcom
month
recurr
wheez
ci
bacteri
resist
ci
current
evid
support
use
antibiot
treatment
point
ill
prevent
bronchiol
symptom
howev
studi
children
randomis
point
bronchiol
studi
randomis
children
point
symptom
persist
confirm
need
rct
inform
clinic
practic
bronchiol
indigen
antibiot
persist
symptom
respiratori
nil
conflict
interest
declar
mccallum
gb
morri
p
grimwood
k
maclennan
c
white
chatfield
md
et
al
frontier
pediatr
tahan
f
ozcan
koc
n
european
respiratori
journal
endobronchi
transbronchi
needl
aspir
positron
emiss
tomographi
crucial
mediastin
stage
cell
lung
cancer
nsclc
howev
specif
assess
malign
statu
mediastin
hilar
lymph
node
total
lesion
glycolysi
tlg
defin
lesion
volum
multipli
lesion
suvmean
prognost
valu
nsclc
knowledg
use
predict
malign
statu
lymph
node
aim
determin
tlg
improv
specif
analysi
predict
malign
statu
mediastin
hilar
lymph
node
nsclc
retrospect
studi
patient
nsclc
underw
januari
decemb
westmead
hospit
perform
blind
experienc
nuclear
medicin
physician
measur
tlg
lymph
node
sampl
via
malign
statu
lymph
node
determin
histopatholog
result
surgic
sampl
perform
identifi
patient
met
studi
criteria
total
mediastin
hilar
lymph
node
analys
use
tlg
sensit
specif
receiv
oper
characterist
curv
gener
show
good
accuraci
tlg
area
curv
tlg
may
help
tool
determin
malign
potenti
mediastin
hilar
lymph
node
nsclc
particular
increas
specif
analysi
turn
would
aid
avoid
unnecessari
procedur
associ
cost
delay
surgeri
prospect
studi
requir
evalu
novel
tool
nil
determin
effect
preoper
exercis
train
postop
outcom
includ
risk
develop
postop
pulmonari
complic
postop
durat
intercost
cathet
length
hospit
stay
adult
schedul
undergo
lung
resect
cell
lung
cancer
nsclc
search
cochran
central
regist
control
trial
pubm
embas
pedro
scielo
scientif
electron
librari
onlin
march
randomis
control
trial
rct
includ
studi
particip
schedul
undergo
lung
resect
nsclc
alloc
receiv
either
preoper
exercis
train
exercis
train
two
review
author
independ
screen
assess
studi
inclus
risk
bia
assess
use
cochran
seven
domain
tabl
conduct
possibl
five
rct
involv
particip
identifi
overal
risk
bia
includ
studi
high
pool
data
three
studi
demonstr
preoper
exercis
train
reduc
risk
develop
postop
pulmonari
complic
rr
ci
compar
control
group
number
day
patient
intervent
group
need
intercost
cathet
lower
md
day
ci
day
pool
data
two
studi
postop
length
hospit
stay
also
lower
intervent
group
md
day
ci
day
pool
data
three
studi
preoper
exercis
train
appear
reduc
risk
develop
postop
pulmonari
complic
durat
intercost
cathet
postop
length
hospit
stay
peopl
undergo
lung
resect
nsclc
find
review
interpret
caution
due
dispar
studi
methodolog
limit
risk
bia
small
sampl
size
systemat
review
emphasis
need
larger
rct
catherin
granger
support
nhmrc
translat
research
practic
fellowship
cancer
australia
australia
viniciu
cavalheri
support
cancer
council
wa
postdoctor
fellowship
nil
nomin
award
physiotherapi
access
qualiti
cancer
servic
import
determin
patient
outcom
respiratori
malign
exist
australian
data
limit
retrospect
analys
patient
proven
malign
data
fulli
describ
journey
patient
suspect
respiratori
malign
prospect
registri
develop
inform
servic
requir
benchmark
qualiti
patient
refer
st
john
god
midland
hospit
gener
secondari
hospit
assess
possibl
respiratori
malign
prospect
includ
analys
clinic
data
descript
novemb
septemb
patient
refer
refer
gener
practition
seen
outpati
clinic
referr
trigger
symptom
radiolog
abnorm
incident
find
abnorm
ct
scan
perform
lung
cancer
screen
commonest
abnorm
mass
pulmonari
nodul
singl
multipl
invas
diagnost
investig
undertaken
establish
tissu
diagnosi
malign
lung
cancer
ct
surveil
recommend
four
patient
investig
median
time
outpati
referr
first
review
eight
day
rang
outpati
seen
within
day
patient
requir
endobronchi
ultrasound
tertiari
centr
wait
median
day
rang
first
review
referr
treatment
compar
median
day
rang
pilot
registri
describ
wide
variat
diagnost
pathway
taken
investig
possibl
lung
cancer
addit
provid
prompt
outpati
assess
lung
cancer
servic
need
inpati
present
acut
unwel
wait
time
outpati
assess
diagnost
test
short
major
patient
delay
patient
highlight
need
ongo
servic
improv
nil
malign
pleural
effus
mpe
malign
ascit
contribut
signific
breathless
patient
advanc
cancer
manag
fluid
requir
frequent
admiss
repeat
needl
thoracocentesi
pleurodesi
sinc
ad
indwel
tunnel
cathet
manag
option
avail
clinician
within
lhd
project
retrospect
review
experi
pleurx
cathet
insert
manag
mpe
patient
report
immedi
improv
breathless
two
hundr
pleurx
cathet
insert
indic
mpe
bilater
pleural
pleurx
insert
patient
pleural
periton
cathet
insert
simultan
patient
technic
success
rate
achiev
drain
remain
situ
mean
day
rang
day
almost
patient
die
pleurx
cathet
insitu
pleurodesi
achiev
patient
pleurx
remov
without
fluid
accumul
remain
patient
remain
aliv
pleurx
insitu
pleurx
insert
patient
mpe
due
nsclc
breast
gastricesophag
pancreat
ovarian
colorect
adenocarcinoma
unknown
origin
mesothelioma
hepatocellular
carcinoma
sclc
melanoma
bladder
cholangiocarcinoma
renal
cell
carcinoma
angiosarcoma
endometri
alcohol
cirrhosi
othersunknown
complic
drain
insert
includ
wound
infect
block
cathet
fell
outcuff
expos
leakag
drain
site
bowel
injuri
n
cost
per
patient
averag
entir
durat
pleural
periton
pleurx
respect
ongo
hardwar
cost
insert
cost
averag
number
pleural
drainag
bottl
periton
drainag
bag
per
patient
respect
studi
demonstr
safe
use
tunnel
pleurx
cathet
patient
present
mpe
insert
subsequ
drainag
effus
ascit
manag
comfort
patient
home
believ
use
pleurx
cathet
consid
first
line
approach
manag
refractori
mpe
nil
conflict
interest
disclos
new
pathway
district
health
board
greater
auckland
region
develop
incorpor
rapid
access
clinic
rac
upfront
scan
consid
potenti
curabl
initi
assess
order
enabl
quicker
lung
cancer
diagnosi
pilot
patient
grade
high
suspicion
lung
cancer
seen
rac
spirometri
perform
statu
assess
avail
radiolog
chest
ct
scan
consid
potenti
curabl
surgeri
radiotherapi
litr
ecog
score
advanc
diseas
evid
imag
comorbid
preclud
radic
treatment
receiv
upfront
scan
receiv
standard
ct
scan
alreadi
done
time
pathway
measur
compar
histor
data
region
lung
cancer
databas
period
year
pilot
patient
complet
pathway
found
lung
cancer
patient
upfront
scan
confirm
lung
cancer
subsequ
palli
treatment
cancer
diagnos
cancer
nodul
follow
metastasi
cancer
patient
scan
later
pathway
subsequ
cur
treatment
median
time
referr
first
treatment
reduc
day
patient
cur
treatment
intent
day
palli
treatment
intent
day
significantli
reduc
time
referr
multidisciplinari
meet
mdm
mdm
first
treatment
achiev
referr
treatment
target
compar
histor
data
region
lung
cancer
pathway
incorpor
rac
upfront
scan
potenti
cur
patient
result
improv
diagnost
delay
treatment
target
find
subsequ
led
implement
pathway
region
studi
fund
new
zealand
ministri
health
project
grant
multidisciplinari
team
mdt
care
affect
lung
cancer
outcom
includ
treatment
project
analys
lung
cancer
outcom
accord
mdt
care
australian
dataset
aim
adjust
outcom
statu
charlson
index
colinet
simplifi
score
consecut
cohort
case
diagnos
januari
decemb
identifi
local
clinic
cancer
registri
clincr
histopatholog
tnm
stage
ecog
statu
surviv
analys
accord
mdt
care
charlson
index
calcul
via
icd
code
colinet
simplifi
score
complet
via
valid
item
institut
medic
record
case
primari
lung
carcinoma
identifi
present
mdt
mdt
sclc
compris
mdt
case
tnm
data
show
higher
rate
stage
vs
unstag
case
mdt
group
compar
group
vs
p
stage
iv
patient
half
like
present
mdt
stage
stage
iv
vs
stage
combin
ecog
statu
better
record
mdt
v
p
surviv
analysi
adjust
age
diseas
stage
ecog
statu
show
overal
increas
rel
probabl
death
vs
mdt
patient
hr
ci
p
initi
data
extract
compris
icd
code
subset
patient
includ
mdt
case
case
score
less
analysi
adjust
age
tnm
stage
ecog
statu
mdt
care
associ
improv
surviv
project
seek
updat
analysi
adjust
statu
accord
two
previous
valid
measur
et
al
mja
et
al
cancer
et
al
plo
one
nil
exercis
desatur
walk
test
associ
poorer
outcom
patient
interstiti
lung
diseas
ild
test
stst
faster
requir
less
space
howev
util
ild
patient
assess
aim
compar
oxygen
desatur
stst
ild
patient
consecut
subject
recruit
rpah
ild
clinic
patient
perform
stst
randomis
order
recoveri
perform
accord
atser
standard
stst
perform
singl
oper
requir
patient
sit
stand
chair
mani
time
possibl
whilst
oxygen
satur
heart
rate
hr
monitor
nadir
defin
lowest
record
exercis
recoveri
period
signific
desatur
defin
nadir
subject
studi
mean
age
year
male
underli
caus
ild
idiopath
pulmonari
fibrosi
connect
tissu
diseas
mean
fvc
dlco
rest
median
rang
nst
rang
patient
desatur
stst
mean
nadir
vs
p
strong
correl
nadir
stst
spearman
rho
p
area
receiv
oper
curv
signific
desatur
use
nadir
stst
ci
nadir
stst
gave
sensit
specif
signific
desatur
ild
cohort
nadir
stst
correl
strongli
stst
suitabl
offic
set
nadir
stst
appear
rule
signific
destaur
nil
pulmonari
arteri
hypertens
pah
caus
pulmonari
vascular
remodel
reduc
express
bone
morphogenet
protein
receptor
causal
link
pah
previous
augment
endotheli
progenitor
cell
epc
transplant
monocrotalin
mct
pah
rat
model
result
amelior
diseas
assess
effect
epc
therapi
vascular
remodel
pah
rat
model
rat
inject
mct
day
rat
intraven
inject
epc
transfect
epc
adtrackluc
transfect
epc
uninject
day
pah
assess
lung
extract
process
paraffin
bloc
immunohistochem
analysi
vessel
less
perform
muscl
actin
prolifer
cell
nuclear
antigen
pcna
day
pah
attenu
shown
signific
reduct
rvsp
mpap
fulton
index
epc
group
compar
diseas
epc
irrelev
epc
group
treat
anim
signific
reduct
vessel
muscularis
vessel
thick
signific
reduct
cellular
prolifer
shown
pcna
stain
compar
diseas
amelior
pah
achiev
use
modifi
epc
signific
reduct
distal
vessel
muscularis
cellular
prolifer
follow
epc
treatment
greater
effect
seen
group
nhmrc
rah
immunosuppress
therapi
follow
lung
transplant
fail
prevent
bronchiol
obliteran
syndrom
bo
primarili
diseas
small
airway
shown
associ
lack
suppress
lymphocyt
also
recent
shown
reduc
glucocorticoid
receptor
gcr
histon
deacetylas
heat
shock
protein
lymphocyt
follow
transplant
hypothes
lymphocyt
target
small
airway
bo
blood
bronchoalveolar
lavag
proxim
distal
airway
bronchial
brush
collect
patient
bo
stabl
lung
transplant
patient
healthi
control
intracellular
cytokin
express
gcr
measur
lymphocyt
subset
follow
cultur
use
flow
cytometri
bo
associ
increas
nk
cell
distal
airway
compar
stabl
patient
control
increas
reduc
gcr
express
lymphocyt
subset
patient
bo
compar
stabl
patient
control
correl
percentag
cell
express
gcr
distal
brush
gcr
bo
associ
increas
nk
cell
distal
airway
treatment
increas
gcr
lymphocyt
subset
may
reduc
graft
reject
rah
respiratori
clinic
trial
declar
interest
lung
transplant
best
option
patient
lung
diseas
chronic
reject
major
complic
half
lung
transplant
recipi
experi
chronic
reject
earli
cours
diseas
symptom
clinic
appar
aim
studi
investig
use
biomark
earli
chronic
lung
reject
forti
adult
lung
transplant
patient
alfr
blood
collect
lung
function
measur
time
point
month
measur
plasma
perform
use
sandwich
immunoassay
clinic
variabl
includ
age
bmi
smoke
histori
histori
acut
graft
reject
also
record
univari
multivari
analys
assess
clinic
variabl
associ
plasma
level
util
biomark
diseas
progress
assess
characterist
curv
analysi
diseas
progress
defin
greater
fall
percent
predict
forc
vital
capac
second
month
time
point
seventeen
patient
experienc
declin
lung
function
month
patient
experienc
diseas
progress
higher
level
plasma
month
remain
stabl
mean
stabl
pgml
vs
mean
progress
pgml
p
increas
level
predict
diseas
progress
area
curv
biomark
abl
detect
diseas
progress
chronic
reject
patient
experi
lung
function
declin
biomark
diseas
progress
idiopath
pulmonari
fibrosi
fibrot
lung
diseas
share
mechan
pathogenesi
chronic
reject
elev
level
may
detect
prior
clinic
manifest
lung
function
declin
level
may
biomark
diseas
progress
chronic
reject
nil
cardiopulmonari
exercis
test
cpet
frequent
use
evalu
patient
pulmonari
hypertens
ph
patient
distal
cteph
repres
uniqu
subgroup
ph
microvascular
diseas
resembl
pulmonari
arteri
hypertens
pah
may
predomin
efficaci
medic
therapi
avail
howev
littl
known
regard
detail
cpet
profil
distal
cteph
whether
ventil
ga
exchang
respons
differ
pah
consecut
patient
distal
cteph
accord
multidisciplinari
team
assess
match
pah
patient
underw
cpet
right
heart
catheter
patient
follow
median
year
pulmonari
haemodynam
similar
distal
cteph
pah
group
patient
distal
cteph
achiev
lower
percentag
predict
peak
oxygen
consumpt
vs
p
peak
exercis
higher
physiolog
deadspac
fraction
vdvt
vs
p
larger
tidal
carbon
dioxid
gradient
vs
p
observ
distal
cteph
compar
pah
ventilatori
effici
express
slope
also
impair
distal
cteph
vs
lminlmin
p
distal
cteph
group
higher
vdvt
correl
lower
peak
oxygen
consumpt
r
p
associ
wors
surviv
compar
pah
distinct
pattern
pathophysiolog
observ
distal
cteph
character
increas
deadspac
ventil
result
wors
ventilatori
effici
greater
impair
exercis
capac
distal
cteph
deadspac
ventil
correl
exercis
capac
may
potenti
prognost
relev
nil
patient
interstiti
lung
diseas
ild
frequent
experi
intermitt
hypoxaemia
ih
exercis
sleep
chronic
ih
associ
increas
oxid
stress
maladapt
cardiovascular
consequ
includ
pulmonari
hypertens
ph
aim
compar
plasma
marker
oxid
stress
protein
carbonyl
pc
thiol
concentr
two
ild
cohort
expos
intervent
oxygen
versu
medic
air
two
previous
describ
ild
patient
cohort
either
signific
hypoxia
sleep
time
desatur
walk
test
particip
randomis
studi
pair
plasma
sampl
taken
follow
supplement
oxygen
medic
air
usag
either
sleep
increment
cardiopulmonari
exercis
test
sensit
immunosorb
assay
elisa
use
pc
detect
thiol
quantifi
use
dtnb
assay
plate
method
eleven
patient
patient
studi
combin
popul
femal
mean
age
yr
bmi
fvc
dlco
nadir
rvsp
sleep
time
baselin
plasma
pc
concentr
air
elev
rang
nmolmg
normal
nmolmg
baselin
thiol
concentr
deplet
rang
normal
lower
thiol
concentr
associ
lower
nadir
sleep
increas
rvsp
applic
oxygen
sleep
exercis
plasma
pc
level
significantli
reduc
compar
air
thiol
level
howev
significantli
improv
oxygen
sleep
exercis
cohort
sleep
air
oxygen
exercis
air
oxygen
ild
patient
ih
sleep
exercis
increas
burden
oxid
stress
lower
thiol
level
associ
sever
sleep
hypoxia
ph
supplement
oxygen
improv
capac
ild
cohort
primari
care
peopl
sever
mental
ill
smi
lower
life
expect
gener
popul
signific
proport
excess
mortal
due
higher
preval
cardiac
metabol
diseas
less
known
preval
respiratori
diseas
group
cross
section
observ
studi
aim
assess
preval
respiratori
diseas
symptom
patient
admit
inpati
mental
health
unit
inpati
structur
interview
questionnair
complet
questionnair
includ
diagnos
common
diseas
screen
question
design
detect
respiratori
diseas
sleep
disord
breath
spirometri
perform
basi
symptom
smoke
statu
access
primari
care
assess
includ
surrog
marker
comprehens
care
vaccin
statu
patient
report
high
rate
respiratori
symptom
includ
wheez
dyspnoea
cough
product
cough
significantli
associ
tobacco
use
p
patient
report
daili
tobacco
use
use
cannabi
least
monthli
ten
patient
spirometri
consist
copd
formal
diagnosi
copd
previous
symptom
suggest
sleep
disord
breath
common
patient
report
wit
apnoeic
episod
sleep
vaccin
rate
low
pneumococc
influenza
vaccin
peopl
smi
high
rate
respiratori
symptom
high
preval
copd
spirometri
half
copd
case
previous
diagnos
suggest
hidden
burden
respiratori
diseas
patient
smi
mental
ill
copd
smoke
princ
charl
foundat
novic
research
grant
evid
suggest
asthma
patient
fail
use
inhal
correctli
result
frequent
exacerb
educ
health
profession
subsequ
patient
may
contribut
factor
innov
technolog
augment
realiti
access
via
smartphon
applic
function
educ
tool
address
issu
therefor
aim
studi
obtain
health
profession
asthma
patient
key
commun
stakehold
perspect
feasibl
augment
realiti
technolog
improv
asthma
inhal
techniqu
educ
patient
inform
poster
display
imag
asthma
inhal
devic
produc
base
exist
evid
base
recommend
resourc
augment
realiti
technolog
utilis
provid
video
demonstr
correct
inhal
techniqu
devic
made
access
via
free
smartphon
applic
interview
health
profession
asthma
patient
key
commun
stakehold
conduct
august
septemb
data
analys
themat
use
triandi
model
interperson
behaviour
interview
asthma
patient
highlight
perceiv
compet
inhal
techniqu
howev
health
profession
key
commun
stakehold
identifi
percept
misguid
poor
inhal
techniqu
facilit
condit
incorrect
inhal
use
diseas
manag
deliv
inhal
techniqu
educ
use
augment
realiti
favour
particip
particularli
around
eas
use
abil
visual
display
variou
inhal
techniqu
devic
howev
particip
identifi
barrier
particulalri
use
among
elderli
augment
realiti
may
novel
mean
address
poor
inhal
techniqu
among
certain
cohort
asthma
patient
serv
prompt
health
profession
initi
review
inhal
devic
randomis
control
trial
design
need
evalu
efficaci
technolog
use
clinic
care
set
hospit
research
foundat
coi
none
peopl
sever
refractori
asthma
sra
like
face
sizeabl
burden
beyond
peopl
milder
diseas
aim
explor
experi
peopl
live
sra
particip
identifi
sra
via
australasian
sever
asthma
network
andor
specialist
asthma
clinic
across
seven
australian
state
invit
telephon
interview
interview
conduct
consecut
new
theme
emerg
interview
record
transcrib
themat
analys
particip
age
yr
femal
experienc
daili
symptom
key
theme
bodi
hindranc
sra
place
limit
life
daili
chore
career
relationship
famili
life
alon
asthma
interviewe
felt
alon
understand
experi
asthma
suffer
emot
distress
includ
frustrat
hopeless
andor
depress
formal
emot
support
servic
lack
strive
adapt
particip
express
vari
degre
adjust
diagnosi
denial
full
accept
concern
experi
treatment
interviewe
accept
need
medicin
concern
oral
corticosteroid
dislik
relianc
treatment
felt
took
life
medic
care
particip
report
need
access
knowledg
gp
better
commun
gpsspecialist
acut
care
exacerb
frighten
participantsfamili
yet
avoid
emerg
depart
present
avoid
disrupt
hospitalis
place
daili
live
support
need
practic
emot
support
vari
none
provis
willingfatigu
famili
particip
felt
compel
push
due
parentingfinanci
respons
sra
impos
debilit
burden
consid
differ
milder
asthma
urgent
need
improv
support
servic
primari
care
sra
patient
assist
famili
fund
asthma
australia
independ
research
grant
boehring
ingelheim
glaxosmithklin
novarti
approxim
one
five
patient
attend
gener
practic
daili
smoker
inform
previou
quit
experi
smoke
cessat
prefer
smoker
attend
gener
practic
necessari
inform
effect
intervent
year
pack
year
recruit
gener
practic
across
melbourn
studi
cluster
randomis
control
trial
interdisciplinari
model
care
reduc
burden
smoke
lung
diseas
australian
primari
care
patient
complet
exhal
carbon
monoxid
co
test
confirm
smoke
statu
structur
questionnair
interview
particip
identifi
across
gener
practic
clinic
melbourn
current
smoker
daili
smoker
median
exhal
co
read
iqr
scale
low
high
motiv
median
iqr
confid
quit
median
iqr
modest
among
current
smoker
current
smoker
attempt
quit
previou
month
report
two
attempt
past
year
common
pharmacolog
treatment
use
nicotin
replac
therapi
vareniclin
popular
treatment
hypnotherapi
approxim
smoker
would
use
medic
aid
futur
quit
attempt
use
current
smoker
least
one
quit
attempt
previou
year
would
consid
help
futur
quit
attempt
current
smoker
mani
smoker
primari
care
consid
use
smoke
cessat
aid
healthcar
profession
use
motiv
counsel
emphasis
treatment
provid
support
smoker
nhmrc
cyril
tonkin
scholarship
boehring
ingelheim
lung
foundat
australia
eastern
melbourn
phn
diagnosi
manag
copd
underpin
strong
scientif
evid
local
guidelin
avail
guid
decis
make
howev
previou
studi
suggest
underdiagnosi
misdiagnosi
copd
primari
care
describ
experi
review
airway
dysfunct
interdisciplinari
care
adult
smoker
trial
australian
gener
practic
year
pack
year
includ
exist
diagnosi
copd
recruit
gener
practic
across
melbourn
follow
use
vitalograph
inc
kansa
usa
underw
spirometri
copd
diagnosi
made
base
spirometri
copd
assess
test
cat
score
modifi
medic
research
council
mmrc
dyspnoea
scale
grade
particip
individu
exist
diagnosi
copd
spirometri
referr
made
individu
spirometri
perform
confirm
copd
current
manag
copd
spirometr
confirm
test
posit
predict
valu
copd
risk
patient
use
handheld
devic
measur
subsequ
spirometri
test
reveal
continu
copd
diagnost
spirometri
essenti
avoid
misdiagnosi
copd
australian
primari
care
nhmrc
cyril
tonkin
scholarship
boehring
ingelheim
lung
foundat
australia
eastern
melbourn
phn
high
global
burden
asthma
tobacco
smoke
among
indigen
peopl
may
potenti
reduc
appropri
intervent
target
prevent
tobacco
smoke
uptak
improv
asthma
manag
undertook
pilot
studi
two
darwin
school
high
proport
indigen
youth
determin
feasibl
innov
educ
program
call
asthma
smoke
prevent
project
aspp
subset
children
report
persist
respiratori
symptom
also
clinic
evalu
determin
lower
airway
inflammatori
profil
optimis
asthma
manag
aspp
found
program
improv
asthma
manag
prevent
uptak
tobacco
smoke
program
use
approach
senior
student
peer
leader
deliv
aspp
grade
student
use
activ
video
game
student
complet
questionnair
relat
asthma
smoke
baselin
program
deliveri
student
respiratori
symptom
invit
comprehens
clinic
evalu
test
includ
sputum
induct
aspp
well
receiv
student
involv
indigen
complet
baselin
questionnair
asthma
high
student
report
smoke
report
exposur
tobacco
home
student
clinic
evalu
indigen
clinic
import
airway
inflamm
high
fraction
exhal
nitric
oxid
level
airway
neutrophilia
airway
eosinophilia
optimis
medic
manag
requir
student
studi
demonstr
feasibl
implement
prevent
intervent
program
group
high
preval
clinic
import
airway
inflamm
suboptim
asthma
manag
highlight
need
studi
persist
respiratori
symptom
adolesc
reduc
burden
chronic
lung
diseas
particularli
indigen
australian
asthma
allergi
rhinoviru
common
trigger
acut
exacerb
allerg
asthma
airway
epithelium
target
rhinoviru
infect
import
sourc
mediat
airway
epitheli
cell
aec
patient
allerg
asthma
exhibit
phenotyp
aim
characteris
cytokin
environ
allerg
asthma
alter
respons
aec
rhinoviru
investig
signal
pathway
involv
cell
human
airway
epitheli
line
cultur
without
cytokin
hour
stimul
poli
c
agonist
imiquimod
agonist
infect
quantit
pcr
ncounter
assay
use
characteris
chang
express
mrna
mediat
well
viral
molecul
allerg
cytokin
environ
enhanc
express
mrna
cytokin
induc
poli
c
imiquimod
express
respons
gene
induc
poli
c
follow
rhinoviru
infect
cell
cytokin
exhibit
significantli
higher
express
cfb
express
either
unchang
modestli
increas
cell
cytokin
alter
accompani
increas
express
pattern
recognit
receptor
gene
also
cell
surfac
receptor
rhinoviru
cytokin
appear
promot
increas
product
mediat
follow
rhinoviru
infect
furthermor
impair
host
defenc
observ
allerg
asthmat
unlik
due
effect
cytokin
increas
viral
entri
togeth
enhanc
signal
via
may
explain
exagger
inflammatori
respons
rhinoviru
infect
observ
patient
allerg
asthma
nil
previou
studi
shown
intrauterin
growth
restrict
iugr
associ
asthma
children
howev
reason
unknown
earli
childhood
preval
asthma
greater
male
femal
aim
studi
investig
impact
matern
iugr
airway
hyperrespons
male
femal
juvenil
mice
pregnant
femal
balbc
mice
hous
hypox
condit
gestat
day
iugr
group
gestat
period
day
follow
hypox
exposur
mice
return
normox
environ
second
group
pregnant
mice
hous
normox
condit
throughout
pregnanc
control
group
weight
offspr
record
week
age
point
respons
methacholin
thorac
ga
volum
tgv
assess
iugr
offspr
lighter
birth
compar
control
offspr
week
age
differ
length
abdomin
circumfer
group
week
age
week
airway
resist
methacholin
challeng
greater
male
iugr
offspr
compar
control
femal
iugr
offspr
compar
control
contrast
differ
peripher
lung
mechan
male
iugr
offspr
control
iugr
femal
offspr
increas
tissu
damp
elast
methacholin
challeng
compar
control
differ
tgv
group
matern
hypoxia
induc
iugr
offspr
smaller
birth
exhibit
catch
growth
week
age
physiolog
consequ
iugr
juvenil
period
sex
depend
airway
hyperrespons
male
offspr
impair
peripher
mechan
femal
offspr
sexual
dimorph
respons
iugr
may
contribut
differ
preval
asthma
male
femal
earli
childhood
nhmrc
asthma
foundat
wa
none
individu
suscept
otherwis
innocu
rna
virus
rhinovirus
rv
well
understood
may
link
variat
cytokin
product
viru
sens
receptor
tlr
determin
key
demograph
immunolog
genet
factor
associ
cytokin
product
cold
frequenc
document
questionnair
dna
rna
extract
whole
blood
plasmacytoid
dendrit
cell
pdc
number
assess
use
express
mononuclear
cell
stimul
rv
synthet
tlr
ligand
relationship
variabl
evalu
multivari
regress
subject
mean
age
year
women
recruit
tabl
indic
variabl
independ
associ
rv
ligand
stimul
interferon
ifn
tnf
p
p
ns
signific
cytokin
product
independ
associ
sever
variabl
particularli
sex
pdc
number
tnf
product
link
cold
frequenc
futur
experi
examin
genet
variant
predict
two
x
chromosom
gene
modifi
cytokin
product
viru
suscept
nhmrc
asthma
foundat
qld
astra
zeneca
bronchial
hyperrespons
bhr
typic
measur
use
dichotom
variabl
log
transform
dose
respons
slope
logdr
lead
loss
inform
furthermor
regress
logdr
consid
initi
result
estim
difficult
interpret
contrast
linear
mix
model
lmm
standard
biostatist
tool
appear
never
use
bhr
overcom
limit
use
data
collect
produc
intuit
estim
aim
test
util
model
bhr
use
lmm
associ
known
risk
factor
regress
logdr
use
comparison
subsampl
tasmanian
longitudin
health
studi
tah
cohort
assess
questionnair
spirometri
methacholin
challeng
repeat
measur
model
use
lmm
linear
regress
use
model
logdr
predictor
evalu
model
sex
age
height
smoke
asthma
statu
lmm
includ
random
intercept
slope
interact
dose
predictor
model
current
smoke
asthma
statu
age
associ
bhr
sex
height
former
smoke
lmm
use
assess
risk
factor
bhr
incorpor
data
like
sensit
provid
statist
power
identifi
risk
factor
nhmrc
clifford
craig
medic
research
trust
bronchoconstrict
bc
major
physiolog
event
asthma
lead
clinic
symptom
gener
mechan
forc
within
airway
asthma
characteris
period
good
health
interrupt
exacerb
asthma
exacerb
caus
respiratori
virus
includ
rhinoviru
rv
viral
exacerb
asthma
bc
viral
infect
occur
simultan
factor
may
interact
airway
studi
aim
investig
role
mechan
forc
innat
immun
rv
infect
primari
human
airway
epitheli
cell
primari
airway
epitheli
cell
asthmat
donor
collect
bronchoscopi
air
liquid
interfac
ali
cultur
establish
day
cell
infect
multipl
infect
hour
infect
control
cell
expos
apic
compress
pressur
use
air
minut
everi
hour
hour
cell
harvest
interv
sampl
analys
viral
interferon
ifn
rna
ifn
transform
growth
mucu
protein
compress
induc
releas
protein
across
time
point
hour
post
infect
control
compress
cell
produc
less
ifn
follow
infect
hour
ifnb
viru
alon
compressionviru
infl
viru
alon
sem
pgml
compressionviru
compress
also
induc
increas
viral
replic
demonstr
mechan
forc
similar
induc
bronchoconstrict
vivo
induc
product
impair
innat
immun
primari
human
airway
epitheli
cell
first
time
mechan
forc
shown
impact
innat
immun
data
direct
relev
human
diseas
univers
newcastl
post
graduat
scholarship
singleton
foundat
nil
epithelium
asthmat
differenti
dysregul
may
allow
repair
proper
regener
noxiou
stimuli
eg
virus
allergen
lead
remodel
influenza
viru
one
major
caus
asthma
exacerb
differenti
specif
microrna
eg
may
key
epigenet
factor
involv
aberr
epitheli
cell
differenti
asthmat
upon
exposur
hypothesis
impair
express
epithelium
asthmat
infect
may
link
abnorm
differenti
innat
immun
dysregul
cell
aim
determin
role
primari
bronchial
epitheli
cell
sever
asthmat
determin
target
primari
bronchial
epitheli
cell
pbec
sever
asthmat
subject
cultur
ali
condit
cell
incub
moi
mirna
mrna
isol
use
rnaeasi
mini
kit
modif
subject
taqman
mrna
assay
pbec
asthmat
infect
show
viral
titer
cell
express
decreas
infect
incresas
recov
basal
level
post
infect
cell
asthmat
express
remain
unchang
infect
express
target
mmp
induc
epigenet
regul
mrna
decreas
infect
cell
howev
cell
asthmat
express
increas
infect
remain
unchang
despit
similar
level
infect
express
differ
epitheli
cell
asthmat
infect
reduct
infect
cell
may
repres
mechan
cellular
remodel
mcdonald
jone
home
group
fm
dk
nhmrc
project
grant
dk
mucu
overproduct
patient
asthma
copd
link
increas
hospitalis
morbid
notch
famili
receptor
protein
regul
airway
mucu
product
via
differenti
mechan
direct
cell
toward
secretori
ciliat
morpholog
howev
littl
known
notch
role
mucu
product
follow
differenti
examin
impact
inhibit
notch
signal
mucu
product
fulli
differenti
primari
bronchial
epitheli
cell
pbec
control
subject
well
patient
asthma
copd
hypothes
notch
inhibit
downregul
mucu
product
pbec
donor
cohort
grown
interfac
ali
cultur
day
promot
multicellular
differenti
time
cell
treat
dibenzazepin
dbz
potent
inhibitor
notch
signal
apic
line
fluid
collect
everi
assess
releas
complet
experi
sampl
also
collect
protein
mrna
histolog
analysi
dbz
treatment
significantli
reduc
express
releas
phenotyp
assess
qpcr
elisa
immunofluoresc
western
blottingqpcr
reveal
signific
reduct
intracellular
domain
mrna
pbec
donor
phenotyp
reduc
express
also
observ
restrict
cell
follow
treatment
final
goblet
cell
marker
protein
unchang
across
treatment
notch
inhibit
reduc
express
secret
differenti
pbec
independ
goblet
cell
number
reduct
depend
occur
pbec
control
asthmat
patient
copd
suggest
notch
regul
product
independ
secretori
cell
differenti
decreas
pbec
control
donor
suggest
addit
regul
product
may
compromis
cell
copd
asthma
patient
nhmrc
project
grant
conflict
report
possibl
role
inflammasom
activ
inflamm
copd
hypothes
copd
andor
respons
cigarett
smoke
increas
activ
andor
altern
inflammasom
regul
via
signal
human
primari
alveolar
macrophag
macrophag
analys
releas
elisa
respons
cigarett
smoke
extract
express
local
asc
recruit
cleav
assess
immunofluorescenceconfoc
microscopi
andor
western
blot
effect
inhibitor
antagonist
glyburid
treatment
receptor
regul
without
exposur
cigarett
smoke
extract
investig
alveolar
macrophag
cigarett
smoke
induc
increas
intracellular
express
p
pool
data
donor
particul
stain
cleav
increas
insid
outsid
cell
fold
p
pool
data
particl
partial
particul
also
increas
macrophag
cigarett
smoke
induc
similar
complex
inhibit
glyburid
p
significantli
protect
macrophag
cigarett
activ
inflamm
cigarett
macrophag
initi
inflammasom
former
regul
signal
system
suggest
novel
therapeut
target
copd
signal
pathway
recent
implic
pathogenesi
idiopath
pulmonari
fibrosi
ipf
hypothesis
effect
involv
b
immun
regul
analys
immun
cell
composit
human
lung
biopsi
tissu
examin
effect
b
cell
deplet
lung
fibrosi
vivo
trend
toward
increas
activ
factor
april
observ
ipf
patient
serum
versu
age
match
control
addit
observ
increas
number
matur
b
cell
lung
ipf
patient
genet
deplet
b
cell
attenu
fibrosi
therapeut
potenti
deplet
follicular
b
cell
use
treatment
assess
mice
given
two
dose
antibodi
provid
genentech
inc
usa
isotyp
control
ip
day
prior
day
bleomycin
extent
fibrosi
measur
day
last
dose
fac
analysi
blood
taken
day
day
reveal
almost
complet
deplet
b
cell
howev
extent
fibrosi
assess
use
imag
hplc
analysi
hydroxyprolin
level
significantli
differ
treatment
group
although
antibodi
deplet
follicular
b
cell
effect
fibrosi
residu
b
cell
remain
lung
mice
current
studi
analys
b
cell
subset
fibrot
lung
tissu
mice
ipf
patient
work
fund
nhmrc
project
grant
british
lung
foundat
prime
grant
obes
import
risk
factor
develop
sever
asthma
dietari
fatti
acid
increas
serum
obes
peopl
activ
system
innat
immun
respons
furthermor
shown
singl
high
fat
meal
increas
airway
inflamm
impair
bronchodil
recoveri
asthma
aim
studi
investig
whether
dietari
fatti
acid
directli
caus
inflamm
andor
synergis
cytokin
human
pulmonari
fibroblast
elucid
underli
mechan
primari
human
pulmonari
fibroblast
incub
fatti
acid
stimul
anoth
releas
measur
use
elisa
act
gener
marker
inflamm
potent
neutrophil
chemoattract
follow
fatti
acid
use
arachidon
acid
aa
eicosapentaeno
acid
epa
palmit
acid
pa
satur
fatti
acid
increas
concentr
aa
induc
substanti
p
p
releas
pulmonari
fibroblast
epa
pa
induc
releas
stimul
combin
aa
result
greater
p
p
releas
aa
alon
effect
combin
releas
greater
sum
individu
effect
aa
indic
synergi
find
suggest
dietari
fatti
acid
import
modul
inflammatori
respons
interact
arachidon
acid
result
synerget
inflammatori
respons
pulmonari
fibroblast
could
indic
obes
asthmat
compar
lean
individu
prone
airway
inflamm
high
fat
meal
nil
innat
immun
respons
within
lung
mucosa
instanc
cigarett
smoke
cs
depend
activ
pattern
recognit
receptor
via
multiprotein
complex
call
inflammasom
facilit
matur
releas
cytokin
interleukin
il
recent
year
plethora
data
clinic
studi
mous
diseas
model
demonstr
excess
inflammasom
activ
promot
sever
diseas
regard
emphysema
major
debilit
compon
copd
shown
link
diseas
despit
observ
causal
role
specif
inflammasom
emphysema
unknown
therefor
aim
reveal
novel
function
link
inflammasom
activ
pathogenesi
emphysema
identifi
whether
inflammasom
promot
emphysema
utilis
genet
model
ff
spontan
emphysema
acut
day
model
characteris
elev
alveolar
type
ii
cell
atiic
apoptosi
driven
cytokin
demonstr
lung
tissu
emphysema
patient
well
spontan
ff
mice
emphysema
mous
model
character
excess
product
gene
encod
form
cytoplasm
inflammasom
protein
furthermor
genet
blockad
ff
mice
prevent
develop
emphysema
suppress
augment
atiic
apoptosi
posit
correl
also
exist
elev
mrna
level
mrna
protein
express
level
emphysema
patient
collect
defin
first
time
endogen
axi
lung
augment
atiic
apoptosi
turn
caus
emphysema
final
believ
studi
also
potenti
aid
futur
therapeut
strategi
target
inflammasom
alon
combin
human
emphysema
nil
cell
repres
bridg
innat
adapt
immun
report
increas
number
steroid
resist
senesc
cell
bal
copd
associ
increas
cytotox
bronchial
epitheli
cell
cell
express
drug
efflux
pump
loss
glucocorticoid
receptor
gcr
recent
loss
histon
deacetylas
heat
shock
protein
report
cell
copd
patient
hypothes
molecul
may
decreas
cell
particularli
subset
blood
collect
group
copd
patient
age
match
control
express
gcr
cytokin
determin
cell
presenc
prednisolon
cyclosporin
bind
complex
theophyllin
follow
cultur
use
flow
cytometri
western
blot
immunofluoresc
loss
gcr
express
identifi
cell
compar
counterpart
loss
gcr
associ
increas
product
increas
steroid
resist
upregul
gcr
note
presenc
prednisolon
low
dose
cyclosporin
increas
note
presenc
prednisolon
theophyllin
steroid
resist
cell
associ
multipl
mechan
combin
prednisolon
cyclosporin
theophyllin
treatment
therapi
inhibit
cytokin
product
cell
may
reduc
system
inflamm
copd
nhmrc
declar
interest
physic
decondit
common
patient
copd
limit
exercis
toler
test
effect
bronchodil
alon
exercis
train
ext
combin
standardis
physic
activ
selfmanag
bm
programm
exercis
endur
time
eet
patient
copd
randomis
partial
placebo
p
trial
site
australia
new
zealand
usa
canada
europ
intervent
bm
p
tiotropium
olodaterol
week
ext
ext
eet
log
transform
endur
test
eswt
symptom
limit
assess
week
primari
end
point
week
patient
men
randomis
treat
full
analysi
set
mean
l
predict
eet
significantli
increas
ext
versu
p
week
figur
patient
reach
test
termin
criteria
minut
without
symptom
limit
p
ext
week
safeti
concern
identifi
alon
combin
ext
improv
eet
eswt
compar
p
moder
sever
copd
studi
fund
boehring
ingelheim
pf
receiv
past
year
honoraria
educ
advisori
board
involv
andor
receiv
confer
attend
support
follow
global
initi
copd
gold
improv
foundat
lung
foundat
australia
remedi
healthcar
astrazeneca
boehring
ingelheim
glaxosmithklin
menarini
mundipharma
novarti
tt
princip
investig
proactiv
project
receiv
speakersconsult
fee
boehring
ingelheim
novarti
bayer
jb
receiv
research
fund
via
research
institut
mcgill
univers
health
centr
astrazeneca
boehring
ingelheim
glaxosmithklin
merck
novarti
nycom
pfizer
theratechnolog
serv
speaker
consult
panel
andor
advisori
board
pharmaceut
compani
fm
consult
boehring
ingelheim
serv
advisori
board
boehring
ingelheim
glaxosmithklin
pfizerand
receiv
payment
lectur
includ
servic
speaker
bureau
boehring
ingelheim
glaxosmithklin
nycom
pfizer
nl
employe
evidera
work
varieti
compani
organ
expressli
prohibit
receiv
payment
honoraria
directli
organ
servic
render
de
dd
lk
ah
employe
boehring
ingelheim
wj
serv
advisori
board
andor
speaker
bureau
astra
zeneca
boerhing
ingelheim
novarti
gsk
kll
receiv
grantsresearch
support
gsk
consult
fee
merck
frosst
serv
speaker
bureaushonoraria
gsk
pfizer
merck
frosst
air
liquid
health
intern
declar
interest
statement
peter
frith
receiv
past
year
honoraria
educ
advisori
board
involv
andor
receiv
confer
attend
support
follow
global
initi
copd
gold
improv
foundat
lung
foundat
australia
remedi
healthcar
astrazeneca
boehring
ingelheim
glaxosmithklin
menarini
mundipharma
novarti
field
exercis
test
eg
six
minut
walk
distanc
import
measur
function
exercis
capac
peopl
copd
shorter
test
walk
distanc
may
offer
advantag
popul
lack
inform
respons
chang
studi
examin
reliabl
valid
respons
walk
test
peopl
copd
attend
pulmonari
rehabilit
pr
assess
studi
particip
complet
walk
test
twice
addit
usual
measur
chronic
respiratori
questionnair
assess
follow
standard
pr
program
measur
repeat
global
rate
chang
score
obtain
patient
therapist
program
chang
score
examin
correl
chang
walk
distanc
use
r
estim
minim
import
differ
method
estim
base
standard
error
measur
examin
reliabl
icc
bland
altman
agreement
valid
pearson
correl
report
assess
conduct
particip
year
reliabl
walk
distanc
high
mean
differ
trial
ci
two
walk
distanc
highli
correl
p
assess
complet
patient
year
anchor
clinic
meaning
chang
minim
import
differ
walk
distanc
area
ci
agre
estim
walk
distanc
significantli
improv
sampl
contrast
qol
measur
improv
walk
distanc
least
follow
pr
program
correspond
clinic
meaning
chang
due
learn
effect
first
second
trial
practic
walk
test
recommend
nil
control
trial
psycholog
intervent
peopl
chronic
obstruct
pulmonari
diseas
copd
gener
target
generalis
anxieti
depress
randomis
control
trial
aim
determin
whether
ad
cognit
behaviour
therapi
program
sensat
breathless
comprehens
pulmonari
rehabilit
program
cprp
significantli
improv
health
outcom
beyond
achiev
cprp
alon
eight
week
cprp
cycl
repatri
gener
hospit
block
randomis
includ
cbt
breve
social
group
cpr
intervent
peopl
copd
least
moder
airflow
obstruct
pred
gold
grade
elig
inclus
primari
six
minut
walk
test
hospit
anxieti
depress
scale
secondari
outcom
multidimension
dyspnoea
profil
chronic
respiratori
crq
sedentari
physic
activ
accelerometri
symptom
score
assess
one
month
one
six
month
post
intervent
particip
feedback
sought
complet
month
assess
differ
group
intent
treat
assess
across
four
assess
point
random
effect
mix
model
particip
met
inclus
criteria
signific
p
differ
subject
elig
particip
declin
gold
grade
particip
trial
mean
age
sd
male
pred
preliminari
analysi
indic
statist
clinic
signific
differ
group
assess
point
had
analysi
secondari
outcom
ongo
particip
feedback
uniformli
posit
form
intervent
despit
overwhelmingli
posit
feedback
cbt
program
combin
cpr
cbt
program
specif
sensat
breathless
result
greater
improv
function
exercis
capac
anxieti
depress
beyond
achiev
standard
cpr
pulmonari
rehabilit
chronic
obstruct
pulmonari
diseas
cognit
behaviour
therapi
nation
health
medic
research
council
project
grant
clinic
trial
registr
downhil
walk
dw
enhanc
quadricep
contractil
muscl
fatigu
cmf
less
symptom
level
walk
lw
patient
copd
studi
sought
determin
effect
dw
compar
lw
part
comprehens
pulmonari
rehabilit
program
patient
copd
copd
patient
pred
randomis
pr
dw
lw
exercis
capac
walk
test
primari
outcom
cycl
endur
test
muscl
function
qualiti
life
assess
program
complet
train
respons
proport
patient
exceed
minim
import
differ
mid
compar
group
via
test
magnitud
improv
similar
across
outcom
group
tabl
howev
significantli
greater
proport
patient
dw
exceed
mid
compar
lw
vs
tabl
train
respons
lw
dw
result
support
use
downhil
walk
use
adjunct
pulmonari
rehabilit
program
patient
copd
grant
support
cac
cnpqbrazil
co
er
ltrf
hd
erssepar
ltrf
fwobelgium
studi
evalu
effect
qualiti
life
hrqol
endur
exercis
capac
daili
physic
activ
addit
ongo
feedback
intervent
group
ig
versu
feedback
control
group
cg
unsupervis
mainten
walk
program
follow
supervis
walk
train
program
peopl
copd
particip
randomis
baselin
ig
cg
group
complet
supervis
walk
train
program
follow
unsupervis
mainten
walk
program
ig
receiv
ongo
feedback
telephon
call
biofeedback
progress
goal
set
cg
receiv
feedback
particip
enter
mainten
program
mean
sd
age
yr
predict
complet
studi
differ
hrqol
endur
exercis
capac
daili
physic
activ
level
complet
mainten
program
compar
baselin
measur
st
georg
respiratori
questionnair
sgrq
total
score
mean
differ
md
point
ci
endur
shuttl
walk
test
eswt
time
md
second
ci
daili
step
md
step
ci
compar
assess
follow
supervis
train
sgrq
total
score
md
point
ci
eswt
time
md
second
ci
daili
step
md
step
ci
studi
demonstr
follow
supervis
walk
train
program
ongo
feedback
effect
feedback
maintain
hrqol
endur
exercis
capac
daili
physic
activ
level
peopl
copd
unsupervis
mainten
walk
program
australian
nation
health
medic
research
council
project
grant
nil
physiotherapi
six
minut
walk
test
clinic
tool
wide
use
evalu
function
exercis
capac
primari
outcom
six
minut
walk
distanc
current
practic
recognis
use
minim
import
differ
mid
key
index
respons
pulmonari
rehabilit
pr
howev
also
provid
inform
dyspnoea
heart
rate
hr
degre
desatur
nadir
achiev
test
inform
typic
consid
evalu
patient
outcom
pr
whilst
individu
may
achiev
mid
possibl
indic
may
reflect
improv
aim
studi
compar
chang
peak
dyspnoea
hr
nadir
follow
pr
particip
clinic
signific
chang
group
achiev
mid
data
retrospect
analys
subject
complet
pre
post
pr
year
period
measur
prior
immedi
follow
wk
twice
weekli
pr
program
dyspnoea
borg
scale
hr
record
immedi
end
nadir
measur
test
subject
achiev
mid
wherea
subject
achiev
mid
group
follow
pr
subject
report
lower
dyspnoea
p
lower
nadir
p
wherea
hr
remain
unchang
beatsmin
mid
group
nadir
p
lower
follow
pr
tendenc
dyspnoea
lower
end
exercis
hr
mid
group
remain
unchang
beatsmin
data
demonstr
benefit
use
data
obtain
evalu
overal
respons
pr
individu
may
show
clinic
improv
may
less
breathless
suggest
improv
respons
exercis
whilst
remain
primari
outcom
exercis
relat
indic
test
consid
evalu
overal
respons
intervent
nil
cilia
extens
cell
bodi
motil
immotil
depend
function
airway
contain
motil
cilia
move
mucu
wherea
cilia
eye
act
immotil
sensori
antenna
ciliopathi
diseas
caus
development
defect
motil
immotil
cilia
relationship
motil
ciliari
diseas
immotil
ciliari
diseas
studi
case
report
emerg
infer
patient
exist
phenotyp
consist
diseas
hypothesis
patient
immotil
ciliopathi
retin
pigmentosa
also
alter
motil
cilia
inferior
nasal
turbin
brush
sampl
airway
epithelium
patient
rang
year
retin
pigmentosa
epitheli
strip
patient
examin
videomicroscopi
captur
ciliari
waveform
beat
frequenc
epithelium
also
process
electron
microscopi
cilia
photograph
ciliari
structur
orient
quantifi
photograph
u
test
use
analys
differ
ciliari
orient
patient
without
retin
pigmentosa
ciliari
beat
frequenc
patient
retin
pigmentosa
normal
mean
ciliari
waveform
uncoordin
video
playback
mean
ciliari
deviat
normal
patient
keep
previous
publish
normal
valu
mean
ciliari
deviat
retin
pigmentosa
patient
consid
almost
random
orient
cilia
cell
surfac
data
demonstr
share
development
link
motil
immotil
cilia
may
help
explain
previous
report
predisposit
respiratori
problem
patient
retin
pigmentosa
airway
cilia
movement
uncoordin
cilia
may
malfunct
due
almost
random
ciliari
orient
clinic
evalu
requir
characteris
respiratori
histori
patient
retin
pigmentosa
nil
audio
characterist
abnorm
paediatr
breath
sound
digit
techniqu
captur
wide
investig
studi
aim
defin
audiolog
featur
abnorm
paediatr
breath
sound
object
compar
abil
digit
stethoscop
detect
auscult
use
standard
stethoscop
twenti
children
normal
breath
sound
gener
wheez
crackl
diagnosi
cystic
fibrosi
auscult
paediatr
consult
digit
record
use
digit
electron
stethoscop
digit
stethoscop
use
spectrograph
analysi
record
playback
detect
abnorm
breath
sound
defin
audio
waveform
characterist
digit
stethoscop
sensit
standard
auscult
detect
wheez
studi
patient
wheez
period
waveform
segment
increas
intens
frequenc
compar
background
breath
sound
mostli
span
expir
period
second
frequenc
occasion
span
shorter
inspiratori
segment
record
patient
crackl
reveal
brief
millisecond
discontinu
sound
distinguish
waveform
identifi
within
digit
breath
sound
analysi
may
sensit
manual
auscult
detect
breath
sound
abnorm
children
potenti
applic
improv
diagnosi
data
share
diseas
monitor
research
develop
need
nil
spacer
devic
use
current
recommend
aerosolis
corticosteroid
reduc
mouth
throat
deposit
produc
larger
particl
gener
inhal
anecdot
spacer
seldom
use
prescrib
particularli
observ
adolesc
age
group
princess
margaret
hospit
children
perth
recommend
use
spacer
may
necessari
new
asthma
medic
produc
smaller
particl
size
aerosol
aim
assess
effect
particl
size
pmdi
without
spacer
fourteen
adolesc
age
year
mild
stabl
asthma
randomis
use
pmdi
without
spacer
randomis
studi
radiolabel
corticosteroid
differ
mass
median
aerodynam
diamet
fluticason
propion
becolmethason
diproprion
inhal
use
correct
techniqu
assess
clinic
nurs
specialist
dose
drug
quantifi
immedi
gamma
camera
scan
radiat
detect
quantifi
per
region
interest
account
attenu
bodi
tissu
drug
deposit
lung
orogastr
region
compar
adolesc
inhal
drug
without
spacer
use
wilcoxon
match
pair
test
fourteen
adolesc
complet
two
visit
without
spacer
observ
signific
differ
qvar
group
lung
deposit
without
spacer
median
vs
flixotid
group
lung
deposit
without
spacer
median
vs
howev
may
power
detect
differ
given
small
sampl
size
dataset
preliminari
data
suggest
qvar
may
use
without
spacer
adolesc
provid
inhal
techniqu
assess
appropri
train
clinic
profession
would
still
recommend
flixotid
use
spacer
princess
margaret
hospit
foundat
utero
smoke
exposur
associ
abnorm
lung
function
wheez
asthma
infanc
throughout
childhood
neg
influenc
utero
smoke
exposur
modifi
genet
polymorph
gene
import
detoxifi
tobacco
includ
glutathion
gst
gene
respiratori
longterm
effect
utero
exposur
respiratori
health
adulthood
unclear
perth
infant
asthma
follow
studi
longitudin
birth
cohort
subject
recruit
antenat
gener
popul
lung
function
carri
month
year
age
antenat
smoke
histori
collect
parent
recruit
dna
collect
year
subgroup
subject
either
parent
smoke
pregnanc
associ
wheez
ci
asthma
ci
offspr
year
age
thereaft
matern
smoke
pregnanc
associ
reduc
lung
function
offspr
month
mean
vmaxfrc
sd
versu
year
age
mean
predict
sd
versu
later
assess
amongst
children
expos
utero
tobacco
smoke
homozygot
null
genotyp
associ
significantli
lower
lung
function
year
age
compar
genotyp
mean
predict
sd
versu
utero
tobacco
smoke
exposur
neg
impact
lung
function
respiratori
symptom
year
age
effect
persist
adulthood
polymorph
gene
may
contribut
wors
lung
function
children
expos
utero
tobacco
smoke
nhmrc
grant
asthma
foundat
western
australia
phd
top
scholarship
pmh
foundat
seed
grant
primari
ciliari
dyskinesia
pcd
cystic
fibrosi
cf
inherit
progress
incur
respiratori
condit
caus
signific
morbid
mortal
lung
damag
reflect
spectrum
structur
chang
detect
comput
tomographi
ct
monitor
diseas
progress
guid
therapi
score
system
ct
scan
develop
cf
quantifi
extent
sever
chang
seen
research
examin
structur
lung
chang
ct
scan
use
score
system
deriv
cf
cohort
studi
date
describ
lung
damag
pcd
use
tool
assum
lung
damag
two
condit
ident
potenti
result
failur
identifi
chang
studi
address
assumpt
retrospect
analys
ct
scan
adult
paediatr
patient
pcd
follow
abnorm
found
cf
score
accord
presenc
extent
bronchiectasi
bronchial
wall
thicken
atelectasi
mucou
plug
air
trap
addit
experienc
respiratori
radiologist
review
scan
look
presenc
abnorm
differ
bronchial
wall
thicken
common
abnorm
air
trap
least
common
abnorm
present
significantli
often
middl
lower
lobe
compar
upper
lobe
p
valu
present
abnorm
significantli
extens
middl
lower
lobe
compar
upper
lobe
bronchiectasi
mucu
plug
atelectasi
p
air
trap
present
significantli
often
pcd
cohort
respect
cf
cohort
chang
identifi
dextrocardia
extens
pattern
whole
lobe
atelectasi
interlobar
interlobular
septal
thicken
signific
structur
chang
seen
ct
scan
patient
pcd
consist
previous
describ
patient
cf
find
illustr
need
develop
score
system
function
tool
object
assess
diseas
statu
progress
efficaci
therapi
nil
earli
postnat
environ
preterm
infant
develop
rel
hyperox
compar
utero
addit
preterm
infant
often
requir
breath
support
includ
supplement
oxygen
neonat
exposur
nichd
diagnost
criterion
bronchopulmonari
dysplasia
bpd
neonat
supplement
may
alter
chemoreceptor
reset
therefor
aim
quantifi
hypox
ventilatori
respons
hvr
preterm
infant
w
gestat
neonat
period
determin
neonat
supplement
last
effect
hvr
correct
postnat
age
pna
hvr
evalu
preterm
infant
w
postmenstru
age
pma
correct
pna
breath
variabl
includ
tidal
volum
v
respiratori
rate
f
minut
ventil
v
e
inspiratori
flow
vt
measur
normox
hypox
condit
hypoxia
induc
chang
breath
variabl
assess
use
wilcoxon
test
preterm
infant
bpd
hvr
w
pma
p
contrast
hvr
present
pna
bpd
manifest
hypoxia
increas
v
mean
differ
mlkg
ci
mlkg
p
increas
v
e
mlminkg
increas
v
tt
ml
p
low
birth
weight
spearman
rho
increas
durat
supplement
associ
smaller
increas
v
hypoxia
preterm
infant
bpd
less
chang
v
v
e
hypoxia
pna
compar
preterm
infant
without
bpd
infant
born
preterm
absent
ventilatori
respons
hypoxia
neonat
period
persist
blunt
hvr
beyond
first
year
life
infant
bpd
warrant
investig
nhmrc
app
swiss
nation
scienc
foundat
chest
comput
tomographi
ct
gold
standard
detect
structur
lung
diseas
cystic
fibrosi
cf
howev
lack
outcom
measur
appropri
young
children
aim
studi
develop
valid
quantit
measur
structur
lung
diseas
children
age
year
hypothesis
outcom
biolog
relev
suitabl
use
clinic
trial
outcom
patient
undergo
annual
surveil
ct
bronchoalveolar
lavag
bal
includ
assess
structur
lung
diseas
extent
method
develop
grid
overlaid
ct
slice
annot
hierarch
presenc
bronchiectasi
bronchial
wall
thicken
mucou
plug
inspiratori
scan
trap
air
expiratori
scan
overal
diseas
di
trap
air
ta
express
proport
cell
diseas
trap
air
respect
compar
healthi
thirti
scan
randomli
select
rescor
assess
repeat
intraclass
correl
coeffici
icc
linear
mix
model
analysi
use
compar
ct
outcom
presenc
neutrophil
elastas
ne
infect
bal
scan
patient
includ
final
analysi
icc
assess
repeat
grade
excel
ct
outcom
associ
presenc
histori
ne
infect
sampl
size
calcul
show
multicentr
clinic
trial
intervent
perform
around
patient
sensit
tool
monitor
structur
lung
diseas
cf
highli
repeat
biolog
plausibl
associ
clinic
marker
lung
diseas
suitabl
use
outcom
measur
multicentr
clinic
trial
studi
provid
rational
mean
test
intervent
aim
prevent
structur
lung
diseas
young
children
cf
microrna
express
profil
interest
biomark
tuberculosi
tb
effect
therapi
mirna
profil
pulmonari
tb
patient
unknown
examin
studi
plasma
mirna
level
mirna
compar
tb
patient
match
healthi
control
china
mirna
differenti
regul
two
group
ten
analys
test
cohort
pulmonari
tb
patient
sampl
prior
commenc
antibiot
therapi
one
two
six
month
treatment
six
mirna
differenti
express
test
group
tb
patient
mir
whilst
mir
combin
mirna
distinguish
pulmonari
tb
healthi
control
sensit
specif
auc
within
one
month
treatment
signific
modul
mir
seen
success
treat
patient
although
mirna
return
baselin
complet
treatment
six
mirna
differenti
express
test
group
tb
patient
mir
whilst
mir
combin
mirna
distinguish
pulmonari
tb
healthi
control
sensit
specif
auc
within
one
month
treatment
signific
modul
mir
seen
success
treat
patient
although
mirna
return
baselin
complet
treatment
nhmrc
rl
cooper
medic
research
foundat
australian
respiratori
council
perpetu
trust
airway
inflamm
cigarett
smoke
copd
induc
autophagi
bronchial
airway
epitheli
cell
baec
zinc
zn
defici
also
stimulu
autophag
dysfunct
hypothesis
zn
defici
potenti
copd
cigarett
smoke
exposur
caus
autophag
insuffici
epitheli
fragil
aim
determin
whether
cigarett
produc
zn
dyshomeostasi
autophag
dysfunct
impair
epithelia
barrier
induc
product
phenotyp
emphysemat
mous
lung
tissu
assess
via
immunofluoresc
interfac
ali
cultur
human
baec
expos
zn
deplet
cigarett
smoke
extract
end
point
includ
western
analysi
zn
transport
autophagyapoptosi
regul
eg
light
sequestosom
inhibitor
apoptosi
xiap
tight
junction
protein
transmiss
electron
microscopi
visualis
autophagi
barrier
function
assess
includ
permeabl
fluorescein
tracer
elisa
rant
thymic
stromal
lymphopoietin
tslp
lung
tissu
cigarett
mice
show
significantli
reduc
epithelium
human
baec
stimul
show
increas
decreas
increas
autophagi
reduc
capac
degrad
cellular
debri
autophag
dysfunct
associ
induct
apoptosi
via
reduct
xiap
protein
p
reduc
epitheli
barrier
function
evid
decreas
protein
reduc
electr
imped
p
increas
permeabl
signific
increas
rant
tslp
observ
zndep
withwithout
demonstr
cigarett
smoke
deplet
airway
epithelium
zn
defici
signific
potenti
autophag
apoptot
dysregul
product
potent
inflammatori
mediat
epitheli
fragil
combin
cigarett
smoke
exposur
zn
dyshomeostasi
may
major
determin
pathogenesi
copd
phenotyp
thorac
societi
australia
new
zealand
astrazeneca
earli
career
research
fellowship
nation
health
medic
research
council
applic
royal
adelaid
hospit
research
fund
recent
advanc
implic
airway
epithelium
key
driver
asthma
pathogenesi
partli
due
dysregul
respons
damag
novel
therapi
focus
protect
repair
vulner
airway
particularli
earli
life
could
transform
asthma
treatment
prevent
diseas
developmentprogress
analys
primari
airway
epitheli
cell
paec
migrat
pattern
identifi
mechan
potenti
therapeut
target
enhanc
wound
repair
process
paec
obtain
asthmat
paediatr
airway
scratch
wound
perform
paec
monolay
assess
repair
imag
everi
minut
incucyt
essen
bioscienc
migrat
trajectori
paec
analys
use
imagej
integrin
gene
protein
express
investig
qpcr
western
respect
total
rna
sequenc
illumina
differenti
analysi
perform
ingenu
system
qiagen
respons
wound
asthmat
children
defici
lack
specif
significantli
lower
mean
migrat
distanc
asthma
veloc
direction
forward
migrat
index
major
regul
cell
migrat
ie
integrin
investig
paec
lower
gene
p
p
protein
p
p
level
paec
asthmat
children
compar
control
analysi
identifi
differenti
express
gene
asthmat
children
rel
control
overrepres
gene
ontolog
relat
integrin
extracellular
matrix
drug
databas
screen
identifi
sever
clinic
safe
drug
examin
drug
repurpos
potenti
restor
integrin
express
aid
wound
repair
novel
experi
demonstr
abnorm
migrat
behaviour
asthmat
airway
epithelium
mechan
control
diseas
phenomenon
identifi
like
decreas
integrin
multipl
transcript
mechan
dysregul
asthmat
target
exist
drug
support
airway
epitheli
repair
barrier
integr
may
novel
therapeut
avenu
asthma
nhmrc
apa
uwa
centr
cell
therapi
regen
medicin
phd
scholarship
asthma
foundat
wa
fiona
staniforth
phd
scholarship
ann
woolcock
new
investig
award
janet
elder
intern
travel
award
oral
prize
none
rhinoviru
infect
trigger
acut
exacerb
asthma
express
instruct
cytokin
type
inflamm
upregul
experiment
rhinoviru
infect
asthmat
subject
correl
product
cytokin
eosinophil
inflamm
use
novel
model
viru
allergen
exposur
sought
determin
whether
therapi
attenu
asthma
exacerb
mice
simul
synergist
effect
viru
infect
allergen
exposur
asthma
suscept
mice
expos
low
dose
pneumonia
viru
mous
pvm
low
dose
cockroach
antigen
cre
earli
life
later
life
four
week
final
cre
exposur
mice
inocul
rhinoviru
dexamethason
administ
intraperiton
twiceweek
cre
rv
challeng
daili
euthanasia
exposur
pvm
cre
necessari
diseas
onset
progress
level
elev
immedi
follow
final
cre
exposur
persist
airway
time
challeng
mice
pvmcre
cre
pvm
alon
present
eosinophil
inflamm
increas
number
type
innat
lymphoid
cell
mucou
hypersecret
elev
level
follow
rv
infect
treatment
dexamethason
attenu
type
inflamm
effect
mucou
product
critic
dexamethason
promot
express
antivir
cytokin
acceler
viral
clearanc
dexamethason
suppress
magnitud
type
inflamm
acut
exacerb
howev
ad
benefit
boost
antivir
immun
lower
viral
burden
pfizer
inc
australian
infecti
diseas
research
excel
award
univers
queensland
end
life
eol
trajectori
chronic
obstruct
pulmonari
diseas
copd
known
complic
prognost
potenti
prevent
time
transit
palli
care
thu
primari
respons
care
provis
remain
famili
person
copd
aim
explor
experi
older
peopl
live
stage
iv
copd
rural
commun
copd
influenc
relationship
ident
eleven
older
peopl
stage
iv
copd
live
region
nsw
undertook
narr
interview
discuss
copd
journey
interview
transcrib
analys
interpret
accord
hermeneut
phenomenolog
methodolog
spousal
care
gener
well
accept
expect
marri
particip
extens
marit
role
howev
adult
children
involv
care
decis
make
particip
express
guilt
frustrat
perceiv
actual
burden
place
burden
ground
experi
care
love
one
flow
effect
uptak
cope
treatment
strategi
advanc
care
plan
acp
well
creat
commun
barrier
parti
parent
aim
protect
adult
children
distress
impact
live
prioritis
children
wish
whilst
simultan
need
diseas
specif
inform
paradox
mani
particip
went
design
acp
refus
treatment
rather
extend
impact
children
live
contrari
children
acp
request
protect
adult
children
primari
determin
end
life
decis
make
critic
establish
formal
effect
commun
pathway
famili
health
profession
facilit
good
death
within
famili
group
charl
sturt
univers
faculti
scienc
fee
waiver
higher
degre
research
student
increas
interest
role
physic
activ
pa
develop
asthma
potenti
asthma
influenc
pa
hinder
progress
understand
given
lack
relev
longitudin
data
children
primari
aim
studi
explor
whether
asthma
lead
lower
pa
level
whether
lower
pa
level
lead
asthma
children
adolesc
age
year
analysi
conduct
children
particip
longitudin
studi
australian
children
lsac
age
data
asthma
pa
collect
via
questionnair
time
use
diari
biennial
sinc
children
year
old
relationship
investig
use
model
pa
asthma
implement
use
structur
equat
model
asthma
defin
doctor
diagnosi
sinc
previou
wave
either
use
asthma
medic
current
wheez
past
month
pa
time
minut
spent
medium
vigor
physic
activ
day
includ
confound
gender
older
sibl
socioeconom
bodi
mass
index
bmi
effect
estim
regress
suggest
associ
pa
asthma
age
either
direct
adjust
regress
coeffici
effect
asthma
subsequ
pa
similarli
adjust
log
effect
pa
asthma
age
result
suggest
pa
observ
age
prospect
predict
asthma
longitudin
analysi
similarli
asthma
predict
futur
pa
observ
age
na
author
report
conflict
interest
author
alon
respons
content
write
paper
asthma
adolesc
children
physic
activ
respons
biolog
therapi
differ
among
sever
allerg
asthma
saa
patient
therapi
may
help
identifi
subgroup
demonstr
greater
clinic
benefit
omalizumab
overal
saa
popul
analysi
innov
trial
data
humbert
et
al
allergi
perform
determin
impact
treatment
exacerb
rate
aqlq
saa
patient
stratifi
peripher
blood
eosinophil
per
mcl
eo
serum
ige
iuml
neg
binomi
regress
util
within
biomark
strata
estim
respons
omalizumab
vs
placebo
control
potenti
confound
exacerb
reduct
observ
among
patient
vs
placebo
strata
exacerb
reduct
increas
upon
enrich
strata
accord
increas
ige
iuml
mean
benefit
aqlq
exceed
minim
differ
demonstr
statist
signific
improv
strata
p
benefit
aqlq
appar
stratum
p
analysi
among
first
examin
combin
biomark
assess
respons
omalizumab
saa
patient
suggest
subgroup
combin
increas
ige
eo
may
experi
greater
clinic
benefit
howev
caution
must
use
interpret
result
given
natur
analysi
support
novarti
pharma
ag
genentech
asthma
heterogen
inflammatori
disord
consist
multipl
endotyp
neutrophil
asthma
na
innat
immun
activ
tend
resist
corticosteroid
therapi
shown
asthma
involv
innat
cytokin
specul
involv
respons
aim
studi
examin
express
asthma
inflammatori
phenotyp
determin
relationship
immun
factor
involv
asthma
pathogenesi
hypothesis
sputum
gene
express
would
increas
particip
na
compar
asthma
phenotyp
induc
sputum
sampl
adult
stabl
asthma
assess
total
differenti
cell
count
along
gene
express
inflammatori
phenotyp
determin
use
singl
sputum
sampl
eosinophil
asthma
ea
neutrophil
neutrophil
asthma
na
neutrophil
eosinophil
paucigranulocyt
asthma
pa
eosinophil
neutrophil
particip
mean
age
year
male
prescrib
inhal
corticosteroid
predict
lowest
na
mean
significantli
lower
pa
sputum
gene
express
subunit
significantli
increas
na
compar
ea
furthermor
express
na
significantli
p
higher
pa
particip
mrna
level
significantli
neg
correl
degre
airflow
obstruct
p
gene
express
subunit
mrna
posit
associ
sputum
total
cell
count
p
neutrophil
p
age
p
elev
gene
express
suggest
may
import
cytokin
pathogenesi
na
nhmrc
canada
research
chair
program
vocal
cord
dysfunct
vcd
character
inappropri
adduct
vocal
cord
give
rise
symptom
dyspnea
voic
chang
wheez
throat
tight
vcd
misdiagnos
asthma
result
delay
inappropri
treatment
high
proport
patient
asthma
report
also
vcd
one
hundr
seventeen
consecut
difficult
asthma
patient
refer
respiratori
specialist
underw
alfr
assess
protocol
vocal
cord
dysfunct
diagnos
either
ent
specialist
clinic
base
characterist
symptom
support
posit
pittsburgh
vcd
index
univari
analys
perform
identifi
clinic
factor
associ
vocal
cord
dysfunct
predictor
comar
use
unpair
test
appropri
predictor
includ
multivari
logist
regress
model
predictor
assess
confound
signific
continu
variabl
express
mean
sd
forti
difficult
asthma
patient
vcd
major
also
asthma
demonstr
variabl
airflow
obstruct
patient
vcd
like
femal
ci
poorer
asthma
control
qualiti
life
act
vs
aqlq
vs
p
frequent
exacerb
versu
six
month
less
sever
obstruct
ratio
vs
multivari
logist
regress
independ
predictor
vcd
aqlq
vcd
present
third
patient
difficult
asthma
vcd
associ
femal
sex
poorer
asthma
outcom
despit
better
lung
function
improv
lung
function
poorer
qualiti
life
independ
predictor
vcd
find
highlight
import
identifi
address
vcd
challeng
patient
group
nil
express
high
postn
genotyp
shown
predict
respons
inhal
steroid
mild
asthma
gene
signatur
sputum
cell
clc
alpl
distinguish
asthma
inflammatori
phenotyp
aim
determin
gene
express
signatur
endobronchi
biopsi
adult
asthma
relat
asthma
sever
airway
inflammatori
phenotyp
adult
asthma
current
respiratori
symptom
evid
variabl
airflow
obstruct
asthma
sever
defin
accord
gina
inflammatori
phenotyp
use
bal
cell
count
gene
analyz
qpcr
use
extract
rna
biopsi
evalu
sever
asthma
mildmoder
asthma
differ
age
sex
atopi
smoke
histori
group
gene
express
significantli
increas
sever
compar
mildmoder
asthma
invers
associ
predict
particip
asthma
gene
express
clc
significantli
increas
eosinophil
asthma
compar
paucigranulocyt
asthma
respect
alpl
increas
eosinophil
compar
asthma
gene
express
clc
associ
asthma
bal
eosinophil
gene
express
increas
neutrophil
compar
paucigranulocyt
asthma
significantli
associ
bal
neutrophil
express
bronchial
biopsi
associ
sever
asthma
clc
gene
express
associ
bal
eosinophilia
neutrophilia
respect
john
hunter
hospit
charit
trust
viral
respiratori
infect
trigger
sever
exacerb
asthma
worsen
diseas
symptom
impair
lung
function
investig
mechan
underli
viral
exacerb
establish
mous
model
respiratori
syncyti
viru
rsv
exacerb
allergen
sensitis
challeng
investig
effect
rsv
infect
induct
asthma
exacerb
mous
model
airway
ahr
assess
flexiv
experi
pulmonari
macrophag
deplet
neutral
monoclon
antibodi
rsv
infect
balbc
mice
result
significantli
increas
ahr
macrophag
neutrophil
lung
infiltr
exacerb
accompani
increas
level
inflammatori
cytokin
includ
kc
compar
uninfect
mice
mice
expos
rsv
dexamethason
treatment
complet
inhibit
featur
allerg
diseas
includ
ahr
eosinophil
infiltr
uninfect
mice
convers
dexamethason
treatment
follow
exacerb
partial
suppress
ahr
fail
dampen
macrophag
neutrophil
infiltr
inflammatori
cytokin
product
kc
mimic
clinic
observ
patient
exacerb
associ
increas
neutrophil
often
poorli
respond
corticosteroid
therapi
interestingli
also
observ
increas
level
sputum
sampl
neutrophil
asthmat
patient
exacerb
resist
steroid
treatment
inhibit
function
deplet
macrophag
suppress
featur
diseas
includ
ahr
macrophag
neutrophil
infiltr
find
highlight
critic
role
macrophag
inflammatori
cytokin
includ
exacerb
asthma
suggest
examin
pathway
novel
therapeut
approach
diseas
manag
rsv
macrophag
steroid
resist
airway
hyperrespons
asthma
exacerb
mous
model
nomin
new
investig
award
na
airway
epitheli
cell
aec
cf
lung
respond
viral
infect
poor
innat
immun
respons
contribut
defect
cf
transmembran
conduct
regul
cftr
channel
function
known
investig
whether
cftr
correct
drug
could
improv
respons
cf
aec
human
rhinoviru
hrv
primari
aec
obtain
children
cf
five
class
ii
six
class
iii
mutat
six
healthi
control
bronchial
brush
expand
vitro
monolay
stimul
purifi
multipl
infect
hour
without
hour
treatment
cftr
therapi
lumacaftor
andor
ivacaftor
rna
collect
sequenc
illumina
hiseq
platform
supernat
assess
elisa
interferon
ifn
inflammatori
cytokin
data
interpret
ratio
treatment
respons
unstimul
aec
healthi
aec
stimul
result
increas
rant
respons
healthi
aec
significantli
chang
presenc
cftr
modul
contrast
aec
cf
genotyp
gener
respons
p
interestingli
respons
cf
aec
longer
signific
follow
cftr
modul
treatment
combin
cftr
therapi
class
ii
cf
also
found
reduc
rant
product
p
ifn
respons
mix
minim
level
detect
follow
stimul
except
elev
cf
aec
supernat
p
longer
signific
cftr
modul
therapi
class
ii
ii
p
cftr
therapi
effect
respons
cf
aec
current
analys
rnaseq
data
compar
innat
immun
gene
network
treatment
phenotyp
glenn
brown
memori
grant
us
cystic
fibrosi
foundat
iron
homeostasi
appear
abnorm
lung
individu
genet
diseas
cystic
fibrosi
cf
disrupt
iron
homeostasi
lung
may
promot
bacteri
infect
gener
oxid
stress
therefor
test
hypothesi
iron
homeostasi
airway
epitheli
cell
aec
cf
patient
abnorm
result
oxid
stress
cultur
aec
cf
patient
mutat
immort
cell
line
expos
ferric
ammonium
citrat
fac
respons
iron
regulatori
pathway
assess
revers
transcript
polymeras
chain
reaction
proteom
interleukin
il
level
also
assess
aec
cultur
supernat
determin
whether
iron
exposur
result
respons
control
aec
immort
cell
line
underw
ident
challeng
procedur
comparison
cf
aec
demonstr
signific
increas
express
transferrin
receptor
tfr
iron
uptak
baselin
challeng
compar
aec
aec
also
demonstr
signific
increas
express
iron
export
ferroportin
fpn
baselin
compar
aec
follow
fac
challeng
express
significantli
reduc
aec
express
fpn
remain
essenti
unchang
level
significantli
increas
cftr
mutant
compar
aec
supernat
baselin
aec
line
demonstr
signific
increas
product
follow
fac
challeng
preliminari
pathway
analys
proteom
data
reveal
signific
differenti
express
protein
involv
oxid
stress
mitochondri
stress
respons
compar
aec
airway
epithelium
cf
demonstr
abnorm
iron
regul
exhibit
phenotyp
activ
cell
pathway
involv
oxid
stress
iron
cystic
fibrosi
airway
epitheli
cell
new
investig
award
nhmrc
tpch
foundat
chest
comput
tomographi
ct
potenti
surrog
endpoint
children
cystic
fibrosi
cf
relationship
structur
abnorm
earli
age
long
term
function
outcom
previous
describ
aim
determin
whether
ct
score
children
year
predict
later
lung
function
volumetr
limit
slice
ct
scan
obtain
annual
children
enrol
arest
cf
program
age
year
follow
spirometri
measur
avail
arest
cf
cohort
age
cox
regress
mix
effect
model
use
determin
age
extent
score
predict
futur
lung
function
declin
result
present
adjust
intrins
diseas
sever
homozyg
mutat
meconium
ileu
presenc
gender
time
elaps
ct
scan
spirometri
test
centr
spirometri
measur
avail
mean
age
year
total
score
year
greater
median
significantli
associ
shorten
time
fall
z
score
hazard
ratio
extent
mucu
plug
trap
air
age
year
strongli
associ
lower
z
score
age
p
respect
predict
power
ct
score
young
children
consist
stronger
time
elaps
initi
ct
scan
spirometri
mucu
plug
score
explain
variat
z
score
age
variat
year
later
lung
abnorm
young
children
cf
import
marker
futur
diseas
progress
structur
abnorm
predict
futur
trajectori
repres
promis
endpoint
earli
intervent
trial
nhmrc
usa
cf
foundat
cf
foundat
usa
recent
updat
infect
control
guidelin
includ
recommend
patient
cystic
fibrosi
cf
wear
surgic
face
mask
commun
area
health
facil
reduc
transmiss
aerosolis
pathogen
aim
studi
investig
effect
face
mask
cough
etiquett
techniqu
reduc
viabl
bioaerosol
patient
cf
chronic
p
aeruginosa
infect
subject
enrol
adult
cf
centr
princ
charl
hospit
brisban
posit
valid
devic
perform
activ
minut
surgic
mask
cough
surgic
mask
mask
hand
cover
mouth
andersen
cascad
impactor
posit
metr
collect
size
viabl
aerosol
quantit
sputum
aerosol
cultur
perform
subject
rate
comfort
level
mask
male
adult
mean
sd
age
year
predict
enrol
subject
produc
viabl
p
aeruginosa
unmask
cough
cough
etiquett
surgic
mask
reduc
infecti
cough
aerosol
respect
surgic
mask
rate
comfort
face
mask
effect
reduc
cough
gener
infecti
droplet
nuclei
peopl
cf
surgic
mask
provid
enhanc
patient
comfort
cough
etiquett
provid
less
protect
mask
cff
therapeut
usa
princ
charl
hospit
foundat
australia
infect
play
critic
role
pathogenesi
earli
cystic
fibrosi
cf
lung
diseas
differ
nasopharyng
microbiota
subject
cf
healthi
control
appar
earli
infanc
studi
aim
compar
composit
structur
lower
airway
microbiota
infant
month
age
without
cf
bronchoscopi
bronchoalveolar
lavag
bal
procedur
perform
infant
newli
diagnos
cf
follow
newborn
screen
infant
undergo
bronchoscopi
recruit
control
quantit
microbiolog
cultur
inflammatori
marker
neutrophil
elastas
measur
undertaken
contemporan
ribosom
rna
gene
sequenc
conduct
store
sampl
seventeen
infant
cf
median
age
month
interquartil
rang
iqr
month
male
homozyg
nine
control
infant
median
age
month
iqr
month
male
contribut
bal
sampl
divers
reduc
cf
compar
control
bal
sampl
median
shannon
divers
index
iqr
iqr
respect
firmicut
preval
phylum
group
accout
total
read
respect
howev
staphylococcu
predomin
cf
sampl
total
read
next
preval
genera
cf
sampl
streptococcu
haemophilu
granulicatella
gemella
contrast
five
abund
genera
control
sampl
streptococcu
fusobacterium
neisseria
gemella
veillonella
staphylococcu
haemophilu
account
total
read
substanti
perturb
structur
composit
lower
airway
microbiota
infant
cf
first
month
life
notabl
increas
preval
staphylococcu
reduc
divers
larger
longitudin
studi
requir
determin
clinic
signific
find
kbf
support
tsanzvertex
cf
paediatr
clinic
fellowship
australian
cystic
fibrosi
research
trust
postgradu
studentship
royal
children
hospit
cystic
fibrosi
research
trust
rrna
gene
sequenc
fund
grant
murdoch
children
research
institut
cf
rch
cf
research
trust
twf
scr
ga
kmw
support
nation
institut
health
nih
grant
nation
health
medic
research
council
award
bodi
role
studi
design
data
analysi
interpret
report
result
conflict
interest
six
minut
walk
test
object
tool
use
assess
function
exercis
capac
cystic
fibrosi
cf
howev
relationship
outcom
need
hospitalis
treatment
pulmonari
exacerb
pe
studi
therefor
primari
aim
determin
relationship
six
minut
walk
distanc
subject
breathless
modifi
borg
score
oxygen
satur
frequenc
durat
hospitalis
adult
cf
retrospect
cohort
studi
adult
cf
patient
treat
princ
charl
hospit
brisban
complet
maximum
modifi
borg
score
nadir
correl
number
hospit
admiss
total
hospit
day
treatment
pe
calendar
year
perform
subject
mean
age
predict
median
iqr
hospit
admiss
median
iqr
hospit
day
reduc
significantli
correl
number
yearli
hospit
admiss
total
yearli
hospit
day
treatment
pe
howev
strongest
correl
seen
maximum
modifi
borg
score
nadir
total
hospit
day
tabl
maximum
perceiv
breathless
oxygen
desatur
strongli
correl
hospit
utilis
distanc
walk
suggest
subject
exert
dyspnoea
hypoxaemia
may
import
predictor
exacerb
frequenc
nil
whilst
much
focu
legal
claim
arena
asbesto
coal
worker
pneumoconiosi
queensland
past
month
justifi
showcas
lung
diseas
caus
toxic
exposur
work
senat
select
committe
health
state
fifth
interim
report
april
litani
regul
failur
regulatori
captur
industri
indiffer
incompet
inconsist
risk
mitig
patchi
sometim
compromis
health
monitor
australia
respons
return
diseas
consid
erad
year
ago
theodora
ahila
present
right
compens
worker
occup
lung
diseas
theodora
discuss
legal
entitl
flow
diagnosi
occup
lung
diseas
differ
legal
statutori
entitl
follow
differ
state
togeth
complex
assess
claim
particularli
presenc
littl
known
mani
australian
expos
potenti
hazard
agent
workplac
lifetim
assess
exposur
statu
use
current
job
data
miss
earlier
exposur
potenti
effect
account
chang
occup
exposur
time
analysi
determin
proport
nation
sampl
australian
adult
potenti
hazard
agent
work
life
individu
recruit
telephon
particip
studi
control
nation
sampl
idiopath
pulmonari
fibrosi
ipf
case
australia
individu
match
age
sex
state
consent
particip
complet
telephon
interview
collect
data
includ
demograph
environment
exposur
detail
occup
histori
report
job
code
finnish
job
exposur
matrix
finjem
assign
associ
exposur
relev
time
period
particip
consid
expos
agent
job
probabl
exposur
data
job
particip
occup
histori
collat
assess
lifetim
exposur
statu
descript
statist
conduct
assess
proport
particip
complet
interview
male
femal
age
report
total
job
finjem
analysi
produc
follow
result
respir
dust
anim
dust
iron
plant
dust
asbesto
environment
tobacco
smoke
mould
quartz
dust
silica
analysi
occup
exposur
data
yield
higher
proport
dusti
environ
gasesfumeschem
asbesto
silica
expect
significantli
male
expos
femal
agent
p
consider
number
older
australian
expos
potenti
harm
agent
within
work
life
data
lifetim
occup
exposur
requir
examin
potenti
occup
risk
factor
diseas
ipf
nation
health
medic
research
council
project
grant
mja
hold
investig
initi
grant
unrel
research
pfizer
author
declar
compet
interest
develop
progress
chronic
lung
diseas
bronchiectasi
involv
recurr
episod
sever
bacteri
respiratori
infect
inhal
environment
dust
exposur
exacerb
immun
respons
respiratori
infect
mice
whether
dust
exposur
lead
common
sever
bacteri
infect
human
airway
yet
known
aim
determin
impact
geogen
dust
particul
matter
diamet
immort
human
airway
epitheli
cell
particular
aim
determin
effect
haemophilu
influenza
nthi
infect
geogen
dust
collect
remot
town
western
australia
extract
cell
expos
pb
vitro
addit
live
moi
trypan
blue
stain
use
determin
cell
viabil
bacteri
infect
attach
invas
determin
use
gentamicin
surviv
assay
epitheli
releas
assess
use
bead
base
immunoassay
cell
dust
significantli
increas
abil
nthi
attach
invad
cell
p
respect
dust
exposur
respons
increas
respons
suppress
geogen
dust
prepar
increas
nthi
infect
human
airway
cell
may
contribut
common
sever
respiratori
infect
import
implic
lung
health
individu
live
arid
environ
remot
australia
expos
high
load
geogen
dust
brightspark
foundat
rain
medic
research
foundat
none
australian
aborigin
children
much
higher
incid
infecti
diseas
counterpart
mani
aborigin
commun
expos
high
level
ambient
dust
geogen
origin
previous
report
associ
dust
exposur
poor
health
remot
aborigin
commun
aim
studi
examin
associ
dust
exposur
infecti
diseas
aborigin
children
collect
data
dust
level
dust
suppress
program
commun
survey
environment
health
need
survey
ehn
remot
aborigin
commun
western
australia
health
data
infecti
diseas
hospitalis
record
western
australia
aborigin
child
health
survey
waach
link
ehn
odd
ratio
associ
health
outcom
exposur
calcul
use
multivari
logist
regress
model
within
framework
take
account
hierarch
structur
data
dust
exposur
level
associ
preval
infecti
diseas
children
p
comparison
lack
dust
suppress
program
associ
increas
risk
chronic
ear
infect
ci
p
higher
level
dust
exposur
associ
increas
risk
hospitalis
upper
ci
lower
ci
respiratori
tract
infect
lack
dust
suppress
program
associ
increas
risk
hospitalis
skin
infect
ci
gastrointestin
diseas
ci
acknowledg
dust
exposur
instanc
data
suggest
exposur
high
level
geogen
dust
may
contribut
increas
preval
sever
infecti
diseas
aborigin
children
nil
identifi
radiolog
pattern
sever
queensland
case
coal
worker
pneumoconiosi
correl
clinic
symptom
occup
histori
retrospect
review
ct
plain
radiograph
find
twenti
coal
miner
radiolog
clinic
diagnosi
coal
worker
pneumoconiosi
radiolog
grade
diseas
base
ilo
classif
correl
clinic
symptom
length
occup
exposur
job
role
statist
analysi
perform
fisher
exact
test
categor
data
wilcoxon
test
continu
data
preliminari
result
highlight
difficulti
diagnosi
coal
worker
pneumoconiosi
although
data
collect
ongo
radiolog
grade
major
case
date
low
grade
ilo
addit
case
seri
highlight
earli
stage
coal
worker
present
soft
ground
glass
nodul
low
densiti
therefor
extrem
difficult
detect
plain
radiograph
case
progress
massiv
fibrosi
coal
exposur
alon
clinic
occup
histori
predict
diagnosi
patient
symptomat
cough
strong
occup
histori
dust
exposur
resurg
coal
worker
pneumoconiosi
queensland
worker
occup
histori
heavi
dust
exposur
usual
symptomat
radiograph
chang
often
subtl
particularli
plain
radiograph
nil
assess
commun
health
impact
particl
exposur
event
eg
fire
difficult
one
approach
involv
collect
particl
sampl
expos
dwell
proxi
particl
gener
exposur
event
follow
studi
fire
collect
particl
ceil
hous
differ
distanc
particl
sourc
use
mous
model
aim
determin
whether
utero
exposur
particl
alter
lung
function
mous
dam
intranas
expos
ceil
particl
salin
carbon
black
particl
control
salin
alon
gestat
day
e
two
week
age
lung
volum
tgv
lung
mechan
airway
resist
raw
tissu
damp
g
tissu
elast
h
measur
anaesthetis
tracheostomis
mice
use
plethysmographi
forc
oscil
techniqu
fot
respect
effect
utero
exposur
ceil
dust
carbon
particl
tgv
mice
femal
p
male
p
similarli
effect
exposur
particl
raw
femal
p
male
p
g
femal
p
male
p
howev
effect
femal
p
male
mice
expos
ceil
dust
p
carbon
p
higher
h
magnitud
respons
associ
distanc
particl
sourc
utero
exposur
particl
ceil
dust
increas
lung
stiff
male
mice
data
suggest
exposur
ceil
dust
may
impact
lung
growth
sex
specif
manner
respons
appear
unrel
rel
contamin
ceil
dust
particl
combust
sourc
uta
research
enhanc
grant
scheme
car
cre
author
declar
compet
interest
despit
grow
worldwid
recognit
bronchiectasi
caus
substanti
morbid
healthcar
utilis
littl
known
preval
burden
diseas
australian
new
zealand
australasian
bronchiectasi
registri
abr
establish
fill
gap
promot
intern
collabor
research
comprehens
registri
develop
australasian
bronchiectasi
consortium
support
lung
foundat
australia
lfa
european
embarc
us
bronchiectasi
registri
common
data
field
ensur
interoper
futur
collabor
uniqu
captur
inform
specif
australia
new
zealand
investig
identifi
particip
episod
care
local
databas
patient
elig
bronchiectasi
report
comput
tomographi
chest
scan
patient
demograph
clinic
inform
obtain
baselin
annual
review
clinic
exacerb
linkag
medicar
pharmaceut
benefit
scheme
pb
inform
provid
opportun
studi
health
care
resourc
utilis
first
step
toward
region
standardis
registri
project
initi
hospit
includ
adult
paediatr
metropolitan
region
site
enrol
commenc
pilot
site
concord
hospit
march
octob
undertaken
site
remaind
await
research
govern
approv
date
patient
enrol
femal
mean
age
year
abr
secur
platform
captur
first
comprehens
longitudin
data
set
patient
bronchiectasi
australia
new
zealand
uniqu
featur
includ
use
consent
collect
paediatr
data
linkag
pbsmedicar
data
allow
first
time
topograph
map
bronchiectasi
australia
new
zealand
abr
initi
lfa
support
copd
foundat
embarc
bayer
insm
aradigm
pfizer
immunocompromis
haematolog
patient
increas
risk
develop
invas
pulmonari
infect
signific
morbid
mortal
pulmonari
sepsi
suspect
usual
practic
perform
chest
imag
refer
fibreopt
bronchoscopi
fob
evalu
diagnost
yield
bal
impact
time
complic
rate
singl
centr
cohort
perform
retrospect
studi
patient
haematolog
condit
undergo
fob
search
alfr
bronchoscopi
databas
review
electron
medic
record
patient
underw
bronchoscopi
averag
age
year
rang
year
bronchoscopi
perform
within
hour
hrct
within
hour
sixti
percent
patient
return
posit
bal
cultur
fungi
common
follow
bacteri
viral
malign
caus
radiolog
diagnosi
suggest
correl
bal
find
case
bal
find
concord
sputum
isol
viral
swab
major
complic
record
experienc
minor
bleed
bal
yield
may
limit
late
referr
treatment
commenc
prior
bal
caus
complic
poorli
record
impact
manag
difficult
determin
find
new
organ
like
lead
commenc
new
therapi
neg
find
unlik
lead
rationalis
treatment
bal
import
role
diagnosi
invas
pulmonari
infect
haematolog
patient
centr
demonstr
high
diagnost
yield
prompt
perform
procedur
like
low
complic
rate
none
declar
nil
pathogen
detect
hospit
diagnost
microbiolog
laboratori
hdml
standard
oper
procedur
diagnosi
howev
caus
pathogen
often
identifi
symptomat
respiratori
tract
infect
studi
compar
pathogen
detect
research
laboratori
hdml
determin
differ
test
sensit
commun
acquir
respiratori
virus
carv
sampl
deriv
prospect
longitudin
studi
lung
transplant
ltx
recipi
swab
donor
explant
lung
collect
well
bronchoalveolar
lavag
bal
fluid
day
bal
sampl
replic
sent
hdml
research
laboratori
multipl
uniplex
pcr
run
human
rhinoviru
hrv
respiratori
syncyti
viru
influenza
flu
influenza
b
flu
b
parainfluenza
viru
piv
human
metapneumoviru
consecut
ltx
subject
recruit
bilater
heart
lung
age
year
mean
follow
day
rang
day
use
multiplex
pcr
hdml
detect
flu
flu
b
donor
swab
plu
hrv
bal
sampl
research
laboratori
detect
flu
swab
explant
lung
plu
bal
hrv
flu
n
flu
b
n
piv
overal
concord
unweight
kappa
se
pcr
use
research
laboratori
appear
greater
sensit
carv
detect
compar
hdml
multiplex
pcr
perhap
reflect
greater
cycl
threshold
valu
allow
detect
lower
viral
load
research
laboratori
carv
particular
flu
common
earli
ltx
import
low
level
persist
carv
follow
ltx
yet
elucid
nil
pleural
effus
common
complic
pneumonia
chronic
diseas
pleural
procalcitonin
postul
use
differenti
parapneumon
effus
ppe
aetiolog
aim
assess
util
addit
pleural
procalcitonin
measur
differenti
ppe
consecut
patient
pleural
effus
requir
thoracentesi
recruit
clinic
anthropometr
data
record
pleural
fluid
serum
collect
standard
analysi
addit
procalcitonin
level
measur
ppe
identifi
exud
effus
light
criteria
pleuralserum
ratio
protein
lactat
dehydrogenas
ldh
radiolog
evid
lower
respiratori
tract
infect
malign
pleural
effus
exclud
data
compar
use
mann
whitney
test
unpair
correl
analysi
via
spearman
p
consid
signific
patient
year
male
ppe
pleural
serum
ratio
significantli
differ
p
protein
ppe
median
iq
rang
ldh
ppe
serum
procalcitonin
equival
ppe
ugl
vs
ugl
respect
pleural
procalcitonin
significantli
greater
ppe
compar
ugl
ugl
respect
p
signific
differ
ppe
serum
crp
mgl
vs
mgl
pleural
ldh
ul
vs
ul
serum
wcc
vs
p
serum
pleural
procalcitonin
correl
significantli
ppe
r
p
compar
pleural
procalcitonin
significantli
greater
subject
ppe
correl
serum
procalcitonin
howev
differ
small
unlik
assist
clinic
manag
ppe
effus
nil
emerg
organ
link
injudici
antibiot
prescrib
previous
show
singl
educ
session
increas
adher
antibiot
guidelin
chronic
obstruct
pulmonari
diseas
copd
commun
acquir
pneumonia
cap
aim
measur
effect
educ
intervent
data
collect
respiratori
admiss
australian
tertiari
hospit
cap
copd
exacerb
three
consecut
month
period
period
oct
period
period
oct
follow
period
emerg
respiratori
depart
staff
attend
educ
session
adher
guidelin
period
compar
earlier
period
use
test
independ
proport
period
compris
patient
copd
cap
year
length
hospit
stay
loh
day
death
period
patient
copd
cap
year
loh
day
death
period
patient
copd
cap
year
loh
day
death
period
appropri
initi
antibiot
prescrib
copd
improv
p
decreas
subsequ
month
signific
reduct
period
p
compar
rate
guidelin
adher
cap
improv
immedi
declin
toward
rate
period
sustain
improv
appropri
chang
antibiot
cap
period
period
mortal
significantli
differ
period
loh
significantli
lower
period
copd
cap
educ
intervent
led
signific
increas
adher
antibiot
guidelin
copd
cap
impact
wane
time
count
ratio
nlcr
demonstr
use
predict
marker
diseas
sever
retrospect
studi
investig
prognost
impact
biomark
patient
influenza
infect
retrospect
analys
patient
confirm
influenza
andor
b
infect
nasopharyng
swab
juli
septemb
clinic
characterist
laboratori
marker
includ
nlcr
radiolog
find
assess
influenza
complic
includ
pneumonia
respiratori
failur
intens
care
unit
icu
admiss
length
stay
mortal
evalu
use
nlcr
cut
valu
strength
associ
report
odd
ratio
confid
interv
ci
total
patient
includ
studi
mean
age
year
studi
cohort
requir
icu
admiss
inpati
mortal
overal
mean
nlcr
significantli
higher
patient
develop
complic
patient
nlcr
greater
significantli
associ
increas
risk
develop
pneumonia
ci
p
respiratori
failur
ci
p
longer
length
stay
hour
vs
hour
p
signific
associ
rate
icu
admiss
mortal
elev
nlcr
high
nlcr
associ
increas
unfavour
outcom
patient
influenza
util
nlcr
predict
marker
pneumonia
respiratori
failur
influenza
guid
clinic
decis
make
warrant
evalu
nil
previous
shown
consumpt
high
energi
fast
food
meal
rich
satur
fatti
acid
sfa
polyunsatur
fatti
acid
simpl
carbohydr
cho
caus
increas
airway
neutrophilia
asthma
studi
aim
compar
individu
effect
macronutri
airway
inflamm
asthma
randomis
crossov
studi
adult
asthma
obes
conduct
subject
consum
differ
isocalor
meal
separ
occas
minimum
washout
period
day
meal
sfa
deliv
doubl
cream
butter
sfa
deliv
safflow
oil
simpl
cho
deliv
glucos
confectionari
cho
blood
induc
sputum
collect
hour
consumpt
meal
measur
inflammatori
cell
postprandi
chang
sputum
cell
gene
express
measur
microarray
analysi
total
white
blood
cell
blood
neutrophil
count
increas
obes
subject
follow
high
fat
meal
increas
follow
high
cho
meal
sputum
neutrophil
increas
subject
follow
high
sfa
meal
median
iqr
versu
chang
follow
cho
meal
postprandi
chang
airway
cell
obes
subject
gene
significantli
upregul
subject
follow
high
sfa
meal
sfa
cho
caus
acut
increas
airway
neutrophilia
asthmat
associ
activ
inflammasom
airway
obes
subject
appear
resist
inflammatori
effect
sfa
possibl
due
desensitis
result
chronic
exposur
high
circul
sfa
level
nhmrc
project
grant
asthma
major
unmet
need
asthma
manag
effect
treatment
urgent
requir
howev
develop
hamper
lack
understand
pathogen
mechan
involv
increas
bodi
evid
show
high
fat
diet
hfd
andor
obes
associ
asthma
howev
precis
mechan
involv
remain
unclear
studi
show
obes
caus
increas
airway
ahr
mice
respons
driven
respons
howev
whether
hfdobes
affect
steroid
respons
whether
therapeut
inhibit
inflammasom
effect
treatment
experiment
asthma
unknown
develop
novel
mous
model
hfdobes
combin
establish
model
steroid
sensit
allerg
airway
diseas
aad
effect
steroid
treatment
role
potenti
target
respons
lung
aad
examin
use
therapeut
treatment
dexamethason
potent
highli
select
inhibitor
show
hfd
result
signific
increas
adipos
weight
gain
significantli
hfdobes
induc
increas
eosinophil
number
lung
ahr
absenc
presenc
aad
also
show
hfd
result
increas
stain
airway
epithelium
well
signific
increas
activ
whole
lung
tissu
significantli
treatment
suppress
ahr
absenc
presenc
aad
develop
novel
murin
model
obes
induc
aad
also
identifi
previous
unrecognis
role
respons
lung
develop
aad
thu
hfdobes
induc
increas
inflammasom
respons
lung
may
therapeut
target
treatment
asthma
nhmrc
hmri
conflict
interest
none
respiratori
acidosi
ra
associ
airway
ahr
sever
ssi
asthma
treatment
sodium
bicarbon
use
correct
ra
improv
lung
function
sever
asthma
thu
dysfunct
mechan
govern
homeostat
balanc
airway
may
induc
ra
cardin
featur
ssi
asthma
produc
cellular
respir
hydrat
carbon
anhydras
carbon
acid
dissoci
h
transport
plasma
lung
convert
back
expel
breath
reduc
lung
function
occur
ssr
asthma
impair
remov
volatil
result
acid
accumul
increas
arteri
patient
sever
asthma
often
develop
complic
increas
skew
ratio
result
increas
h
concentr
reduc
ph
develop
mous
model
respiratori
infect
ssi
allerg
airway
diseas
ssiaad
highli
repres
human
diseas
microarray
analys
lung
mice
ssiaad
show
three
infect
decreas
express
chlorid
pump
crucial
secret
airway
lumen
thu
assess
role
potenti
target
ra
ssiaad
show
respiratori
infect
suppress
induct
airway
epithelium
aad
associ
increas
level
free
h
ion
bronchoalveolar
lavag
treatment
ssiaad
suppress
ahr
complementari
studi
administr
acetazolamid
carbon
anhydras
inhibitor
aad
mimic
effect
decreas
respons
induc
steroid
resist
ahr
identifi
previous
unrecognis
role
promot
ra
ssraad
nhmrc
hmri
electron
cigarett
heat
aerosolis
liquid
produc
inhal
aerosol
often
contain
nicotin
flavour
littl
known
potenti
impact
health
howev
research
indic
increas
airway
resist
healthi
asthmat
individu
may
facilit
asthma
attack
aim
assess
effect
use
lung
function
earli
late
phase
asthmat
respons
epr
lpr
respect
mice
without
exist
allerg
airway
diseas
assess
volum
lung
function
use
plethysmographi
techniqu
asthmat
adult
femal
balbc
mice
minut
minut
acut
aerosol
exposur
also
measur
airway
ahr
second
group
mice
hour
minut
aerosol
exposur
four
type
test
epr
studi
acut
exposur
littl
effect
lung
function
except
mice
expos
vapour
exhibit
immedi
temporari
impair
lung
function
littl
differ
asthmat
mice
lpr
studi
previou
exposur
exacerb
function
asthmat
respons
protect
effect
nicotin
free
vapour
inflamm
studi
sensitis
challeng
ovalbumin
increas
ahr
cellular
inflamm
exacerb
eosinophilia
neutrophilia
expos
asthmat
mice
studi
show
acut
aerosol
exposur
limit
effect
respiratori
health
mous
model
allerg
airway
diseas
aerosol
exposur
neg
protect
effect
respiratori
health
appar
depend
type
excipi
inform
avail
caution
exercis
advoc
safe
altern
tobacco
smoke
especi
asthmat
none
support
asthma
foundat
western
australia
project
grant
sever
asthma
heterogen
diseas
caus
signific
diseas
burden
often
refractori
treatment
associ
comorbid
confound
manag
multidimension
assess
mda
follow
manag
target
treatabl
trait
propos
superior
treatment
approach
aim
test
hypothesi
mda
sever
asthma
would
lead
improv
control
measur
asthma
control
questionnair
randomis
control
trial
mda
intervent
group
ig
versu
usual
sever
asthma
care
uc
conduct
particip
sever
asthma
underw
baselin
mda
week
intervent
involv
individualis
therapi
tailor
treatabl
trait
airway
comorbid
deliv
via
uc
arm
receiv
treatment
within
sever
asthma
clinic
particip
randomis
ig
uc
femal
mean
sd
age
year
intervent
result
signific
improv
asthma
control
compar
uc
mean
differ
se
post
ig
compar
uc
ig
also
result
signific
improv
mean
differ
se
asthma
qualiti
life
questionnair
compar
uc
sputum
eosinophil
increas
uc
compar
ig
also
signific
reduct
ig
crp
compar
uc
manag
sever
asthma
base
multidimension
assess
follow
therapi
target
treatabl
trait
result
signific
improv
studi
support
medicin
approach
sever
asthma
hunter
medic
research
institut
univers
newcastl
john
hunter
hospit
physic
inact
sedentari
behaviour
like
particularli
extrem
sever
asthma
sa
popul
secondari
high
symptom
comorbid
burden
degre
inact
sa
howev
quantifi
aim
object
measur
physic
activ
pa
sedentari
time
st
patient
sa
compar
control
describ
correl
behaviour
clinic
outcom
studi
adult
physician
diagnos
sa
healthi
control
hc
conduct
particip
underw
multidimension
assess
involv
measur
lung
function
exercis
capac
airway
system
inflamm
asthma
control
qualiti
life
pa
st
measur
consecut
day
use
triaxial
acceleromet
actigraph
sa
group
includ
femal
age
year
hc
group
includ
femal
median
iqr
age
yr
compar
control
peopl
sa
spent
significantli
less
minutesday
moder
vigor
intens
pa
versu
p
took
less
step
per
day
versu
p
howev
sa
particip
perform
minutesday
light
pa
control
versu
p
statist
signific
differ
st
found
two
popul
moder
correl
pa
st
system
inflamm
exercis
capac
asthma
control
qualiti
life
compar
control
peopl
sa
perform
less
moder
intens
activ
despit
engag
light
physic
activ
amount
activ
associ
import
diseas
outcom
data
show
potenti
benefit
target
inact
strategi
manag
sever
asthma
sever
asthma
physic
activ
sedentari
behaviour
correl
nomin
new
investig
award
john
hunter
hospit
charit
trust
idiopath
pulmonari
fibrosi
ipf
fatal
lung
diseas
unknown
etiolog
occur
predominantli
elderli
mechan
link
age
persist
accumul
lung
fibroblast
lf
ipf
remain
incomplet
understood
fibroblast
senesc
character
growth
arrest
apoptosi
resist
secretori
phenotyp
sasp
occur
age
may
contribut
ipf
aim
studi
character
senesc
human
lf
vitro
ascertain
role
mitochondri
dysfunct
acquisit
andor
reinforc
senesc
phenotyp
line
establish
lung
tissu
ipf
patient
compar
lf
control
cell
prolifer
telomer
length
sasp
cytokin
product
activ
level
assess
cell
count
pcr
elisa
cytochemistri
immunoblot
respect
increas
level
mitochondri
dna
superoxid
featur
mitochondri
dysfunct
evalu
pcr
mitosox
fluorogen
dye
respect
rotenon
use
disrupt
mitochondri
activ
display
slower
growth
accompani
decreas
level
cellular
protein
telomer
length
compar
p
convers
resist
cytox
p
also
exhibit
increas
activ
sasp
cytokin
product
level
p
furthermor
lower
level
protein
bax
higher
level
mitochondri
dna
superoxid
product
rotenon
increas
mitochondri
superoxid
preced
increas
marker
senesc
studi
suggest
exhibit
senesc
like
featur
includ
replic
arrest
resist
oxid
cytox
induct
sasp
mitochondri
dysfunct
tightli
link
senesc
like
contribut
healingrepair
malfunct
lf
ipf
nhmrc
lfa
david
wilson
scholarship
report
defect
efferocytosi
associ
cigarett
smoke
andor
airway
inflamm
chronic
lung
diseas
includ
chronic
obstruct
pulmonari
diseas
sever
asthma
also
show
defect
phagocytosi
h
influenza
nthi
common
colon
lower
airway
copd
defect
could
substanti
overcom
azithromycin
howev
chronic
usag
may
induc
bacteri
resist
investig
two
novel
macrolid
molecul
significantli
diminish
antibiot
activ
aureu
pneumonia
catarrhali
h
influenza
macrolid
effect
efferocytosi
phagocytosi
nthi
cell
viabil
receptor
involv
recognit
apoptot
cell
andor
nthi
flow
cytometri
secret
cleav
intracellular
cba
immunofluoresc
confoc
microscopi
test
primari
alveolar
macrophag
macrophag
cigarett
smoke
extract
dose
respons
experi
show
optim
effect
low
concentr
compar
find
azithromycin
macrolid
significantli
improv
phagocytosi
apoptot
cell
nthi
eg
increas
efferocytosi
phagocytosi
nthi
respect
macrophag
viabil
remain
follow
exposur
either
macrolid
concentr
secret
intracellular
cleav
decreas
macrolid
signific
chang
recognit
molecul
mertk
particul
cytoplasm
immunofluoresc
inflammasom
also
significantli
reduc
conclud
may
use
reduc
airway
inflamm
chronic
lung
diseas
without
induc
bacteri
resist
support
nation
health
medic
research
council
project
grant
career
develop
award
chronic
fetal
hypoxemia
common
pregnanc
complic
associ
intrauterin
growth
restrict
iugr
respiratori
diseas
birth
later
life
molecular
mechan
respons
understood
hypoxia
oxid
stress
link
poorer
cardiovascular
outcom
birth
later
life
antenat
antioxid
administr
amelior
effect
investig
effect
chronic
fetal
hypoxemia
antenat
administr
antioxid
vitamin
c
molecular
regul
lung
structur
function
lamb
chronic
catheteris
pregnant
sheep
carri
femal
singleton
expos
normoxia
n
hypoxia
h
either
salin
vitamin
c
matern
iv
daili
term
lung
tissu
collect
lamb
month
birth
lung
express
gene
marker
oxid
stress
nadph
oxidas
airway
remodel
elastin
eln
surfact
matur
surfact
protein
sp
quantifi
numer
densiti
posit
cell
lung
tissu
determin
point
count
data
analys
anova
p
treatment
n
vs
h
drug
vs
vc
h
induc
fetal
growth
restrict
effect
h
vc
bodi
weight
rel
lung
weight
lamb
month
h
increas
gene
express
ns
vs
hs
mean
normalis
express
mne
eln
ns
vs
hs
mne
postnat
lung
tissu
amelior
antenat
vc
administr
hvc
eln
mne
effect
h
vc
express
surfact
protein
number
surfact
produc
cell
present
lung
tissu
show
effect
chronic
fetal
hypoxemia
molecular
program
oxid
stress
airway
remodel
lung
earli
adulthood
matern
antenat
antioxid
treatment
protect
offer
insight
mechan
possibl
treatment
improv
offspr
respiratori
outcom
british
heart
foundat
nhmrc
australia
iron
essenti
mani
biolog
process
much
littl
iron
result
wide
varieti
patholog
alter
iron
level
andor
dysregul
iron
homeostasi
associ
number
lung
diseas
includ
chronic
obstruct
pulmonari
diseas
lung
cancer
cystic
fibrosi
howev
mechan
underpin
associ
whether
iron
play
role
pathogenesi
lung
diseas
yet
fulli
elucid
determin
effect
system
iron
overload
iron
level
lung
assess
effect
increas
iron
lung
structur
function
level
system
pulmonari
iron
lung
structur
function
assess
transferrin
receptor
tfr
mutant
mice
wt
balbc
mice
fed
carbonyl
iron
diet
compar
wt
normal
diet
control
respect
effect
increas
iron
load
murin
model
fibrosi
hous
dust
mite
hdm
allerg
airway
diseas
aad
also
assess
excess
iron
accumul
observ
lung
genet
model
iron
overload
increas
iron
level
lung
associ
alveolar
enlarg
small
airway
collagen
deposit
alter
baselin
lung
function
increas
airway
ahr
whilst
iron
overload
absenc
bleomycin
administr
result
gener
fibrosi
small
airway
ahr
similar
level
observ
fibrosi
iron
overload
minim
addit
effect
combin
bleomycin
iron
overload
also
result
increas
eosinophil
inflamm
sever
ahr
aad
data
show
increas
iron
level
lung
result
emphysema
airway
fibrosi
correspond
reduc
lung
function
model
use
better
understand
role
iron
pathogenesi
lung
diseas
nhmrc
hmri
none
idiopath
pulmonari
fibrosi
ipf
chronic
fibros
interstiti
pneumonia
unknown
caus
median
surviv
year
previous
shown
dysregul
activ
transcript
factor
character
function
differ
subset
fibroblast
presenc
correl
ipf
progress
question
drive
phenotyp
diverg
cell
prolong
lifespan
remain
unansw
hypothesi
activ
transcript
factor
increas
fibrot
lung
tissu
ipf
patient
contribut
senesc
via
role
cytokin
express
mitochondri
dysfunct
aim
work
evalu
whether
role
senesc
lung
fibroblast
lf
ipf
primari
cultur
lf
establish
lung
tissu
ipf
patient
control
donor
senesc
induc
expos
cell
hydrogen
peroxid
hr
activ
assess
differ
passag
follow
immunoblot
senesc
evalu
measur
activ
product
express
arrest
protein
mitochondri
superoxid
product
assess
use
mitosox
flourogen
assay
inhibit
pharmacolog
inhibitor
transfect
sirna
higher
percentag
posit
earlier
equival
passag
level
mitochondri
superoxid
p
earli
late
passag
produc
p
baselin
level
higher
increas
follow
treatment
target
attenu
product
level
mitochondri
superoxid
product
data
suggest
display
acceler
senesc
associ
increas
activ
superoxid
product
contribut
senesc
ipf
regul
mitochondri
activ
research
fund
nhmrc
grant
lung
foundat
australia
david
wilson
scholarship
award
david
water
key
word
nomin
new
investig
award
idiopath
pulmonari
fibrosi
ipf
chronic
progress
lethal
interstiti
fibrot
lung
diseas
poor
surviv
rate
diagnosi
airway
andor
lung
remodel
major
featur
ipf
associ
accumul
extracellular
matrix
ecm
protein
import
ecm
protein
four
variat
stabil
ecm
protein
one
variant
predomin
human
mice
involv
lung
fibrosi
determin
level
ipf
patient
elucid
role
pathogenesi
pulmonari
fibrosi
measur
ipf
patient
lung
fibrosi
model
defici
mice
use
investig
mechan
regul
remodel
lung
fibrosi
increas
lung
tissu
ipf
patient
protein
increas
experiment
lung
fibrosi
mice
mice
reduc
airway
remodel
lung
fibrosi
protect
lung
function
impair
day
bleomycin
challeng
experiment
lung
fibrosi
interact
fibronectin
periostin
stabilis
collagen
deposit
around
small
airway
whole
lung
regul
transform
growth
activ
bind
latent
bind
protein
mediat
phosphoryl
level
downstream
molecular
pathway
process
also
regul
myofibroblast
number
collagen
deposit
interestingli
mice
also
less
inflammatori
cell
interleukin
il
lung
experiment
lung
fibrosi
wt
mice
data
demonstr
novel
role
lung
remodel
ipf
inibhit
may
therapeut
target
ipf
nhmrc
grant
lfalizott
famili
research
award
pulmonari
rehabilit
pr
cornerston
care
copd
new
model
use
programm
shown
equival
clinic
outcom
programm
compar
direct
intervent
cost
econom
evalu
sought
determin
compar
cost
benefit
intervent
model
period
particip
stabl
copd
randomli
assign
complet
either
home
pr
complet
case
analysi
undertaken
particip
complet
questionnair
end
pr
month
follow
programm
complet
enabl
classif
health
statu
use
calcul
life
year
qali
direct
provid
cost
healthcar
utilis
collect
hospit
depart
health
human
servic
period
complet
data
avail
particip
femal
mean
sd
age
year
predict
complet
pr
peopl
femal
mean
age
year
predict
undertook
programm
particip
programm
lower
cost
outpati
appoint
mean
differ
ci
tend
lower
cost
hospit
admiss
ci
overal
healthcar
provid
cost
tend
lower
group
ci
differ
qali
significantli
differ
group
ci
month
follow
pr
healthcar
provid
cost
equival
lower
particip
compar
peopl
undertak
programm
group
also
demonstr
equival
qali
result
support
clinic
implement
new
model
pr
lung
foundat
australia
nation
health
medic
research
council
none
declar
biochem
evid
cardiac
dysfunct
common
exacerb
chronic
obstruct
pulmonari
diseas
copd
even
patient
without
clinic
suspect
cardiac
disord
investig
associ
abnorm
natriuret
peptid
troponin
abnorm
electrocardiogram
chest
radiograph
patient
hospitalis
exacerb
copd
electrocardiogram
assess
tachycardia
atrial
fibril
right
left
ventricular
hypertrophi
ischaem
chang
patient
chest
radiograph
assess
sign
heart
failur
patient
assess
done
two
independ
examin
blind
cardiac
biomark
statu
associ
abnorm
least
moder
agreement
high
cardiac
biomark
troponin
analys
high
valu
associ
atrial
fibril
vs
right
ventricular
hypertrophi
vs
left
ventricular
hypertrophi
vs
ischaemia
vs
electrocardiogram
cardiomegali
vs
chest
radiograph
high
troponin
valu
associ
tachycardia
vs
right
ventricular
hypertrophi
vs
ischaem
chang
vs
electrocardiogram
none
test
sensit
specif
biochem
indic
cardiac
dysfunct
indic
ischaem
chang
sensit
specif
troponin
best
indic
tachycardia
ischaem
chang
sensit
specif
respect
abnorm
electrocardiogram
chest
radiograph
associ
abnorm
cardiac
biomark
may
indic
cardiac
diseas
patient
exacerb
copd
howev
electrocardiogram
chest
radiograph
poor
sensit
specif
diagnos
acut
cardiac
dysfunct
set
cardiac
biomark
provid
addit
inform
acut
cardiac
dysfunct
patient
exacerb
copd
partial
support
waikato
medic
research
fund
heart
foundat
new
zealand
chronic
obstruct
pulmonari
diseas
copd
lead
caus
chronic
morbid
death
worldwid
cigarett
smoke
major
caus
copd
develop
countri
current
therapi
limit
efficaci
fail
halt
diseas
progress
caus
advers
side
effect
effect
treatment
urgent
requir
howev
develop
hamper
lack
understand
mechan
promot
pathogenesi
diseas
function
microrna
mir
health
diseas
firmli
establish
aberr
express
associ
sever
lung
diseas
includ
copd
studi
aim
identifi
mir
promot
develop
copd
assess
therapeut
potenti
target
mir
identifi
perform
mir
microarray
analys
lung
mice
expos
highli
repres
cigarett
smoke
cs
model
experiment
copd
identifi
one
highest
upregul
mir
role
potenti
target
lung
examin
use
treatment
specif
inhibitor
antagomir
lung
express
increas
throughout
cs
exposur
experiment
copd
reduc
lung
function
human
copd
patient
correl
lung
express
treatment
inhibit
lung
express
suppress
airway
inflamm
small
airway
fibrosi
improv
lung
function
experiment
copd
silico
analys
identifi
potenti
axi
put
target
neg
regul
known
induc
activ
significantli
cs
exposur
decreas
lung
model
treatment
restor
level
decreas
express
activ
identifi
previous
unrecognis
pathogen
role
axi
experiment
copd
data
highlight
novel
therapeut
target
treatment
copd
nhmrc
none
pulmonari
hypertens
import
complic
chronic
obstruct
pulmonari
diseas
copd
howev
difficult
identifi
reduct
carbon
monoxid
transfer
factor
tlco
featur
emphysema
pulmonari
hypertens
ct
quantifi
emphysema
via
emphysema
index
ei
addit
pulmonari
arteri
distens
pad
known
correl
mean
pulmonari
arteri
pressur
measur
right
heart
catheteris
measur
simultan
use
ct
impact
pulmonari
arteri
distens
relationship
emphysema
index
ei
tlco
never
examin
aim
studi
determin
effect
pad
ei
tlco
hypothesi
addit
pad
data
would
help
account
variabl
tlco
unexplain
two
paramet
patient
analys
cohort
prospect
group
patient
recruit
year
period
acut
exacerb
copd
subsequ
ecg
gate
ct
pulmonari
function
test
perform
stabl
period
exclud
patient
miss
data
signific
motion
artefact
ct
unabl
perform
tlco
patient
enter
multipl
linear
regress
model
tlco
correct
haemoglobin
enter
depend
variabl
order
ei
pad
enter
regress
model
independ
variabl
overal
model
abl
explain
variat
tlco
correct
ei
significantli
correl
tlco
control
variabl
r
p
ei
r
p
howev
control
ei
pad
significantli
correl
tlco
r
p
significantli
posit
correl
emphysema
index
significantli
neg
correl
tlco
control
variabl
addit
pad
data
appear
add
analysi
nil
preval
chronic
obstruct
pulmonari
diseas
copd
use
spirometri
cirteria
extens
studi
howev
littl
evid
exist
use
transfer
factor
carbon
monoxid
tlco
diagnosi
classif
copd
guidelin
global
initi
chronic
obstruct
lung
diseas
gold
current
utilis
spirometri
predomin
aid
copd
sinc
rel
small
proport
smoker
develop
copd
aim
assess
tlco
serv
use
earli
biomark
detect
lung
diseas
younger
smoker
normal
spirometri
perform
analysi
subject
spirometri
tlco
measur
respiratori
laboratori
monash
lung
sleep
monash
health
subject
includ
male
femal
age
year
normal
spirometri
least
smoke
histori
one
hundr
six
subject
age
normal
spirometri
signific
smoke
histori
identifi
cohort
subject
group
tlco
lower
limit
normal
use
at
criteria
cohort
equal
divid
male
low
tlco
femal
low
tlco
low
transfer
factor
carbon
monoxid
tlco
preval
amongst
younger
smoker
normal
spirometri
low
tlco
may
import
earli
indic
potenti
lung
damag
copd
exacerb
action
plan
consid
key
compon
copd
intervent
studi
intervent
show
contradictori
result
systemat
cochran
review
assess
effect
copd
intervent
includ
exacerb
action
plan
compar
usual
care
literatur
search
articl
independ
assess
two
author
studi
inclus
criteria
randomis
control
trial
publish
intervent
includ
written
action
plan
copd
exacerb
iter
process
patient
healthcar
provid
identifi
record
studi
includ
time
two
month
statist
signific
benefici
effect
detect
qualiti
life
st
georg
respiratori
questionnair
total
score
mean
differ
ci
studi
particip
hospitalis
ci
studi
particip
furthermor
borderlin
signific
trend
toward
fewer
hospitalis
ci
studi
particip
observ
effect
mortal
found
risk
differ
ci
studi
particip
intervent
includ
copd
exacerb
action
plan
associ
better
qualiti
life
lower
probabl
hospitalis
excess
mortal
risk
observ
lung
foundat
australia
cochran
airway
australia
scholarship
lung
foundat
netherland
grant
number
follow
radic
treatment
cell
lung
cancer
nsclc
surveil
recomend
endobronchi
ultrasound
transbronchi
needl
aspir
emerg
bronchoscop
modal
sampl
pulmonari
lymph
node
detect
surveil
imag
previou
treatment
patient
receiv
may
make
reinterpret
imag
perhap
bronchoscop
lymph
node
sampl
difficult
perform
audit
patient
underw
investig
abnorm
ct
lymph
node
appear
follow
radic
treatment
nsclc
combin
bronchoscopi
report
patholog
report
imag
report
chart
review
use
identifi
patient
inform
overal
case
identifi
median
durat
treatment
month
pet
scan
perform
patient
pulmonari
lymph
node
sole
site
metastas
case
node
sampl
frequenc
tbna
sampl
posit
malign
frequenc
biopsi
posit
malign
post
surgeri
post
chemoradi
post
radiat
alon
patient
sampl
posit
malign
went
chang
treatment
case
receiv
chemotherapi
receiv
radiat
receiv
surgeri
high
yield
detect
region
lymph
node
recurr
diseas
post
radic
treatment
set
addit
region
lymph
node
frequent
readili
avail
biopsi
target
yield
posit
biopsi
higher
case
seri
surgic
patient
compar
chemoradiotherapi
radiat
allow
chang
manag
signific
number
patient
endobronchi
ultrasound
nomin
new
investig
award
na
nil
compet
interest
studi
tisseel
combin
synthet
aprotinin
factor
viii
fibrinogen
combin
thrombin
fibrin
sealant
indic
use
adjunct
haemostasi
patient
undergo
surgeri
control
bleed
convent
surgic
techniqu
ineffect
impract
wide
use
gener
surgic
procedur
remain
approach
manag
haemoptysi
recent
case
report
describ
effect
usag
massiv
haemoptysi
techniqu
bronchial
embolis
bronchoscop
suction
surgic
resect
fail
may
ineffect
howev
tisseel
use
independ
endoscopi
migrat
dislodg
even
expector
fibrin
clot
common
complic
lead
recurr
haemoptysi
present
first
ever
report
case
success
endobronchi
use
tisseel
control
activ
distal
bronchial
bleed
year
old
ladi
suffer
ongo
haemoptysi
secondari
recurr
non
small
cell
lung
cancer
involv
later
segment
left
lower
lobe
underw
therapeut
bronchoscopi
utilis
therapeut
video
scope
olympu
introduc
via
rigid
bronchoscop
provid
secur
airway
access
identifi
sourc
bleed
tisseel
inject
distal
size
spirat
ibv
insert
add
stabil
prevent
expector
fibrin
clot
ml
tisseel
inject
proxim
top
valv
excel
seal
procedur
resolut
bleed
combin
tisseel
endobronchi
valv
provid
safe
effect
therapeut
option
medium
term
control
distal
bronchial
bleed
secondari
malign
nil
lung
volum
reduct
lvr
endobronchi
valv
ebv
sever
emphysema
establish
evid
demonstr
subject
object
clinic
respons
australia
major
procedur
fund
perform
privat
sector
audit
assess
cohort
patient
treat
public
hospit
set
implement
public
fund
program
patient
select
establish
criteria
multidisciplinari
patient
underw
ebv
insert
first
month
program
one
patient
complet
post
procedur
lung
function
exclud
chang
residu
volum
rv
total
lung
capac
tlc
rel
chang
calcul
patient
test
done
prior
ebv
insert
compar
three
month
post
procedur
follow
minim
clinic
import
differ
mcid
use
assess
object
respons
patient
also
underw
clinic
review
ascertain
subject
chang
wellb
rel
increas
mean
p
decreas
mean
residu
volum
p
decreas
mean
tlc
ml
p
follow
ebv
insert
regard
minim
clinic
import
differ
patient
cohort
greater
volum
reduct
rv
wherea
patient
cohort
rel
increas
one
patient
pneumothorax
follow
valv
insert
one
nine
patient
valv
migrat
requir
reposit
patient
subject
respons
first
clinic
review
post
valv
insert
one
patient
longer
requir
home
oxygen
audit
demonstr
subject
object
benefit
ebv
insert
care
select
patient
symptomat
emphysema
best
current
manag
program
success
public
hospit
set
local
support
nil
peripher
lung
nodul
hilar
mediastin
node
opportun
singl
biopsi
ebu
tbna
alon
give
diagnosi
stage
avoid
subsequ
procedur
confirm
nodal
metastasi
audit
medic
record
patient
underw
hilar
mediastin
lymph
node
diagnost
procedur
peripher
lung
lesion
royal
brisban
women
hospit
brisban
australia
patient
distant
metastasi
exclud
case
ebu
tbna
diagnost
malign
patient
malign
diagnos
subsequ
procedur
side
effect
ebu
tbna
observ
tabl
method
diagnosi
malign
tabl
malign
type
diagnos
ebu
tbna
case
nsclc
no
patient
underw
pet
scan
report
consist
primari
lung
lesion
nodal
metastasi
malign
case
discuss
multidisciplinari
case
confer
patient
peripher
lung
nodul
hilar
mediastin
lymph
node
enlarg
ebu
tbna
effect
method
provid
diagnosi
stage
avoid
addit
procedur
use
combin
patholog
pet
give
convinc
evid
nodal
diseas
peripher
lung
lesion
nil
analysi
textur
featur
lesion
identifi
radial
endobronchi
ultrasound
ebu
imag
characteris
benign
versu
malign
previous
report
analys
expert
defin
roi
correctli
classifi
lesion
posit
predict
valu
ppv
howev
main
limit
studi
restrict
roi
maximum
pixel
aim
studi
assess
whether
unconstrain
roi
select
result
larger
portion
lesion
analys
would
improv
result
radial
ebu
imag
predict
set
nguyen
et
al
studi
utilis
use
custom
written
imag
analysi
softwar
expert
physician
identifi
unconstrain
polygon
roi
follow
featur
calcul
mean
maximum
minimum
maximum
minimum
standard
deviat
entropi
contrast
correl
energi
homogen
u
test
use
compar
featur
characterist
roc
curv
gener
optim
point
determin
malign
versu
benign
differenti
sensit
specif
accuraci
ppv
calcul
malign
benign
case
five
textur
featur
maximum
maximum
minimum
mean
standard
deviat
entropi
significantli
differ
malign
benign
group
maximum
maximum
minimum
standard
deviat
roc
curv
respect
optim
valu
maximum
pixel
valu
sensit
specif
ppv
malign
maximum
minimum
pixel
valu
sensit
specif
ppv
standard
deviat
sensit
specif
ppv
maximum
pixel
valu
highest
diagnost
accuraci
textur
analysi
radial
ebu
imag
use
unconstrain
roi
less
expert
depend
characteris
lesion
benign
malign
rel
good
sensit
specif
ppv
formal
valid
seri
pend
nil
nguyen
p
et
al
respirolog
endobronchi
ultrasound
transbronchi
needl
aspir
positron
emiss
tomographi
pet
emerg
common
modal
stage
pulmonari
lymph
node
cell
lung
cancer
nsclc
find
pet
scan
often
limt
factor
infect
inflamm
dust
inhal
bilater
pulmonari
lymphadenopathi
patient
known
small
cell
lung
cancer
frequent
repres
true
lymph
node
stage
perform
audit
patient
known
nsclc
pet
scan
also
underw
explicitli
state
purpos
pulmonari
lymph
node
stage
combin
bronchoscopi
report
patholog
report
imag
report
chart
review
use
identifi
patient
inform
overal
case
identifi
exclud
due
incomplet
collect
date
pet
demonstr
case
low
intermedi
grade
bilater
lymph
node
uptak
case
unilater
lymph
node
uptak
two
case
pet
uptak
case
bilater
uptak
case
sampl
posit
malign
two
case
subsequ
upstag
posit
nodal
involv
underw
surgeri
case
unilater
nodal
involv
pet
scan
frequenc
biobsi
posit
malign
subsequ
underw
surgeri
dust
inhal
seen
biopsi
specimen
patient
bilater
pet
uptak
patient
unilater
pet
uptak
case
seri
also
add
grow
bodi
evid
dust
inhal
associ
pet
posit
although
symmetr
uptak
pet
scan
technic
repres
diseas
surgeri
demonstr
low
rate
posit
lymph
node
metastas
highlight
role
rule
patient
surg
rather
exclud
pet
find
alon
endobronchi
ultrasound
nil
compet
interest
studi
clinic
trial
ipf
design
estim
surviv
analysi
use
surviv
model
predict
life
expect
patient
idiopath
pulmonari
fibrosi
ipf
receiv
pirfenidon
best
support
care
bsc
life
expect
estim
area
curv
parametr
surviv
distribut
fit
surviv
data
clinic
studi
ipf
registri
surviv
data
pirfenidon
deriv
clinic
studi
capac
ascend
recap
surviv
data
bsc
obtain
two
independ
registri
patient
ipf
inova
fairfax
hospit
databas
nation
jewish
health
interstiti
lung
diseas
databas
distribut
chosen
statist
consider
visual
inspect
fit
curv
clinic
interpret
account
differ
patient
enrol
clinic
trial
registri
covari
adjust
use
propens
score
use
mean
life
expect
confid
interv
calcul
year
pirfenidon
year
bsc
inova
year
bsc
therefor
pirfenidon
improv
life
expect
rel
bsc
year
year
measur
inova
registri
respect
surviv
model
suggest
pirfenidon
significantli
improv
life
expect
compar
bsc
almost
year
patient
ipf
although
find
base
comparison
provid
support
pirfenidon
effect
treatment
option
ipf
fund
intermun
intern
ag
becam
wholli
own
subsidiari
f
roch
ltd
trial
assess
efficaci
safeti
nintedanib
patient
idiopath
pulmonari
fibrosi
ipf
patient
complet
treatment
period
visit
week
later
could
receiv
nintedanib
aim
assess
efficaci
safeti
nintedanib
base
data
snapshot
octob
patient
treat
placebo
initi
nintedanib
patient
treat
nintedanib
continu
nintedanib
patient
treat
continu
nintedanib
initi
nintedanib
baselin
characterist
similar
group
mean
sd
exposur
month
mean
sd
total
exposur
patient
treat
nintedanib
continu
nintedanib
month
mean
sd
chang
fvc
baselin
week
ml
nintedanib
group
ml
placebo
group
patient
treat
nintedanib
mean
sd
chang
fvc
ml
baselin
week
ml
week
week
advers
event
profil
nintedanib
similar
recent
data
snapshot
indic
effect
nintedanib
reduc
diseas
progress
observ
maintain
treatment
nintedanib
treatment
month
accept
safeti
toler
profil
new
safeti
signal
identifi
studi
fund
boehring
ingelheim
lt
involv
clinic
trial
conduct
intermun
roch
medamun
merck
bayer
also
receiv
speaker
fee
present
airway
confer
bc
receiv
grant
person
fee
support
rocheintermun
boehring
ingelheim
person
fee
support
sanofi
grant
cardif
lvl
medimmun
person
fee
astrazeneca
mq
ws
ss
employe
bi
mkay
financi
disclosur
mkreuter
receiv
fee
speak
andor
organis
educ
er
almiral
astella
astrazeneca
bayer
boehring
ingelheim
glaxosmithklin
intermun
novarti
nycom
pfizer
roch
consult
fee
boehring
ingelheim
intermun
glaxosmithklin
roch
phase
iii
trial
significantli
lower
proport
patient
idiopath
pulmonari
fibrosi
treat
nintedanib
vs
placebo
diseas
progress
absolut
fvc
declin
predict
week
explor
impact
fvc
chang
week
subsequ
fvc
declin
mortal
descript
analysi
proport
patient
absolut
fvc
declin
predict
baselin
week
chang
fvc
predict
mortal
week
group
conduct
use
pool
data
trial
patient
nintedanib
placebo
includ
fvc
declin
predict
baselin
week
predict
fvc
declin
predict
respect
week
proport
patient
die
week
increas
increas
fvc
declin
baselin
week
among
patient
fvc
declin
predict
baselin
week
patient
treat
nintedanib
vs
placebo
declin
increas
fvc
week
fvc
declin
predict
first
week
predict
fvc
declin
associ
higher
mortal
follow
week
studi
fund
boehring
ingelheim
tc
receiv
unrestrict
educ
grant
travel
assist
serv
advisori
board
boehring
ingelheim
roch
product
ltd
receiv
unrestrict
educ
grant
intermun
pharmaceut
serv
advisori
board
astra
zeneca
lr
serv
scientif
advisori
board
intermun
boehring
ingelheim
fibrogen
glaxosmithklin
anthera
genentech
medimmun
takeda
ucb
promedior
trial
princip
investig
boehring
ingelheim
intermun
gilead
roch
takeda
ucb
receiv
research
grant
intermun
biogen
italian
ministri
health
italian
nation
drug
agenc
wellcom
trust
speaker
fee
intermun
boehring
ingelheim
cipla
aa
member
advisori
board
boehring
ingelheim
shionogi
co
ltd
nintedanib
ipf
steer
committe
boehring
ingelheim
ms
member
steer
committe
consult
boehring
ingelheim
wt
jc
ss
employe
boehring
ingelheim
vc
receiv
honoraria
consult
particip
advisori
board
meet
steer
committe
meet
actelion
bayer
boehring
ingelheim
gilead
glaxosmithklin
intermuneroch
promedior
sanofi
natur
histori
patient
idiopath
pulmonari
fibrosi
ipf
highli
variabl
difficult
predict
advent
new
treatment
slow
diseas
progress
grow
interest
potenti
biomark
method
differeni
rapidli
progress
stabl
ipfdiseas
australian
ipf
registri
link
biobank
blood
patient
store
analysi
use
blood
analys
panel
plasma
protein
thought
import
ipf
pathogenesi
opnp
spa
enrag
crp
plasma
protein
concentr
measur
use
elisa
techniqu
multivari
cox
analysi
adjust
baselin
demograph
featur
age
gender
smoke
bmi
diseas
sever
fvc
predict
use
determin
effect
biomark
predict
mortal
progress
free
surviv
pf
pf
defin
death
fall
baselin
particip
age
male
fvc
blood
avail
analysi
median
concentr
ngml
opnp
spa
enrag
crp
particp
measur
analysi
higher
conentr
enrag
hr
ci
spa
ci
opnp
hr
ci
associ
increas
mortal
wherea
higher
opnp
hr
ci
hr
ci
level
associ
shorter
progress
free
surviv
biomark
potenti
role
predict
mortal
diseas
progress
ipf
previou
analys
patient
idiopath
pulmonari
fibrosi
ipf
receiv
pirfenidon
show
continu
treatment
follow
absolut
rel
declin
percent
predict
forc
vital
capac
fvc
hospit
first
month
treatment
provid
benefit
subsequ
month
aim
explor
potenti
benefit
continu
pirfenidon
treatment
patient
ipf
worsen
walk
distanc
within
first
month
treatment
pool
analysi
includ
patient
random
pirfenidon
mgd
placebo
ascend
capac
studi
n
patient
declin
within
first
month
studi
treatment
select
fvc
mortal
hospit
outcom
assess
subsequ
period
total
patient
pool
pirfenidon
placebo
group
respect
demonstr
declin
within
first
month
treatment
outcom
subsequ
month
continu
treatment
patient
shown
tabl
result
suggest
continu
treatment
pirfenidon
may
confer
signific
benefit
patient
ipf
experienc
declin
within
first
month
treatment
support
f
roch
ltd
pirfenidon
shown
decreas
annual
rate
declin
forc
vital
capac
fvc
volum
patient
idiopath
pulmonari
fibrosi
ipf
analysi
explor
effect
variou
patient
subgroup
patient
random
pirfenidon
mgd
placebo
capac
ascend
studi
includ
annual
rate
declin
fvc
volum
baselin
month
estim
use
model
studi
fix
effect
patient
slope
random
effect
annual
rate
fvc
declin
estim
slope
within
subgroup
defin
demograph
baselin
diseas
activ
measur
total
patient
pirfenidon
group
placebo
group
includ
pool
analysi
overal
adjust
annual
rate
se
fvc
declin
baselin
month
ml
pirfenidon
vs
ml
placebo
differ
ml
annual
rate
fvc
declin
favour
pirfenidon
placebo
across
variou
baselin
demograph
lung
function
subgroup
patient
ipf
treat
pirfenidon
regardless
baselin
demograph
lung
function
significantli
lower
annual
rate
declin
fvc
volum
vs
treat
placebo
month
fund
f
roch
ltd
paradox
mechan
ventil
strategi
acut
respiratori
distress
syndrom
ard
lead
lung
injuri
vili
increas
morbid
mortal
despit
decad
research
progress
design
ventil
strategi
prevent
vili
limit
part
due
inabl
assess
region
respons
mechan
ventil
aim
studi
use
novel
imag
approach
quantifi
region
respons
mechan
ventil
explor
impact
tidal
volum
region
heterogen
vili
balbc
femal
mice
anaesthetis
surgic
intub
ventil
either
injuri
strategi
high
tidal
volum
mlkg
pip
peep
protect
strategi
low
tidal
volum
mlkg
pip
peep
hour
mice
imag
use
laboratori
sourc
acquisit
synchronis
ventil
obtain
imag
imag
use
velocimetri
combin
quantit
ct
obtain
region
volum
data
tidal
volum
frc
situ
qualit
tissu
expans
contour
imag
data
show
substanti
region
variat
tidal
stretch
group
respons
mechan
ventil
global
hour
ventil
mice
protect
strategi
signific
chang
tidal
volum
sd
n
p
frc
sd
n
p
contrast
mice
injuri
strategi
decreas
tidal
volum
sd
n
p
decreas
frc
sd
n
p
preliminari
result
promis
show
clear
region
variat
distens
ventil
group
quantit
data
possibl
region
lobar
basi
imag
technolog
focu
ongo
work
result
investig
lead
better
understand
vili
result
improv
outcom
critic
ill
patient
requir
mechan
ventil
nhmrc
grant
number
multimod
australian
scienc
imag
visualis
environ
massiv
project
larg
small
airway
import
sever
asthma
howev
respons
treatment
particl
fraction
inhal
corticosteroidlong
act
beta
agonist
icslaba
combin
yet
establish
aim
measur
effect
fluticasoneeformoterol
ventil
heterogen
measur
multipl
breath
nitrogen
washout
clinic
outcom
addit
aim
determin
predictor
improv
conduct
scond
acinar
sacin
ventil
heterogen
hypothesis
chang
fluticasoneeformoterol
would
improv
scond
sacin
along
clinic
improv
asthma
control
patient
male
doctor
diagnosi
asthma
uncontrol
compon
asthma
control
questionnair
score
current
ic
icslaba
maximum
fluticason
equival
enrol
baselin
scond
sacin
exhal
nitric
oxid
feno
airway
hyperrespons
ahr
methacholin
dose
respons
slope
spirometri
measur
patient
took
ii
bd
fluticasoneeformoterol
via
spacer
week
repeat
test
relationship
chang
scond
sacin
baselin
ahr
spirometri
feno
examin
treatment
improv
scond
sacin
improv
p
feno
predict
fvc
predict
improv
sacin
scond
predict
baselin
sacin
scond
respect
respect
fluticasoneeformoterol
particl
fraction
improv
ventil
heterogen
symptom
ahr
airway
inflamm
spirometri
peopl
uncontrol
asthma
baselin
sacin
scond
predictor
improv
ventil
heterogen
nhmrc
project
grant
mundipharma
area
heterogen
bronchoconstrict
seen
low
ventil
function
lung
imag
asthma
fundament
characterist
asthma
airway
hyperrespons
ahr
associ
ventil
heterogen
ahr
slow
resolv
treatment
mechan
poorli
understood
aim
studi
determin
treatment
reduc
heterogen
bronchoconstrict
measur
low
ventil
area
vspectct
investig
role
peripher
airway
heterogen
mechan
asthmat
subject
femal
mean
sd
age
yr
pred
baselin
methacholin
challeng
vspectct
scan
week
combin
icslaba
treatment
low
ventil
measur
chang
ventil
volum
two
threshold
vspect
ratio
dose
respons
slope
dr
calcul
measur
ahr
report
logdr
multipl
breath
nitrogen
washout
perform
baselin
treatment
determin
peripher
ventil
heterogen
sacin
result
analys
use
pair
linear
regress
mean
rang
logdr
pre
treatment
pret
logdr
post
treatment
postt
ratio
pret
ratio
postt
sacin
pret
sacin
postt
improv
ratio
treatment
correl
pret
logdr
sacin
treatment
reduc
heterogen
bronchoconstrict
measur
function
lung
imag
reduct
develop
low
ventil
area
challeng
treatment
predict
airway
hyperrespons
peripher
heterogen
improv
treatment
relat
imag
bronchoconstrict
pattern
imag
difficult
quantifi
potenti
could
give
valuabl
mechanist
insight
futur
treatment
improv
nh
mrc
project
grant
mundipharma
high
altitud
exposur
result
acut
hypoxia
increas
ventilatori
drive
hyperventilatori
respons
characteris
worsen
breath
effici
increas
lower
end
tidal
rest
exercis
whilst
chang
hyperventilatori
respons
acclim
climber
date
littl
examin
respons
ascent
return
altitud
larg
group
climber
aim
current
studi
examin
chang
ga
exchang
measur
group
climber
ascent
mt
kilimanjaro
immedi
return
altitud
age
rang
individu
ascend
mt
kilimanjaro
climb
exercis
test
step
test
complet
four
occas
follow
altitud
basecamp
mmhg
mmhg
mmhg
return
base
camp
mmhg
ascent
subject
becam
increasingli
hypox
decreas
nadir
exercis
nadir
exercis
breath
effici
worsen
fell
mmhg
subject
ascend
return
altitud
normalis
howev
persist
evid
hyperventil
breath
effici
remain
abnorm
exercis
mmhg
p
vs
rest
high
altitud
exposur
increas
ventilatori
drive
follow
high
altitud
exposur
normalis
ga
exchang
remain
alter
hypothesis
alter
ga
exchang
may
due
sustain
alkalosi
central
chemoreceptor
remain
reset
defend
lower
establish
high
altitud
exposur
spirometri
use
assess
degre
bronchoconstrict
bronchial
provoc
test
howev
littl
known
specif
featur
proxim
peripher
airway
respond
differ
provoc
agent
studi
aim
determin
proxim
peripher
airway
resist
ventil
heterogen
nitric
oxid
level
chang
airway
respons
standard
direct
indirect
provoc
agent
rel
placebo
newli
diagnos
untreat
patient
atop
asthma
recruit
studi
subject
demonstr
clinic
posit
test
use
spirometri
direct
methacholin
indirect
mannitol
provoc
test
separ
visit
apart
anoth
visit
placebo
provoc
also
perform
immedi
provoc
test
follow
measur
made
airway
resist
use
forc
oscil
techniqu
ventil
heterogen
use
multipl
breath
nitrogen
washout
techniqu
nitric
oxid
flux
alveolar
concentr
use
multipl
exhal
flow
techniqu
data
express
mean
sem
p
respect
placebo
chang
proxim
airway
resist
heterogen
increas
respons
direct
indirect
provoc
rel
placebo
howev
nitric
oxid
flux
decreas
respons
indirect
agent
peripher
airway
heterogen
remain
unchang
peripher
resist
increas
respons
direct
indirect
provoc
howev
alveolar
nitric
oxid
level
decreas
respons
indirect
agent
australia
new
zealand
societi
respiratori
scienc
pharmaxi
copd
patient
often
prescrib
multipl
medic
manag
respiratori
diseas
comorbid
may
result
complex
medic
regimen
increas
risk
poor
adher
medic
error
interact
studi
aim
explor
medic
burden
copd
relationship
clinic
outcom
studi
wherebi
copd
patient
assess
demograph
inform
comorbid
medic
use
clinic
outcom
multidimension
indic
perform
complex
medic
regimen
quantifi
use
valid
medic
regimen
complex
index
mrci
particip
male
mean
sd
age
year
predict
suffer
median
comorbid
nearli
half
particip
take
medic
mean
sd
total
mrci
score
high
medic
regimen
complex
medic
mrci
versu
respect
p
complex
dosag
formul
contribut
higher
mrci
score
medic
dose
frequenc
primarili
drove
complex
associ
medic
particip
gold
quadrant
highest
median
mrci
score
copd
medic
compar
quadrant
b
p
mrci
score
correl
walk
distanc
saint
georg
respiratori
questionnair
p
prior
year
exacerb
histori
multipl
regress
analysi
reveal
comorbid
cardiovascular
gastrointestin
metabol
diseas
contribut
higher
mrci
score
andor
medic
count
charlson
comorbid
index
comorbid
test
show
highest
degre
correl
total
mrci
score
p
p
respect
copd
patient
complex
medic
regimen
associ
diseas
sever
certain
comorbid
data
support
need
reduc
medic
complex
copd
nhmrc
ramaciotti
foundat
lung
foundat
australia
uon
hmri
rapid
largest
random
trial
assess
emphysema
progress
antitrypsin
defici
aatd
complet
date
follow
rapid
extens
trial
subject
rapid
receiv
proteinas
inhibitor
zemaira
csl
behr
placebo
yr
elig
subject
continu
extens
receiv
anoth
yr
cohort
defin
treatment
placebo
rapid
respect
comput
tomographi
ct
lung
densiti
declin
rate
measur
annual
forc
expiratori
volum
sec
measur
quarterli
annual
ct
lung
densiti
declin
rate
first
yr
less
glyr
cohort
glyr
vs
glyr
one
side
cohort
lung
densiti
declin
reduc
glyr
switch
chang
yr
correl
significantli
chang
ct
lung
densiti
rapid
therapi
reduc
rate
lung
densiti
declin
compar
placebo
month
cohort
show
greater
loss
lung
densiti
data
demonstr
effect
therapi
suggest
earli
treatment
may
reduc
emphysema
progress
aatd
patient
trial
fund
csl
behr
airway
pharmacolog
treatment
treatment
copd
manag
asthma
chronic
obstruct
pulmonari
diseas
copd
common
airway
diseas
individu
overlap
asthma
copd
experi
increas
health
impair
sever
diseas
exacerb
efficaci
treatment
option
requir
popul
omalizumab
therapi
effect
patient
sever
persist
asthma
limit
data
avail
efficaci
popul
overlap
asthma
copd
current
studi
sought
assess
effect
omalizumab
treatment
popul
data
australian
xolair
registri
axr
use
compar
treatment
respons
individu
overlap
sever
asthma
alon
particip
assess
baselin
month
omalizumab
treatment
utilis
sever
differ
definit
overlap
first
compar
particip
previou
doctor
diagnosi
copd
particip
copd
diagnosi
made
comparison
base
baselin
lung
function
compar
particip
predict
popul
analysi
stratifi
base
smoke
histori
omalizumab
treatment
markedli
improv
asthma
control
health
relat
qualiti
life
popul
assess
base
aqlq
questionnair
score
omalizumab
treatment
improv
lung
function
popul
enrich
overlap
diagnosi
copd
ever
smoker
studi
suggest
omalizumab
improv
asthma
control
health
relat
qualiti
life
individu
sever
allerg
asthma
overlap
copd
find
provid
efficaci
data
patient
popul
suggest
omalizumab
use
manag
sever
asthma
copd
overlap
australian
xolair
registri
support
novarti
pharmaceut
australia
pti
ltd
studi
analysi
support
fund
nation
health
medic
research
council
centr
excel
sever
asthma
http
wwwsevereasthmaorgau
flame
first
studi
show
superior
indgli
labalama
reduc
risk
exacerb
vs
sfc
labaic
copd
patient
histori
exacerb
report
result
regard
effect
indgli
vs
sfc
copd
exacerb
patient
without
prior
icslabalama
tripl
therapi
flame
randomis
studi
compar
indgli
vs
sfc
patient
sever
copd
exacerb
previou
year
post
hoc
analysi
time
first
copd
exacerb
mild
moder
sever
moderatesever
copd
exacerb
indgli
vs
sfc
analys
addit
treatment
effect
rate
exacerb
assess
patient
patient
includ
analysi
prior
tripl
therapi
indgli
significantli
reduc
risk
exacerb
moderatesever
exacerb
vs
sfc
patient
irrespect
prior
tripl
therapi
tabl
indgli
numer
reduc
rate
moderatesever
copd
exacerb
vs
sfc
patient
withwithout
prior
tripl
therapi
tabl
indgli
significantli
reduc
risk
exacerb
vs
sfc
irrespect
prior
tripl
therapi
exacerb
patient
sever
copd
studi
fund
novarti
pharma
ag
basel
switzerland
shown
improv
exercis
capac
patient
chronic
obstruct
pulmonari
diseas
copd
receiv
bronchodil
bd
exercis
train
ext
ad
programm
smbm
explor
influenc
follow
smbm
physic
activ
pa
perceiv
difficulti
symptom
week
randomis
partial
placebo
p
trial
intervent
week
smbm
p
tiotropium
olodaterol
week
ext
triaxial
acceleromet
assess
pa
stepsday
function
perform
inventori
assess
difficulti
engag
pa
chronic
respiratori
questionnair
assess
parel
dyspnoea
patient
post
predict
randomis
treat
full
analysi
set
chang
stepsday
week
shown
tabl
signific
gain
pa
seen
ad
toext
smbm
versu
smbmp
howev
difficulti
dyspnoea
significantli
decreas
week
smbmto
versu
smbmp
moder
sever
copd
smbm
increas
pa
addit
smbm
associ
reduc
difficulti
symptom
pa
compar
smbmp
full
analysi
set
analysi
covari
model
treatment
baselin
covari
common
baselin
mean
stepsday
se
ameasur
via
triaxial
acceleromet
studi
fund
boehring
ingelheim
pf
receiv
past
year
honoraria
educ
advisori
board
involv
andor
receiv
confer
attend
support
follow
global
initi
copd
gold
improv
foundat
lung
foundat
australia
remedi
healthcar
astrazeneca
boehring
ingelheim
glaxosmithklin
menarini
mundipharma
novarti
tt
princip
investig
proactiv
project
receiv
speakersconsult
fee
boehring
ingelheim
novarti
bayer
kll
receiv
grantsresearch
support
gsk
consult
fee
merck
frosst
serv
speaker
bureaushonoraria
gsk
pfizer
merck
frosst
air
liquid
health
intern
nl
employe
evidera
work
varieti
compani
organ
expressli
prohibit
receiv
payment
honoraria
directli
organ
servic
render
fm
consult
boehring
ingelheim
serv
advisori
board
boehring
ingelheim
glaxosmithklin
pfizerand
receiv
payment
lectur
includ
servic
speaker
bureau
boehring
ingelheim
glaxosmithklin
nycom
pfizer
ms
employ
respiplu
organis
contract
studi
sponsor
develop
educ
compon
thetrain
programm
ah
de
dd
lk
employe
boehring
ingelheim
jb
receiv
research
fund
via
research
institut
mcgill
univers
health
centr
astrazeneca
boehring
ingelheim
glaxosmithklin
merck
novarti
nycom
pfizer
theratechnolog
serv
speaker
consult
panel
andor
advisori
board
pharmaceut
compani
flame
studi
compar
effect
indgli
vs
sfc
exacerb
copd
patient
risk
exacerb
present
rate
reduct
moder
sever
exacerb
lung
function
chang
base
blood
eosinophil
sever
copd
patient
multicentr
studi
patient
sever
copd
histori
exacerb
previou
year
randomis
indgli
daili
sfc
twice
daili
data
assess
blood
eosinophil
cut
off
percentag
patient
randomis
indgli
sfc
annualis
rate
moder
sever
exacerb
significantli
lower
vs
patient
eosinophil
count
although
signific
small
number
patient
lung
function
significantli
improv
visit
indgli
vs
sfc
irrespect
eosinophil
count
tabl
patient
high
risk
exacerb
indgli
superior
reduc
moder
sever
exacerb
show
signific
improv
lung
function
vs
sfc
independ
blood
eosinophil
count
studi
fund
novarti
pharma
ag
basel
switzerland
bronchial
thermoplasti
bt
improv
symptom
control
reduc
exacerb
patient
refractori
asthma
precis
mechan
remain
unclear
consist
improv
spirometri
record
postul
assess
lung
function
tidal
breath
oscillometri
measur
respiratori
imped
may
better
reflect
clinic
improv
report
patient
refractori
asthma
gina
step
asthma
control
questionnair
spirometri
resist
hz
reactanc
hz
record
week
complet
bt
one
centr
measur
imped
forc
oscil
techniqu
fot
tremoflo
thorasi
medic
system
canada
impuls
oscillometri
io
sensormed
averag
age
year
fot
group
year
io
group
score
improv
group
fot
group
signific
improv
spirometri
chang
correl
strongli
chang
vital
capac
weakli
improv
symptom
control
follow
bt
may
part
relat
deflat
consequ
improv
lung
mechan
tidal
breath
differ
measur
imped
fot
io
techniqu
discuss
univers
sydney
post
graduat
scholarship
airway
stent
therapeut
intervent
manag
complex
malign
benign
central
airway
obstruct
institut
commenc
airway
stent
program
year
ago
present
audit
patient
outcom
servic
sinc
incept
chart
review
stent
insert
case
perform
liverpool
hospit
dec
juli
indic
stent
select
complic
surviv
impact
stent
symptom
review
stent
silicon
metal
dynam
insert
patient
stent
number
increas
first
year
stabilis
consist
emerg
malign
airway
obstruct
outpati
benign
malign
patholog
patient
local
health
district
refer
health
district
patient
stent
insert
indic
patient
complic
includ
mucou
retent
stent
migrat
obstruct
granul
tissu
mucos
flap
tissu
repeat
bronchoscopi
address
complic
averag
procedur
per
patient
rang
patient
stent
insert
malign
indic
primarili
palli
indic
patient
abl
either
transfer
back
referr
centr
complet
therapi
discharg
acut
hospit
admiss
stent
relat
death
due
post
insert
hospit
acquir
pneumonia
anoth
due
central
airway
lacer
result
massiv
surgic
mediastin
emphysema
stent
offer
symptomat
palliat
central
airway
obstruct
stent
relat
complic
common
particularli
benign
condit
malign
airway
obstruct
short
term
palli
benefit
allow
major
patient
discharg
acut
hospit
admiss
offer
scope
treatment
studi
requir
look
physiolog
qol
improv
death
tbm
massiv
emphysema
ladi
goershal
pneumonia
includ
massiv
mediastin
lymphoma
patient
nil
averag
risk
develop
pneumothorax
follow
ttnb
lung
lesion
disabl
especi
elderli
patient
preexist
respiratori
disord
multipl
comorbid
resullt
hospit
admiss
either
observ
insert
chest
drain
date
studi
directli
correl
risk
factor
predict
poor
toler
iatrogen
pneumothorax
identifi
patient
pneumothorax
post
ttnb
record
outcom
hospit
admissionsto
identifi
age
smoke
histori
preexist
respiratori
diseas
reduc
dlco
risk
factor
poor
toler
pneumothorax
increas
length
stay
hospit
demograph
data
patient
underw
ttnb
age
gender
primari
lung
diseas
medic
histori
smoke
statu
lung
function
test
fvc
dlco
kco
tlc
length
hospit
stay
complic
occur
retrospect
collect
two
center
fiona
stanley
hospit
fremantl
hospit
wa
august
februari
pneumothorax
follow
ttnb
either
admit
observ
vs
requir
chest
drain
record
includ
durat
hospit
admiss
patient
requir
chest
drain
defin
poor
toler
pneumothoraxchi
squar
test
use
determin
associ
age
preexist
copd
smoke
histori
comorbid
reduc
lung
function
dlco
poor
toler
pneumothorax
total
ttnb
procedur
carri
procedur
complic
pneumothorax
patient
requir
aspir
chest
drain
mean
length
stay
lo
day
procedur
poor
toler
pneumothorax
averag
predict
sd
averag
dlco
predict
sd
ie
moder
reduc
patient
patient
requr
chest
drain
copd
chi
squar
test
show
statist
signific
associ
copd
poor
toler
pneumothorax
statist
signific
associ
older
patient
year
poor
toler
pneumothorax
reduc
lung
function
poor
toler
pneumothorax
correl
analysi
show
associ
presenc
copdhav
reduc
lung
functionold
age
poor
toler
pneumothorax
neg
studi
howev
limit
small
number
larger
studi
look
risk
factor
crucial
prevent
unneccessari
lengthi
hospit
stay
chest
drain
insert
caus
routin
ttnb
procedur
nil
declar
interest
interstiti
lung
diseas
ild
heterogen
group
respiratori
condit
requir
clinic
radiolog
patholog
correl
transbronchi
lung
cryobiopsi
tblc
forcep
transbronchi
biopsi
ftbb
ct
guid
core
biopsi
open
lung
biopsi
potenti
method
obtain
lung
tissu
analysi
newest
option
cryobiopsi
place
method
diagnos
ild
yet
fulli
determin
studi
aim
analys
compar
diagnost
yield
complic
two
bronchoscop
deriv
lung
biopsi
type
tblc
versu
ftbb
patient
suspect
ild
context
hospit
academ
tertiari
care
centr
retrospect
observ
studi
patient
radiolog
featur
suspici
ild
undergon
tblc
ftbb
jan
sept
patient
underw
bronchoscopi
elig
patient
femal
male
mean
age
identifi
either
tblc
ftbb
grade
bleed
occur
tblc
ftbb
grade
bleed
occur
tblc
case
similar
proport
patient
group
pneumothorax
vs
better
diagnost
yield
achiev
tblc
vs
howev
statist
signific
odd
ratio
ci
p
valu
mean
maxim
diamet
cryobiopsi
larger
sampl
obtain
ftbb
p
valu
tblc
appear
safe
ftbb
advantag
larger
biopsi
size
although
diagnost
yield
tblc
statist
differ
ftbb
singl
cohort
larger
prospect
studi
need
establish
role
tblc
diagnost
algorithm
ild
nil
endobronchi
ultrasound
guid
sheath
use
locat
biopsi
peripher
lung
lesion
sensit
specif
respect
minim
data
regard
combin
convent
transbronchi
lung
biopsi
ctblb
plu
biopsi
approach
patient
aim
assess
util
approach
assess
complic
rate
retrospect
analysi
patient
underw
ctblb
august
octob
john
hunter
hospit
newcastl
nsw
patient
elig
mean
sd
age
year
male
mean
sd
lesion
size
mm
patient
lesion
success
localis
use
lesion
concentr
eccentr
data
miss
remain
biopsi
posit
patient
definit
atyp
pattern
seen
patient
give
cumul
sensit
brush
via
guid
sheath
posit
patient
ctblb
definit
posit
patient
atyp
cytolog
pattern
seen
patient
give
cumul
sensit
use
non
gs
guid
procedur
standard
brush
posit
patient
four
patient
diagnos
base
ctblb
alon
guid
investig
neg
combin
ctblb
procedur
increas
sensit
one
small
pneumothorax
manag
conserv
one
episod
bleed
requir
local
adrenalin
therapi
ebu
gs
provid
higher
success
rate
diagnosi
peripher
lung
lesion
ctblb
howev
combin
ctblb
may
increas
diagnost
yield
nil
nil
declar
wang
memoli
js
nietert
pj
silvestri
ga
guid
bronchoscopi
evalu
pulmonari
nodul
chest
malign
pleural
effus
mpe
affect
one
million
peopl
year
herald
limit
prognos
talc
pleurodesi
indwel
pleural
cathet
ipc
approv
treatment
similar
benefit
randomis
studi
date
result
equipois
freedom
hospit
intervent
import
goal
manag
australasian
malign
pleural
effus
randomis
trial
aim
determin
whether
ipc
effect
talc
pleurodesi
reduc
total
hospit
day
remain
lifespan
mpe
patient
random
control
trial
recruit
particip
symptomat
mpe
nine
center
australia
new
zealand
singapor
hong
kong
follow
monthsuntil
death
particip
random
ipc
talc
pleurodesi
minim
region
australasia
vs
asia
malign
mesothelioma
vs
other
trap
lung
vs
primari
endpoint
total
number
day
spent
hospit
trial
intervent
death
month
secondari
outcom
includ
pleural
intervent
breathless
score
measur
advers
event
ipc
group
spent
significantli
fewer
day
hospit
pleurodesi
group
median
iqr
vs
day
repres
vs
remain
lifespan
respect
mean
reduct
hospit
day
day
per
patient
ipc
vs
pleurodesi
day
fewer
patient
requir
invas
pleural
drainag
vs
ci
improv
breathless
advers
event
rate
compar
ipc
manag
reduc
time
mpe
patient
spend
hospit
death
minim
need
invas
pleural
intervent
provid
equival
symptomat
improv
compar
convent
talc
pleurodesi
sir
charl
gairdner
research
advisori
committe
cancer
council
western
australia
dust
diseas
board
new
south
wale
australia
author
conflict
interest
mechan
ventil
lifesav
therapi
patient
respiratori
failur
shown
contribut
mortal
induc
inflamm
lead
multisystem
organ
failur
system
effect
differ
region
lung
shown
heterogen
respond
mechan
ventil
suggest
lung
injuri
may
vari
region
howev
impact
mechan
ventil
region
lung
inflamm
unknown
aim
studi
assess
region
gene
express
respons
mechan
ventil
healthi
lung
ventil
two
group
balbc
mice
n
per
group
h
use
protect
low
tidal
volum
moder
posit
end
expir
peep
injuri
high
tidal
volum
zero
peep
ventil
strategi
mrna
level
gene
interest
ten
differ
region
mous
lung
quantifi
use
qpcr
array
compar
two
group
control
group
mrna
level
ten
gene
differenti
express
group
p
five
gene
significantli
differ
mrna
level
depend
ventil
strategi
fo
comparison
five
gene
differenti
express
lung
region
vim
p
comparison
two
gene
differenti
region
express
depend
ventil
strategi
p
knowledg
first
demonstr
region
variat
gene
express
respons
mechan
ventil
result
provid
critic
insight
relationship
region
lung
respons
mechan
ventil
region
injuri
futur
studi
aim
understand
link
local
tissu
stretch
express
injuri
relat
gene
studi
fund
nhmrc
grant
nocturn
respiratori
symptom
report
upto
half
chronic
obstruct
pulmonari
diseas
copd
patient
result
increas
night
time
awaken
circadian
variat
lung
function
may
worsen
copd
symptom
night
lead
poor
sleep
effici
pilot
studi
determin
preval
sleep
disturb
associ
diurnal
chang
lung
function
copd
copd
subject
lung
function
measur
forc
oscil
techniqu
resist
reactanc
hz
spirometri
even
assess
diurnal
chang
lung
function
overnight
subject
undertook
diagnost
sleep
studi
measur
sleep
architectur
lung
function
measur
repeat
morn
well
standard
sleep
questionnair
overnight
chang
lung
function
assess
use
pair
coeffici
repeat
cor
defin
twice
standard
deviat
differ
even
morn
measur
also
determin
subject
characterist
lung
function
sleep
paramet
shown
tabl
subject
identifi
mild
moder
sever
obstruct
sleep
apnoea
signific
declin
even
morn
mean
ml
cor
twice
report
oostveen
et
healthi
subject
chang
morn
even
lung
function
paramet
relat
sleep
paramet
preliminari
result
show
sleep
abnorm
commonli
present
subject
copd
diurnal
variabl
seen
spirometri
fot
paramet
associ
sleep
outcom
ongo
work
help
us
understand
relationship
circadian
chang
lung
function
sleep
qualiti
symptom
copd
menarini
australia
lung
ultrasound
surfac
wave
elastographi
lusw
novel
techniqu
assess
surfac
lung
tissu
elast
properti
measur
surfac
wave
propag
speed
use
ultrasound
detector
system
surfac
wave
propag
lung
noninvas
gener
local
small
mechan
actuat
skin
chest
wallsinc
mani
interstiti
diseas
predominantli
affect
lung
peripheri
may
especi
suitabl
type
assess
without
radiat
exposur
healthi
control
patient
ct
chest
identifi
peripher
distribut
pulmonari
fibrosi
studi
lusw
perform
gener
small
second
harmon
vibrat
hz
indent
mm
area
intercost
space
handheld
shaker
measur
surfac
wave
propag
lung
ultrasound
probe
place
mm
away
intercost
space
three
measur
full
inspir
made
locat
lung
measur
made
hz
result
suggest
lusw
identifi
differ
wave
speed
control
abnorm
peripher
fibrot
lung
reproduc
specif
sensit
abil
detect
longitudin
chang
yet
defin
promis
advantag
nih
nation
heart
lung
blood
institut
chines
popul
compar
preval
obstruct
sleep
apnoea
osa
compar
caucasian
counterpart
notabl
less
obes
craniofaci
dimens
upper
airway
favour
obstruct
describ
chines
popul
suggest
group
osa
phenotyp
less
depend
obes
osa
also
recogn
caus
hypersensit
ventilatori
control
system
high
loop
gain
lg
low
arous
threshold
arth
studi
examin
ethnic
may
influenc
trait
aim
examin
whether
lg
arth
differ
chines
caucasian
individu
osa
chines
caucasian
subject
osa
match
age
gender
index
ahi
studi
measur
lg
includ
chemoreflex
delay
delay
cycl
period
tn
arth
fit
valid
control
system
model
pattern
ventil
spontan
osa
clinic
polysomnographi
data
present
median
iqr
unless
indic
otherwis
despit
match
ahi
chines
subject
lower
bmi
compar
caucasian
subject
vs
p
longer
respiratori
event
durat
mean
sem
apnoea
vs
hypopnoea
vs
whilst
differ
lg
group
arth
vs
rest
ventil
tn
vs
delay
mean
sem
vs
higherlong
chines
group
chines
individu
osa
uniqu
sleep
phenotyp
compar
caucasian
characteris
high
arous
threshold
increas
cycl
period
chemoreflex
delay
reflect
propens
longer
respiratori
event
data
suggest
mechan
caus
osa
influenc
ethnic
use
sed
rais
arous
threshold
may
less
effect
treat
osa
chines
popul
forc
oscil
techniqu
fot
depend
object
measur
airway
function
home
monitor
fot
variabl
may
offer
valu
manag
copd
peak
expiratori
flow
spirometri
studi
assess
relationship
fot
measur
obtain
qualiti
life
symptom
copd
copd
patient
recruit
royal
north
shore
hospit
concord
hospit
woolcock
institut
medic
research
studi
enrol
standard
lung
function
test
perform
fot
devic
restech
srl
resmon
diari
devic
instal
enrol
particip
home
period
month
particip
train
make
unsupervis
measur
fot
obtain
resist
rr
standard
deviat
past
day
sdrr
differ
inspiratori
expiratori
reactanc
measur
expiratori
flow
limit
daili
symptom
assess
base
copd
assess
test
cat
monthli
qualiti
life
via
st
georg
respiratori
questionnair
sgrq
relationship
fot
measur
vs
sgrq
cat
assess
use
mix
model
particip
age
year
baselin
sgrq
median
rang
adher
rr
sdrr
significantli
relat
sgrq
fix
effect
estim
p
estim
respect
significantli
relat
cat
estim
airway
calibr
variabl
copd
relat
monthli
qualiti
life
encompass
symptom
activ
limit
psychosoci
impact
expiratori
flow
limit
relat
daili
symptom
measur
thu
fot
measur
variabl
reflect
outcom
provid
support
evid
util
home
monitor
fot
copd
nhmrc
postgradu
scholarship
lfaboehring
ingelheim
top
research
grant
nhmrc
project
grant
nhmrc
postgradu
scholarship
lfaboehring
ingelheim
top
research
grant
ventil
niv
set
determin
daytim
produc
asynchroni
pva
night
caus
sleep
disrupt
limit
toler
aim
studi
determin
polysomnographi
psg
titrat
niv
result
less
pva
sleep
disrupt
daytim
titrat
alon
prospect
randomis
control
trial
stabl
individu
requir
niv
particip
randomli
alloc
control
daytim
titrat
sham
psg
titrat
psg
daytim
titrat
psg
titrat
primari
outcom
pva
arous
indic
psg
week
secondari
outcom
includ
adher
chang
averag
daili
niv
use
ga
exchang
nocturn
oximetri
symptom
somnol
sleep
qualiti
fatigu
dyspnoea
qualiti
life
hrqol
sixti
particip
randomis
group
particip
neuromuscular
disord
one
death
two
three
particip
group
complet
final
psg
pva
less
frequent
psg
group
psg
vs
control
differ
arous
psg
vs
control
chang
averag
daili
niv
use
differ
psg
vs
control
although
subgroup
poor
earli
adher
increas
use
psg
psg
vs
control
somnol
subject
sleep
qualiti
improv
similar
extent
differ
hrqol
object
sleep
qualiti
nocturn
ga
exchang
psg
titrat
nocturn
niv
associ
less
pva
less
sleep
disrupt
daytim
titrat
psg
titrat
improv
niv
adher
poor
user
initi
clinic
benefit
demonstr
stabl
outpati
popul
studi
may
help
clarifi
role
psg
titrat
niv
austin
medic
research
foundat
institut
breath
sleep
nhmrc
postgradu
scholarship
document
chang
tuberculosi
epidemiolog
far
north
queensland
comparison
nation
data
two
previou
audit
region
retrospect
clinic
audit
case
tuberculosi
notifi
cairn
chest
clinic
januari
august
case
classifi
either
confirm
presum
basi
avail
microbiologyhistolog
evalu
respect
site
diseas
infect
demograph
mycobacteri
sensit
human
immunodefici
viru
hiv
statu
case
identifi
confirm
case
pulmonari
tuberculosi
smear
posit
case
tuberculosi
mostli
nodal
pleural
case
dissemin
tuberculosi
case
identifi
immigr
popul
eighti
percent
papua
new
guinea
png
remain
case
forti
torr
strait
island
nineteen
aborigin
australian
mycobacteri
sensit
known
fulli
sensit
multidrug
resist
one
extens
drug
resist
rate
hiv
less
three
percent
hiv
statu
known
twenti
percent
case
tuberculosi
remain
signific
public
health
problem
far
north
queensland
total
case
number
increas
sinc
first
audit
much
excess
case
burden
come
immigr
popul
although
png
continu
account
major
number
posit
notif
patient
countri
increas
sinc
rate
tuberculosi
amongst
aborigin
australian
fallen
respons
polici
chang
born
previou
audit
tuberculosi
torr
strait
resid
howev
increas
twelv
case
forti
addit
rate
sputum
smear
posit
drug
resist
higher
far
north
queensland
nation
nil
none
nsw
public
hospit
requir
screen
new
health
care
worker
hcw
identifi
high
risk
tuberculosi
tb
tuberculin
skin
test
tst
follow
chest
cxr
tst
posit
hcw
diagnos
tb
diseas
latent
tb
infect
ltbi
refer
manag
audit
undertaken
determin
incid
tb
ltbi
among
hcw
hunter
new
england
health
servic
hneh
manag
follow
diagnosi
audit
tb
databas
clinic
surveil
system
perform
data
hcw
includ
student
collect
includ
countri
birth
result
tbltbi
diagnosi
manag
option
high
risk
hcw
audit
born
australia
follow
china
india
malaysia
hcw
lower
rate
posit
tst
compar
born
oversea
hcw
posit
case
tb
diseas
case
ltbi
tst
revers
default
cxr
includ
tst
revers
case
tb
diseas
case
ltbi
high
risk
hcw
screen
hneh
hcw
receiv
treatment
ltbi
major
receiv
educ
high
rate
nonattend
serial
cxr
high
rate
neg
follow
posit
tst
nil
nil
pulmonari
compon
human
respiratori
virom
subset
human
microbiom
transplant
recipi
time
lung
transplant
ltx
explor
dynam
virom
transplant
role
intercurr
commun
acquir
respiratori
virus
carv
singl
centr
prospect
longitudin
studi
measur
viral
load
recipi
nasopharyng
swab
prior
ltx
swab
explant
lung
donor
lung
prior
implant
bronchoalveolar
lavag
bal
day
sampl
process
isol
nucleic
acid
follow
rna
extract
cdna
synthesi
qpcr
carv
human
rhinoviru
respiratori
syncyti
viru
influenza
b
parainfluenza
viru
human
metapneumoviru
consecut
ltx
subject
bilater
heart
lung
age
year
mean
f
recruit
follow
day
rang
day
frequent
carv
influenza
follow
influenza
b
individu
influenza
viru
detect
swab
explant
lung
low
viral
load
influenza
also
detect
day
bal
increas
viral
load
multipl
patient
influenza
detect
consecut
bal
day
influenza
b
parainfluenza
detect
day
indic
transplant
determin
viral
detect
viral
load
increas
subject
time
ltx
like
associ
immunosuppress
carv
appear
part
transplant
respiratori
virom
analys
bal
show
progress
expans
select
popul
follow
ltx
outcom
associ
ongo
presenc
carv
may
elucid
follow
longitudin
studi
nil
highest
incid
tb
southeast
asia
rel
low
rate
paediatr
notif
bairo
pite
clinic
bpc
dili
manag
fifth
tb
case
countri
improv
understand
tb
epidemiolog
inform
qualiti
improv
activ
focus
recognit
accur
diagnosi
prevent
tb
children
aim
describ
epidemiolog
diagnost
featur
notifi
paediatr
tb
case
bpc
compar
nation
paediatr
tb
notif
rate
prospect
collect
demograph
clinic
laboratori
data
patient
diagnos
tb
bpc
januari
decemb
inclus
comparison
made
nation
notif
data
respect
paediatr
notif
rate
total
tb
case
notifi
children
age
bpc
notifi
case
age
contact
known
tb
case
report
bpc
case
identifi
screen
household
contact
infecti
index
case
evid
bcg
vaccin
document
malnutrit
identifi
hiv
pulmonari
tb
diagnos
bpc
case
paediatr
case
nation
bacteriolog
confirm
occur
pulmonari
case
bpc
case
nation
district
dili
baucau
paediatr
pulmonari
tb
case
sputum
smear
posit
paediatr
tb
common
high
tb
burden
set
malnutrit
import
risk
factor
hiv
rare
opportun
prevent
includ
improv
bcg
coverag
implement
household
contact
trace
consider
given
improv
specimen
collect
strateg
use
pcr
improv
diagnost
certainti
english
famili
foundat
despit
recur
emerg
novel
pathogen
coronavirus
cov
lack
understand
host
immun
diseas
mechan
respiratori
infect
cov
studi
characteris
innat
immun
respons
differenti
primari
bronchial
epitheli
cell
pbec
infect
relat
less
virul
human
pbec
obtain
subject
brush
bronchoscopi
cell
grown
air
liquid
interfac
ali
differenti
cilia
beat
mucu
product
observ
day
cell
infect
multipl
infect
moi
hour
day
supernat
total
cell
protein
extract
rna
collect
time
point
measur
express
viru
replic
demonstr
differ
viral
replic
kinet
replic
earlier
effici
peak
hour
associ
activ
innat
host
respons
induct
type
interferon
ifn
stimul
gene
viperin
contrast
replic
peak
later
hour
day
viru
demonstr
attenu
level
viperin
begun
investig
virul
factor
control
epitheli
respons
cov
sequenc
analysi
viral
protein
embo
needl
reveal
ident
match
highlight
potenti
variat
host
epitheli
interact
studi
demonstr
replic
differenti
pbec
induc
diverg
innat
immun
respons
potenti
link
differ
replic
kinet
understand
interact
less
virul
coronavirus
give
insight
pathogen
mechan
underpin
respiratori
diseas
univers
newcastl
research
scholarship
unrsc
author
conflict
interest
season
influenza
infect
lead
caus
mortal
morbid
literatur
suggest
bacteri
complic
influenza
case
contribut
sever
prolong
cours
ill
challeng
clinic
practic
remain
identif
patient
benefit
empir
antibiot
retrospect
audit
patient
influenza
infect
diagnos
viral
nasopharyng
swab
gchh
juli
septemb
demograph
clinic
microbiolog
data
complic
outcom
collect
data
antibiot
prescript
also
collect
patient
without
bacteri
compar
patient
diagnos
influenza
infect
viral
nasopharyng
swab
bacteri
present
patient
common
bacteri
pathogen
staphylococcu
aureu
streptococcu
pneumonia
pseudomona
aeruginosa
chronic
lung
diseas
copd
associ
significantli
higher
risk
bacteri
p
examin
includ
activ
smoke
activ
malign
chronic
cardiovascular
diseas
renal
failur
diabet
mellitu
immunosuppress
immunocompromis
state
achiev
statist
signific
patient
microbiolog
find
bacteri
receiv
antibiot
prescript
antibiot
group
patient
result
signific
differ
mortal
mortal
icu
admiss
significantli
higher
patient
bacteri
compar
without
although
mortal
similar
two
group
incid
bacteri
cohort
patient
lower
anticip
find
suggest
probabl
overus
antibiot
group
patient
may
benefit
empir
treatment
antibiot
chronic
lung
diseas
copd
prospect
studi
develop
score
system
could
help
identifi
patient
would
benefit
empir
antibiot
nil
rapid
trial
show
intraven
treatment
significantli
reduc
mean
declin
lung
densiti
vs
placebo
follow
rapid
patient
complet
extens
trial
receiv
activ
treatment
howev
unclear
proport
patient
fast
slow
declin
lung
tissu
loss
proport
fast
declin
reduc
follow
treatment
compar
effect
treatment
proport
fast
vs
slow
declin
patient
complet
rapid
rapid
extens
adjust
ct
scan
analys
loss
use
defin
fast
declin
rel
proport
fast
slow
declin
compar
use
fisher
exact
test
rapid
significantli
higher
proport
patient
receiv
classifi
slow
declin
vs
placebo
vs
p
subject
receiv
rapid
extens
proport
subject
classifi
fast
declin
similar
arm
vs
p
treatment
therapi
associ
higher
proport
patient
slow
declin
lung
tissu
loss
compar
placebo
switch
activ
treatment
progress
shift
fast
slow
declin
demonstr
benefit
treatment
cigarett
smoke
caus
oxid
stress
lung
induc
cellular
transcriptom
proteom
chang
cell
activ
recycl
damag
materi
use
autophagi
pathway
fusion
autophagosom
lysosom
form
autophag
flux
howev
accumul
dysregul
lysosom
lead
disrupt
autophagi
consequ
stress
endoplasm
reticulum
er
current
studi
evalu
presenc
lysosom
associ
membran
lysosom
small
airway
sa
epithelium
copd
patient
assess
physiolog
outcom
sa
lung
resect
volunt
classifi
nine
control
nc
eleven
smoker
normal
lung
function
nlf
nine
copd
current
smoker
cs
ten
es
stain
intens
cell
measur
object
per
area
epithelium
use
imag
softwar
imag
proplu
version
repres
percent
express
sa
epithelium
nlf
group
show
signific
increas
percent
lysosom
sa
epithelium
compar
nc
p
significantli
decreas
p
still
higher
nc
suggest
copd
smoke
effect
normal
airway
epithelium
devoid
detect
express
nlf
epitheli
lysosom
accumul
er
close
nucleu
er
disrupt
diffus
express
observ
percent
express
show
posit
correl
patient
smoke
histori
spearman
rho
rs
p
copd
neg
correl
spearman
rho
rs
p
fef
spearman
rho
rs
p
data
suggest
smoke
activ
stimul
lysosom
accumul
sa
epithelium
associ
decreas
lung
function
copd
consequ
dysregul
lysosom
autophagi
warrant
investig
nhmrc
clifford
craig
foundat
inhal
corticosteroid
ic
use
reduc
rate
chronic
obstruct
pulmonari
diseas
copd
exacerb
debat
continu
use
blood
eosinophil
eo
predict
ic
respons
suggest
wisdom
studi
respons
driven
patient
higher
eo
level
analys
wisdom
data
stratifi
prior
exacerb
eo
level
determin
ic
respond
group
could
better
specifi
post
hoc
analysi
rate
moderatesever
exacerb
complet
ic
withdraw
use
neg
binomi
regress
model
estim
exacerb
rate
accord
number
prior
exacerb
estim
base
number
cours
antibiot
steroid
past
year
eo
subgroup
high
eo
count
associ
increas
exacerb
rate
complet
ic
withdraw
patient
prior
exacerb
figur
rate
ratio
ic
withdrawl
moder
sever
exacerb
eo
subgroup
exacerb
histori
withdraw
ic
increas
rate
exacerb
patient
rais
eo
histori
frequent
exacerb
patient
meet
criteria
ic
may
effect
commonli
assum
pasco
et
al
lancet
respir
med
watz
h
et
al
lancet
respir
med
studi
fund
boehring
ingelheim
ds
real
perceiv
conflict
interest
relat
present
pmac
advis
variou
pharmaceut
compani
includ
boehring
ingelheim
glaxosmithklin
astra
zeneca
novarti
nycom
chiesi
almiral
takeda
design
conduct
clinic
trial
spoken
meet
support
whole
part
compani
kt
bd
hf
gma
employe
boehring
ingelheim
cv
serv
advisor
consult
astrazeneca
boehring
ingelheim
glaxosmithklin
novarti
takeda
speaker
member
speaker
bureau
astrazeneca
boehring
ingelheim
glaxosmithklin
novarti
takeda
receiv
grant
clinic
research
glaxosmithklin
grifol
lmf
consult
arrang
lectur
advisori
board
receiv
research
support
boehring
ingelheim
lectur
member
advisori
board
pfizer
hm
relationship
boehring
ingelheim
berlinchemi
almiral
astrazeneca
chiesi
novarti
takeda
bayer
intermun
efmw
report
serv
advisori
committe
nycom
speaker
astrazeneca
glaxosmithklin
novarti
receiv
research
support
astrazeneca
glaxosmithklin
hw
receiv
consult
fee
travel
support
takeda
receiv
consult
fee
almiral
astrazeneca
boehring
ingelheim
glaxosmithklin
novarti
receiv
research
support
astrazeneca
glaxosmithklin
receiv
lectur
fee
astrazeneca
almiral
boehring
ingelheim
berlinchemi
glaxosmithklin
merck
novarti
receiv
payment
develop
educ
present
boehring
ingelheim
berlinchemi
receiv
travel
support
astrazeneca
glaxosmithklin
novarti
pulmonari
hypertens
ph
copd
associ
increas
disabl
reduc
surviv
detect
ph
copd
challeng
due
limit
echocardiographi
potenti
risk
associ
right
heart
catheter
rhc
main
pulmonari
arteri
pa
becom
progress
less
distens
ph
previou
studi
shown
pa
distens
correl
well
measur
mpap
rhc
assess
relationship
pa
distens
cardiac
function
emphysema
index
measur
use
dynam
mdct
patient
stabl
copd
mean
sd
age
male
underw
dynam
retrospect
mdct
emphysema
quantifi
ct
densitometri
base
upon
densiti
threshold
hounsfield
unit
hu
main
pulmonari
arteri
area
csa
measur
interv
interv
pa
distens
calcul
maximum
csa
minimum
csa
minimum
csa
x
cardiac
function
paramet
assess
use
softwar
manual
correct
requir
relationship
pa
distens
emphysema
index
right
ventricular
eject
fraction
rvef
test
via
pearson
r
mean
sd
pa
distens
low
pa
distens
significantli
neg
correl
emphysema
index
p
posit
correl
reduc
rvef
dynam
mdct
permit
simultan
evalu
emphysema
pa
pressur
right
ventricular
perform
increas
sever
emphysema
appear
associ
reduc
pa
distens
impair
pa
distens
appear
associ
decreas
rvef
dynam
mdct
provid
valuabl
tool
assess
interact
copd
nil
estim
antibiot
resist
caus
million
deathsyear
thu
outstrip
cancer
death
patient
die
advanc
cancer
dementia
resid
hospic
antimicrobi
commonli
prescrib
absenc
clinic
symptom
support
bacteri
infect
extent
appropri
antimicrobi
use
patient
chronic
obstruct
pulmonari
diseas
copd
unknown
review
antibiot
prescript
time
death
patient
die
copd
retrospect
medic
record
audit
perform
patient
die
twelv
year
patient
analys
within
three
group
group
radiograph
consolid
group
elev
inflammatori
marker
wcc
crp
radiograph
consolid
group
normal
inflammatori
marker
radiograph
consolid
two
hundr
twenti
one
patient
die
copd
median
age
year
male
median
respiratori
function
fvc
dlco
patient
use
home
oxygen
antimicrobi
prescrib
patient
tabl
antibiot
number
durat
use
similar
three
group
group
patient
receiv
ceftriaxon
receiv
azithromycin
first
line
recommend
treatment
pneumonia
acut
exacerb
copd
aecopd
similarli
group
patient
without
object
evid
infect
receiv
ceftriaxon
receiv
azithromycin
almost
patient
die
copd
receiv
antimicrobi
final
hospit
admiss
irrespect
object
evid
suggest
infect
antibiot
mainli
prescrib
accord
guidelin
patient
pneumonia
guidelin
evid
base
prescript
antibiot
occur
less
patient
die
aecopd
without
object
evid
infect
nil
tabl
first
line
antimicrobi
use
termin
admiss
gold
standard
measur
chang
arteri
respons
therapi
arteri
capillari
blood
ga
measur
howev
measur
pain
allow
monitor
transcutan
carbon
dioxid
monitor
painless
allow
continu
monitor
oxygen
level
limit
agreement
compar
wide
use
diagnos
hypercapnia
limit
agreement
chang
time
well
describ
hypothesis
trend
may
show
precis
agreement
suffici
accur
guid
treatment
pair
sentec
ag
switzerland
data
avail
adult
exacerb
copd
took
part
studi
investig
effect
oxygen
driven
versu
air
driven
nebulis
repeat
measur
taken
minut
limit
agreement
analysi
perform
estim
bia
pair
differ
two
measur
limit
agreement
approxim
plu
minu
individu
measur
obtain
mean
chang
sd
rang
mean
chang
sd
rang
reveal
estim
bia
chang
ci
despit
reason
larg
limit
agreement
two
method
individu
measur
signific
differ
mean
chang
time
measur
two
method
transcutan
devic
use
monitor
effect
chang
time
without
signific
bia
popul
health
research
council
individu
differ
pattern
lung
function
growth
declin
may
differ
risk
develop
copd
investig
trajectori
lung
function
childhood
middl
age
associ
childhood
factor
use
subject
tasmanian
longitudin
health
studi
measur
year
model
group
base
trajectori
model
logist
regress
use
investig
relationship
childhood
factor
trajectori
group
best
fit
model
show
six
distinct
trajectori
figur
base
initi
lung
function
year
lung
function
growth
declin
rate
trajectori
label
earli
low
reduc
growth
acceler
declin
n
earli
normalhigh
normal
growth
acceler
declin
n
earli
low
normal
growth
normal
declin
n
earli
low
acceler
growth
normal
declin
n
persist
high
n
normal
n
first
three
trajectori
increas
risk
copd
lln
age
year
compar
normal
group
childhood
asthma
bronchiti
pneumoniapleurisi
matern
asthma
matern
smoke
posit
associ
three
trajectori
neg
associ
observ
breast
feed
childhood
overweight
first
studi
develop
lung
function
trajectori
childhood
middl
age
gener
popul
identifi
three
trajectori
increas
risk
copd
acceler
lung
declin
adulthood
low
initi
lung
function
childhood
normal
growth
normal
declin
low
initi
lung
function
childhood
reduc
growth
acceler
declin
import
modifi
childhood
risk
factor
three
trajectori
includ
exposur
matern
smoke
childhood
lack
exclus
breast
feed
earli
life
strategi
maxim
lung
function
growth
earli
life
well
prevent
acceler
declin
import
copd
prevent
nation
health
medic
research
council
australia
clifford
craig
medic
research
trust
tasmania
victorian
queensland
tasmanian
asthma
foundat
conflict
interest
respiratori
fast
track
clinic
rftc
introduc
success
southern
district
health
board
sought
improv
model
incorpor
method
biopsi
similar
rural
popul
new
zealand
nz
rftc
introduct
initi
patient
ct
scan
first
specialist
assess
fsa
phase
two
month
biopsi
incorpor
bronchoscopi
biopsi
biopsi
rftc
phase
patient
suspect
lung
cancer
identifi
decemb
may
prior
rftc
phase
time
diagnost
pathway
measur
compar
phase
may
juli
juli
octob
median
time
use
statist
analysi
patient
underw
long
wait
person
clinic
reason
therebi
distort
data
investig
suspect
lung
cancer
preval
age
normal
distribut
peak
prefer
lower
decil
equal
gender
proport
ethnic
distribut
endobronchi
ultrasound
ebu
utilis
biopsi
method
follow
bronchoscopi
time
gp
referr
fsa
phase
improv
significantli
p
similarli
time
fsa
diagnosi
treatment
improv
significantli
median
time
reduc
p
day
p
respect
phase
tabl
rtfc
significantli
shorten
time
diagnosi
treatment
popul
best
knowledg
first
studi
demonstr
reduct
time
treatment
lung
cancer
patient
nz
fast
track
clinic
previou
studi
use
ebu
initi
investig
result
faster
treatment
seem
improv
surviv
ebu
could
easili
incorpor
rftc
model
may
confer
surviv
advantageth
lancet
respiratori
medicin
volum
issu
none
none
current
optimis
procedur
aspect
endobronchi
ultrasound
transbronchi
needl
aspir
aim
converg
rapid
evalu
rose
target
amplicon
sequenc
ta
hotspot
dna
mutat
rna
transloc
enhanc
lung
cancer
diagnosi
explor
comparison
cellular
dna
yield
diffquik
stain
cytolog
smear
formalin
fix
paraffin
embed
ffpe
cell
block
prospect
studi
consecut
patient
lung
malign
mf
ratio
mean
year
perform
use
median
aspir
olympu
needl
smear
cell
block
tumour
cell
abund
assess
experienc
cytopathologist
scale
absent
abund
genom
dna
isol
smear
block
quantifi
sequenc
use
truseq
amplicon
cancer
panel
illumina
san
diego
ca
miseq
platform
diff
quik
slide
digit
scan
use
dna
exract
unexpectedli
overal
cellular
higher
cytolog
slide
cell
block
case
score
tumour
cell
abund
compar
cell
block
p
test
case
provid
adequ
dna
amplicon
sequenc
ng
highest
dna
yield
cell
block
cytolog
slide
respect
mean
standard
deviat
sd
dna
yield
cell
block
ng
ng
cytolog
slide
ng
ng
differ
significantli
p
pair
extract
dna
good
qualiti
exhibit
dna
fragment
size
agaros
gel
diffquik
stain
cytolog
slide
present
numer
advantag
ffpe
cell
block
sourc
dna
molecular
patholog
includ
increas
dna
yield
immedi
visual
confirm
adequ
malign
cell
sampl
patholog
queensland
studi
educ
research
grant
nil
aim
investig
effect
versu
asthma
manag
pregnanc
preval
asthma
grow
asthma
gia
studi
prospect
longitudin
birth
cohort
follow
offspr
asthmat
women
involv
rct
compar
treatment
algorithm
use
feno
combin
asthma
symptom
ascertain
asthma
control
questionnair
acq
feno
group
treatment
algorithm
use
acq
clinic
group
found
reduct
asthma
exacerb
pregnanc
feno
group
consent
children
complet
year
age
four
polymorph
snp
genotyp
found
asthma
manag
pregnanc
significantli
reduc
odd
ratio
asthma
offspr
confid
interv
ci
p
furthermor
frequent
wheez
past
month
ci
p
wheez
ever
ci
p
recurr
bronchiol
ci
p
less
common
feno
group
asthma
significantli
associ
four
variant
children
past
histori
bronchiol
interact
signific
major
snp
p
asthma
also
associ
mrna
level
pbmc
p
children
past
histori
bronchiol
interact
signific
p
notabl
interact
variant
feno
intervent
risk
asthma
observ
asthma
manag
pregnanc
significantli
reduc
asthma
preval
childhood
variant
interact
bronchiol
earli
life
increas
asthma
risk
interact
evid
interact
feno
guid
asthma
mangement
thu
prevent
strategi
may
benefit
children
without
variant
nhmrc
hunter
children
research
foundat
hunter
medic
research
institut
john
hunter
hospit
charit
trust
univers
newcastl
prioriti
research
centr
growupwel
